Obesity, inflammation and colorectal neoplasia by Kim, Sangmi
 
 
 
 
 
Obesity, Inflammation and Colorectal Neoplasia 
 
 
 
 
Sangmi Kim, M.S. 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Epidemiology, School of Public Health 
 
 
 
 
Chapel Hill 
2007 
 
 
 
 
   Approved by: 
 
  Advisor: Robert S. Sandler, MD, MPH 
 
   Reader: Jane C. Schroeder, DVM, PhD 
 
Reader: Temitope Keku, PhD 
 
         Reader: Susan Halabi, PhD 
 
           Reader: Jessie A. Satia, PhD 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2007 
Sangmi Kim 
ALL RIGHTS RESERVED 
 iii 
 
 
 
 
 
ABSTRACT 
 
 
SANGMI KIM: Obesity, Inflammation and Colorectal Neoplasia 
(Under the direction of Robert S. Sandler, MD, MPH) 
 
 
Colorectal cancer is one of the most common cancer in the United States. Several 
environmental and lifestyle risk factors have been identified for colorectal cancer and 
adenomas; however, their mechanism of action in colon carcinogenesis remains largely 
unanswered. Given a wealth of data on the inverse association between non-steroidal anti-
inflammatory drugs (NSAIDs) and colorectal neoplasia, inflammation is a plausible pathway 
to be studied. In addition, a growing literature has redefined obesity, which has been 
positively associated with colorectal neoplasia, as a state of low grade systemic inflammation.  
The goal of this dissertation was to explore the associations between obesity, inflammation 
and colorectal neoplasia using data from three studies 
We examined circulating levels of CRP, IL-6, and TNF-α in relation to risk factors 
and the prevalence of colorectal adenomas in 873 participants from a colonoscopy-based 
cross-sectional study. Several known risk factors for colorectal neoplasia were associated 
with higher levels of inflammatory cytokines such as older age, current smoking, and 
increasing adiposity. The prevalence of colorectal adenomas was associated with higher 
concentrations of IL-6 and TNF-α, and to a lesser degree, with CRP.  For IL-6, adjusted odds 
ratios for colorectal adenomas were 1.69 (95% confidence interval [CI]: 1.13-2.54) for the 
second highest plasma level, and 1.80 (95% CI: 1.22-2.66) for the highest level compared 
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with the reference level. A similar association was found with TNF-α, with adjusted odds 
ratios of 1.51 (95% CI: 1.01-2.27) and 1.59 (95% CI: 1.06-2.40), respectively. Our findings 
suggest that systemic inflammatory cytokines might be involved in the early development of 
colorectal neoplasia, and suggest that systemic inflammation might mediate the association 
with obesity and other risk factors.  
We further investigated whether an inverse associations between NSAIDs and 
colorectal neoplasia was more pronounced in obese individuals, who presumably have 
increased levels of circulating inflammatory cytokines compared to non-obese individuals, 
using the two datasets from 1) a population-based case-control study of distal large bowel 
cancer (i.e., sigmoid, rectosigmoid and rectal cancer) among whites and African Americans 
in North Carolina, and 2) a completed randomized controlled trial of aspirin 325 mg daily to 
prevent colorectal adenomas in patients with a history of colorectal cancer.  
In the case-control study of distal large bowel cancer, regular NSAID use was 
inversely associated with distal colorectal cancer in whites, but not in African Americans (for 
regular vs. non-regular use, whites: OR = 0.51, 95% CI: 0.39-0.66; African Americans: OR = 
0.99, 95% CI: 0.60-1.63). Also, there was an elevated risk of incident colorectal adenomas in 
relation to high BMI in patients with prior colorectal cancer (BMI ≥ 30kg/m2: OR = 1.42, 
95% CI: 0.90-2.24). However, there is little evidence suggesting a more pronounced inverse 
association between NSAIDs/aspirin and colorectal neoplasia among obese versus non-obese 
individuals in either of the two studies.  
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1. REVIEW OF LITERATURE 
 
1.1 Summary 
Colorectal cancer is the third most common cancer in men and women in the United 
States (1). Several risk factors have been identified for colorectal cancer. Obesity is one of 
the risk factors most consistently associated with risk of colorectal cancer (2). It is now 
recognized that adipose tissue is not only a fat store, but also an endocrine organ that 
produces and releases various hormones such as inflammatory cytokines (3). With an 
increasing body of evidence supporting the link between inflammation and cancer, this 
dissertation hypothesizes obesity-driven systemic inflammation as a potential pathway that 
could increase the risk of colorectal cancer. It is further hypothesized that non-steroidal anti-
inflammatory drugs (NSAIDs) might be more protective in preventing colorectal cancer and 
adenomas in obese individuals than lean individuals, possibly by reducing the elevated levels 
of inflammatory cytokines in obese individuals. This chapter aims to review the existing 
literature that leads to the development of these hypotheses. The present review begins with 
colorectal cancer epidemiology and goes on to examine obesity and inflammation in relation 
to colorectal cancer. Finally, the chemopreventive potential of the NSAIDs is reviewed. 
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1.2 Background and Significance 
1.2.1 COLORECTAL CANCER 
A. Descriptive Epidemiology 
Colorectal cancer is the third most common cancer in the United States. It affects 
both men and women similarly with 148,610 new cases (72,800 in men and 75,810 in 
women) estimated in 2006. Among cancer-related deaths, colorectal cancer is second only to 
lung cancer in the United States. It is estimated that the cancer will cause 55,170 deaths 
during 2006 (1). Colorectal cancers are highly treatable if identified at early stages; five-year 
survival is up to 90% for stages I and II, but decreases to 60% for stage III, and less than 10% 
for stage IV (4).  
 
B. Pathogenesis of Colorectal Cancer 
The molecular biologic details of colorectal carcinogenesis are relatively well 
described. As first summarized by Fearon and Vogelstein, colorectal cancer is the result of 
multistep, multipath, and multifocal changes that require cumulative damage to several genes 
(5). The serial somatic mutations as well as epigenetic changes in the epithelium of colon and 
rectum are expressed as hyperplasia, adenomas, and invasive and metastatic cancer (6). 
Although multiple pathways exist to give rise to colorectal cancer, the adenoma-
carcinoma sequence accounts for approximately 80% of sporadic colorectal cancer. 
Adenomas are very common in the adult population, with the prevalence estimated to be 30-
50 percent in those over 65 years in autopsy studies (7;8). While 10% of those who had 
adenomas will have a recurrent adenoma within a year after removal (9), only a small 
proportion of adenomas eventually grow to cancer (10). In terms of architectural type of 
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adenomas, adenomas that preserve tubular gland morphology have low malignant potential. 
Less than 5% of tubular adenomas evolve to adenocarcinoma, whereas 15-20% of 
tubulovillous type and up to 50% of villous type adenomas progress to colorectal cancer (11). 
It has also been reported that multiple and large adenomas defined as ≥ 1cm in diameter were 
good predictors for high-grade dysplasia and invasive cancer (12). However, because it is not 
often clear-cut what distinguishes the adenomas that evolve to cancer from the ones that 
don’t, screening for and surgical or endoscopic removal of adenomas are recommended to 
prevent fatal outcome of colorectal cancers (13).  
 
C. Etiology of Colorectal Cancer 
Inherited Cancer Syndromes 
As with other cancers, both genetic and environmental factors contribute to the 
development of sporadic colorectal cancer. On the other hand, there are inherited colorectal 
cancer syndromes that are almost entirely genetic. Familial Adenomatous Polyposis (FAP) is 
a rare hereditary condition resulting from germline inactivation of one allele of the APC gene, 
which is a tumor suppressor gene (14). The lifetime penetrance is considered to approach 
100%. Affected individuals develop 10-1000 adenomatous polylps at a mean age of 44 years, 
and if untreated, they will eventually develop cancer (15). FAP accounts for about 1% of new 
colorectal cancer cases annually (16).  
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is an inherited autosomal 
dominant syndrome involving germline mutations in the DNA Mismatch Repair complex. 
People with HNPCC have approximately 80% of lifetime risk of colorectal cancer (14). 
Contrary to FAP, HNPCC is not visually distinct from sporadic colorectal cancer. However, 
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people with HNPCC tend to develop cancer at a younger age, and often have cancer in the 
ascending colon and along with cancers of the endometrium, urinary tract, stomach, and 
biliary system. HNPCC is estimated to comprise 2-5% of all colorectal cancer cases (14;15). 
 
Low-Penetrance Genetic Variants 
While the inherited colorectal cancer syndromes account for less than 10% of all 
colorectal cancer cases in the general population, familial aggregation in colorectal cancer 
appears to be more common. As a meta-analysis of 27 studies showed, individuals with the 
first-degree relative with colorectal cancer had more than a 2-fold increase in risk (17). It has 
been expected that highly prevalent, low-penetrance genes would account for the 
uncharacterized familial clustering of colorectal cancer in general population. As a result of 
the advances in molecular techniques, many different single nucleotide polymorphisms 
(SNPs) have been examined. Candidate genes included genes involved in metabolic 
pathways, or in methylation, those modifying the colonic microenvironment, oncogenes, 
tumor suppressor genes, and genes involved in immune response (18) . However, many 
findings from early epidemiologic association studies were not replicated in subsequent 
studies and remain controversial mainly due to small sizes of the early studies. Alternatively, 
individual risks associated with a single polymorphism are indeed small or none, and might 
not be revealed until considered in conjunction with environmental exposures. Considering 
the redundancy in the genetic regulatory pathways and the biologic system, studies of gene-
environment and gene-gene interactions would be relevant approach to study the low-
penetrance genes. 
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Dietary and Lifestyle Risk Factors 
There is wide variation in the incidence of colorectal cancer worldwide: it is 
approximately 7 times higher in developed countries compared to developing countries (19).  
In some parts of the developing countries like Eastern Europe and several Chinese cities, 
however, the incidence of colorectal cancer is rapidly increasing (15). The change in the 
incidence of colorectal cancer after migration into high-risk countries from low-risk countries 
suggests that the carcinogenesis of colon and rectum is largely driven by environmental 
factors like diet and lifestyle.  
 
Vegetables, fruits, and fiber  Epidemiologic studies have examined various dietary 
factors in relation to colorectal cancer. Although not entirely consistent, previous evidence 
suggests that high consumption of fruits and vegetables was associated with reduced risk of 
colorectal cancer. The association was most consistent for cruciferous vegetables than for 
fruits (15;20). However, it remains unclear whether the benefit from vegetables is limited to 
specific foods, or is attributed to specific nutrients abundant in vegetables, or represents a 
dietary pattern of health-conscious people (20). Fiber is one of substances high in vegetables 
as well as in grains (15). A significant risk reduction of colorectal cancer with fiber-rich diet 
has been reported in a meta-analysis of 16 case-control studies (20). However, a pooled 
analysis of 13 prospective studies did not find risk reduction of colorectal cancer with high 
intake of dietary fiber after statistical adjustment for other risk factors (21).   
  
Fat and Meat  There is some evidence that high intake of red meat and animal fat 
increases the risk of colorectal cancer. A recent meta-analysis of 13 studies from 1973 to 
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1999 provided a pooled OR of 1.35 (95% CI: 1.21-1.51) (22). However, further 
investigations are required to determine whether the positive association is attributed to high 
fat diet, or dietary iron found in red meat, or heterocyclic amines formed during the cooking 
of red meat at high temperature (22). 
  
Calcium Calcium has been associated with reduced risk of colon cancer in 
epidemiologic studies. It is hypothesized that calcium could protect against colon 
carcinogenesis by binding secondary bile acids and ionized fatty acids in the colon to form 
insoluble soaps and subsequently reducing the proliferative stimulus. In experimental studies, 
calcium was shown to be anti-carcinogenic by promoting apoptosis and reducing cell 
proliferation (23). In addition, daily 3g of calcium carbonate (1200 mg of element calcium) 
supplementation reduced risk of adenoma recurrence by 20% in a double-blind, randomized 
placebo-controlled trial (24).  This finding was also supported by a study based on two large 
prospective cohorts (Nurses’ Health Study and Health Professionals Study) (25). On the 
other hand, an ongoing randomized trial of postmenopausal women did not find any 
significant risk reduction in colorectal cancer with 1000 mg of elemental calcium and 400 IU 
of vitamin D3 after 7 years of treatment (26), although the trial was criticized for participants’ 
personal intake of calcium, a relatively short duration of follow-up, and lower than optimal 
dose of vitamin D that might not help absorption of calcium (27). More evidence is necessary 
before calcium supplementation is recommended in an attempt to protect against colorectal 
cancer.  
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Folate, methionine, and alcohol  Methylation of DNA plays an important role in gene 
regulation. Several dietary factors such as folate, alcohol, and methionine are involved in the 
DNA methylation process (28). Risk of colon cancer was increased in men with a 
combination of high alcohol intake and low intake of folate and methionine in some but not 
all studies (20;29).  
 
Hormone replacement therapy Observational studies have reported a decreased risk of 
colorectal cancer among women taking postmenopausal hormones (20). Recently, the inverse 
association was supported in an intervention study. In the randomized, double-blind, placebo-
controlled trial of estrogen plus progestin, the risk of colorectal cancer in the hormone group 
was approximately half the risk in the placebo group (30). In a comparison of histologic 
features of colorectal cancers between the two groups, however, colorectal cancers in the 
hormone group showed significantly greater numbers of positive lymph nodes and more 
advanced cancers compared to cancers in the placebo group (30), suggesting that the 
protective effect of the hormones might be limited to the early carcinogenic process. 
 
Non-steroidal anti-inflammatory drugs Numerous epidemiologic studies have 
consistently reported the protective effects of aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs) in preventing colorectal cancer. The anti-carcinogenic 
properties of NSAIDs are supported by experimental studies. The chemopreventive potential 
of NSAIDs is discussed in more detail in the section entitled “Non-steroidal anti-
inflammatory drugs.” 
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Physical activity and Obesity  Low levels of physical activity and obesity are among 
the most consistently reported risk factors for colorectal cancer.(31-34). Given that obesity is 
the result of energy imbalance, and the level of physical activity is an important component 
of energy expenditure, some degree of correlation between physical activity and obesity is 
expected. However, studies have reported both physical inactivity and obesity as independent 
risk factors for colorectal cancer. Nevertheless, at high level, physical activity was more 
strongly associated with risk of colorectal cancer than obesity, whereas obesity became a 
more significant predictor of colon cancer risk at low levels of physical activity (35). More 
discussion on the obesity and colorectal cancer is followed below in the section entitled 
“Obesity and Colorectal Neoplasia.” 
 
 
1.2.2 OBESITY AND COLORECTAL NEOPLASIA 
A. Introduction 
Over the last four decades, the prevalence of obesity have increased from around 13% 
to 30% in the United States. Two thirds of American adults were classified as overweight in 
2000 (36). Although obesity is more prevalent in the industrialized world including the U.S. 
and Europe than in developing countries (37), Westernized diet and modern life style has 
made obesity a global phenomenon estimated to involve 1.7 billion people worldwide (38).  
A range of health problems have been recognized as a consequence of obesity, 
including hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, stroke, sleep 
apnea, gallbladder disease, and osteoarthritis (39). In addition, recently accumulating 
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evidence suggests that obesity might increase risk for some types of cancers. Colorectal 
cancer is one such cancer where risk is increased with obesity.  
This section reviews epidemiologic studies of the association between obesity and 
colorectal neoplasia and possible mechanisms for the association. First, physiology and 
measures of obesity are discussed.  
 
B. Definition of Obesity 
Physiology of Obesity 
Obesity is a result of a chronic imbalance between energy intake and energy 
expenditure. During a positive energy imbalance, excess energy intake is stored as adipose 
tissue. Compared to carbohydrate or protein, adipose tissue can be readily expanded (40), and 
because of the high caloric density and hydrophobic nature of triglyceride, adipose tissue can 
serve as an efficient storage of overloaded energy (41).   
Increase in the number and volume of adipocytes affects the endocrine and metabolic 
functions of adipose tissue, and results in alterations of several physiological parameters such 
as blood pressure, systemic insulin sensitivity, serum triglyceride, and leptin (42). Leptin is 
an important regulator of energy intake and storage possibly by signaling information about 
body-fat deposition to brain. Levels of leptin are positively correlated with increasing 
adiposity (43). In contrast to leptin, adiponectin is inversely associated with obesity. 
Adiponectin is thought to decrease hepatic gluconeogenesis and increases lipid oxidation in 
muscle (44).  
 In addition, it is now recognized that adipocytes synthesize and release cytokines 
such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) (3). The 
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proinflammatory cytokines are positively correlated with increasing obesity and obesity-
related metabolic conditions: TNF-α is associated with impaired insulin sensitivity and 
increased lipolysis in adipocytes (42), and IL-6 induces hypertriglyceridemia by stimulating 
hepatic triglyceride secretion (45). Given that these cytokines are the typical molecules that 
are produced from activated macrophages, the fact that macrophage accumulation is 
increased in proportion to adipocyte size may explain the increased secretion of the 
proinflammatory cytokines in obese individuals (42).  
 
Measures of Obesity 
Obesity refers to accumulation of excess adiposity (46). Therefore, obesity should be 
evaluated based on the amount of body fat but not the amount of body weight. Although 
advanced methods such as underwater weighing, dual photon or dual x-ray absorptiometry 
(DEXA), imaging studies, bioelectric impedance analysis, and total body electrical 
conductivity analysis are available for more accurate measurement of body fatness, they are 
often not feasible in clinical practice and large epidemiologic studies due to their cost and 
invasiveness (47).  
Body mass index (BMI) is the most commonly used surrogate measure of obesity. 
BMI is a measure of relative weight calculated from weight in kilograms divided by the 
square of the height in meters. There have been several indices of weight-for-height proposed, 
but BMI has shown the lowest correlation with height (36). In general, BMI is known to have 
strong correlations (0.6-0.9) with densitometry estimates of body fat composition in adult 
population (36). The most widely used cut-off points for BMI are those recommended by the 
World Health Organization (WHO) (48) and the National Heart Lung and Blood Institute 
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(47), where  BMI between 25 and 30 kg/m2 is defined as grade 1 overweight, and BMI of 30 
kg/m2  or greater is defined as grade 2 overweight, or obese. Normal range of BMI falls 
between 18.5 and 24.9 kg/m2.  
Although BMI is widely accepted as a valuable tool to form an obesity classification 
system (48), and to predict risk for complications of obesity such as blood pressures, blood 
lipids, blood lipoproteins, and long-term mortality (49), there are several limitations inherent 
in BMI. First, BMI is a less valid indicator of adiposity in athletes or military forces that 
build muscular mass for a long period of time. Similarly, the correlation between BMI and 
adiposity becomes weaker in an elderly population due to increasing ratio of fat to lean body 
mass accompanied by aging (46). Race or ethnicity also influences the correlation between 
BMI and body fatness. Compared to Caucasians with the same BMI, many Asian races tend 
to have more fat, while Polynesians have more lean body mass (46).  
Despite the limitations, BMI is the most widely used marker of obesity in 
epidemiologic studies, and it is not likely that BMI will be replaced by a “gold standard” 
measures of adiposity in the near future. Indeed, BMI is an attractive indicator of adiposity 
especially in epidemiologic studies because it can be obtained from self-reported height and 
weight (50). Although self-reported weight tends to be systematically underestimated in 
overweight individuals (51), studies have validated sufficient accuracy of self-reported height 
and weight in the epidemiologic research (50). However, as Prentice and Jebb (46) pointed 
out, usage of BMI as an indicator of adiposity should be articulated based on accumulating 
information in future epidemiologic studies. Application of population-specific cut-off values 
(46), or development of a new guideline of obesity measurement by combining BMI and 
waist circumference (52) are such examples. It is noteworthy that waist circumference 
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appeared to be useful in sub-classifying individuals within the same BMI category to predict 
risk of obesity-related health conditions more accurately. In a recent study, waist 
circumference thresholds differentiated increased risk for coronary events among individuals 
with the same BMI category (52). Similarly, waist circumference was an independent risk 
factor for colon cancer risk even after adjustment for BMI (53), and even a stronger and more 
consistent predictor of levels of inflammatory markers than BMI at least in men (54). Given 
better correlation of waist circumference, or waist-to-hip ratio with visceral abdominal fat 
compared with BMI (55;56),  utilizing both BMI and waist circumference or waist-to-hip 
ratio to define obesity might be a convenient way to improve classification of obesity in 
epidemiologic studies.  
 
C. Epidemiologic Studies of Obesity and Colorectal Neoplasia 
Tables 1.1-1.5 summarize the published epidemiologic studies examining the 
relationship between obesity and colorectal neoplasia in diverse study populations using 
different study designs. BMI was the most widely used marker of obesity, and waist 
circumference or waist-to-hip ratio has been sometimes used in the studies.  
Overall, higher BMI was associated with an increase in risk of colorectal cancer, and 
the association was generally linear. Although the cut-off points for the quartiles vary by 
populations, individuals in the highest quartile have about 2-fold increase in risk of 
developing colorectal cancer compared to those in the lowest quartile of obesity measures.  
Some studies suggested that the relationship of obesity with colon cancer might be 
differential by anatomic site of cancer (53;57-61). Although one review paper reported that 
the association between BMI and colorectal cancer was stronger for cancer of the colon than 
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the rectum, and for the distal than the proximal colon (62), the findings were inconsistent and 
there were small sample sizes by anatomic sites in many of the studies examining the role of 
anatomic site.   
On the other hand, the positive association between obesity and colorectal cancer 
appears to be more prominent in men than in women. Several explanations are possible for a 
weaker association in women. First, more severe misclassification of BMI in women might 
result in attenuation of the real association between BMI and risk of colorectal neoplasia in 
women, given that women tend to underreport their actual weight more than men (63). 
Secondly, BMI might not indicate obesity in women as well as in men. It is known that the 
relationship between body weight and fat distribution varies by sex; women tend to 
accumulate visceral abdominal fat less with weight gain compared to men (55;64). 
Alternatively, adipose-driven estrogens might underlie the gender difference in the 
associations between BMI and risk for colorectal cancer. In the absence of postmenopausal 
hormone therapy, adipose tissue is a major source of estrogen in postmenopausal women. It 
has been reported that estrogen decreases bile acid production which reduces chronic 
irritation on the colonic mucosa, and inhibits cell proliferation, influences microsatellite 
instability, and increases the expression of vitamin D receptors (65). Given that estrogen has 
been negatively associated with risk of colon cancer in the literature, it is plausible that 
adipose-driven estrogens in obese postmenopausal women counteract some harmful 
influence caused by adiposity. This hypothesis concurs with several observations that the risk 
of colorectal cancer increases with increasing BMI for premenopausal women as it does for 
men (36).  
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In fact, it is possible that estrogen acts as a modifier in the association between BMI 
and colorectal cancer. In one study where women subjects were classified as estrogen 
positive versus negative based on menopausal status and use of hormone replacement therapy, 
there was a statistically significant increase in risk of colon cancer in comparison of BMI>30 
with BMI<23 among estrogen-positive women who hypothetically would not benefit from 
adipose-driven estrogen, but not among estrogen-negative women (66). However, another 
study based on US female health professionals found no such association (67), leaving this 
line of studies in need of further research.  
Obesity was also related to an elevated risk of colorectal adenomas, particularly large 
or advanced adenomas, suggesting that obesity might influence growth of adenomas rather 
than their development (62). In the prospective studies of Male Health Professionals (32), 
and Female Nurses (33), Giovannucci and colleagues found a stronger positive relation of 
BMI with large adenomas compared to any adenomas. A similarly stronger association for 
large adenomas was found in a French study (68), but not in a recent study conducted in 
Norway based on a colorectal-cancer screening trial population (69).  
In one study, visceral adiposity was examined in relation to risk of colorectal 
adenomas based on recently-recognized importance of anatomic distribution of body fat mass. 
However, the absolute amount of visceral adipose tissue measured using computerized-
tomograpy scan did not correlate with increasing risk of recurrent adenomas after 4 years of 
follow-up (9), which contradicts consistently positive relationship of BMI or waist 
circumference with colorectal adenomas. As the authors discussed, change in visceral 
adipose tissue over time might be a more important factor to influence risk of recurrent 
adenomas rather than the absolute amount of visceral adipose tissue at baseline (9). However, 
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it is hard to interpret the result of a single study with relatively small sample size (number of 
total subjects = 119) that contradicts findings from the previous literature.   
Finally, obesity increases risk for death attributed to colorectal cancer. Several 
prospective cohort studies have reported excess number of colon cancer deaths among 
overweight people compared to those with normal weight (70-73). Obesity might affect 
diagnosis or treatment of cancer as well as its biologic roles on development and progression 
of cancer (73).  
 
D. Suggested Mechanisms that Link Obesity to Colorectal Cancer 
Insulin, Insulin-like growth factor and colon cancer 
Several hypotheses have been proposed to account for the link between obesity and 
colorectal cancer. One involves hyperinsulinemia leading to increased bioavailability of 
insulin-like growth factor, which is known to promote proliferation and inhibit apoptosis 
(74;75).   
Excess weight or adiposity increases circulating levels of free fatty acids, which leads 
liver, muscle and other tissues to increase storage and oxidation of fats for energy and to 
reduce their capacities for glucose metabolism. Resistance of the body to the actions of 
insulin results in increased pancreatic production of insulin, and ensuing chronic 
hyperinsulinemia (36;76). 
 Increased insulin plays a procarcinogenic roles in the colon. Insulin is known to 
stimulate growth of normal colonic and carcinoma cells in vitro. Also, in Fischer 344 rats 
administered a single dose of azoxymethane, insulin was shown to enhance the growth of 
aberrant crypt foci, and increase the number and size of colon tumors (77). However, 
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procarcinogenic roles of insulin might play a more indirect role by regulating hepatic 
production of IGF-1, and hepatic secretion of IGFBP-1. Increased insulin levels, in turn, lead 
to reduction in blood levels of insulin-like growth factor binding protein 1 (IGFBP1), and its 
synthesis in the liver as well as local production, leaving more insulin-like growth factor 1 
(IGF-1) biologically available (36;78). 
 IGF-1 is a peptide growth hormone that inhibits apoptosis and promotes cell growth 
and proliferation by binding to the cell-surface IGF receptors (67). Both normal and cancer 
cells of colon express IGF-1 receptors in vitro. Activated by IGF-1, the receptor-ligand 
complex inhibits apoptosis and allows progression through the cell cycle. It is likely that 
increased cellular turnover enhances the rate at which specific molecular alterations 
accumulate (62). Additionally, in colon cancer cell lines, IGF-1 increases production of 
vascular endothelial growth factor, an angiogenic factor that supports tumor growth. There is 
also evidence in humans for the link between IGF-1 and colon cancer. Acromegaly is a 
condition characterized by chronic overproduction of growth hormone and IGF-1. It is 
known that patients with acromegaly are at elevated risk of developing both benign and 
malignant colorectal cancers (77). Epidemiologic studies have observed that higher levels of 
IGF-1 are associated with increased risk of colorectal cancer (79), and colorectal adenomas 
(80;81).  
 In addition to the potentially precancerous effects of insulin and IGF-1, insulin 
resistance itself also influences colon carcinogenesis by increasing energy availability, which 
could be utilized for transforming colonocytes as well as inducing changes in cell signaling 
pathways and stimulating reactive oxygen species synthesis (82). 
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Inflammation 
Another hypothesis involves inflammation. Adipose tissue is now recognized as an 
endocrine organ rather than a simple fat storage site. Among a wide range of protein factors 
released from adipose tissue are inflammation mediators such as IL-6 and TNF-α (44;83).  
Approximately 30% of the circulating IL-6 concentration is produced by adipose tissue (84). 
Circulating levels of the inflammation mediators are elevated in the obese (3) possibly by 
increased number of macrophages that are activated in obese individuals compared with that 
of lean persons (85), and the levels decrease after weight loss among the same subjects 
(86;87). Such positive relationships between obesity and inflammation markers appears to 
hold true for younger adults (17-39 years), and independent of other potential factors that 
might affect inflammation mediators such as smoking status, estrogen use, and even presence 
or absence of inflammatory disease, cardiovascular disease or diabetes mellitus (88). 
Furthermore, choice of measures of obesity does not affect the strong correlation between 
obesity and inflammation mediators (89). Altogether, this has led to the definition of obesity 
as a state of chronic systemic low-grade inflammation (3) . 
 Obesity-driven chronic inflammation might promote a procarcinogenic milieu. 
Further discussion of obesity-driven inflammatory mediators and their potential carcinogenic 
actions is followed in the next section titled “Inflammation and Colorectal Cancer.” 
 
 
1.2.3 INFLAMMATION AND COLORECTAL CANCER 
A. Introduction 
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Even before the biologic evidence for the procarcinogenic effects of chronic 
inflammation existed, inflammation was recognized as a part of carcinogenic process (90). 
Considering the long induction period of tumorigenesis, it is plausible that a certain cell 
environment such as stimulated proinflammatory systemic milieu could alter host cell 
susceptibility to carcinogenic insults (91).  
For colorectal cancers, there is ample evidence showing the role of inflammation in 
carcinogenesis. Inflammatory bowel disease is one of the strongest risk factor for colorectal 
cancer, and the risk of developing cancer increases with degree and duration of chronic 
inflammation (92). Also, studies have shown that genetic variations in inflammation-related 
genes such as IL-6, IL-8 and IL-10 alter susceptibility to colorectal cancer and adenomas 
(93;94). Furthermore, as a growing body of literature suggests, the effects of many known 
risk factors for colorectal cancers and adenomas might be mediated by inflammation. This 
section aims to define chronic inflammation and to evaluate evidence suggesting the role of 
chronic inflammation in carcinogenesis of the colon and rectum.  
 
B. Chronic Inflammation 
Definition of Chronic Inflammation 
Inflammation is the first line of immune defense against infection or irritation, and 
involves a signaling cascade of cytokines and chemokines in attempt to heal the afflicted 
tissue (95).  Inflammation is usually self-limited given that as healing progresses, cell 
proliferation and inflammatory responses subside by increasing the production of anti-
inflammatory cytokines compared to proinflammatory cytokines (96).  
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However, if the source of the tissue injury is not adequately cleared, inflammatory 
response can persist (97). Persistent inflammation can promote tumor growth by accelerating 
genomic instability and angiogenesis (95). It might also initiate tumor: in the chronic 
inflammation where adaptive immune response develops and constantly activates innate 
immune response, chronically activated innate immune cells such as leukocytes and 
phagocytic cells can cause DNA damage, and deregulated cytokine production and signaling 
as well as dysfunction of T-cells can lead the damaged cells to evade apoptosis (95;97;98) . 
 
Inflammation Mediators 
During the inflammatory response, a myriad of inflammation mediators is secreted 
into the bloodstream. CRP, TNF-α and IL-6 are among the most studied inflammation 
mediators based on their regulatory roles in inflammation, relevance in carcinogenesis, and 
detectability in serum as suggested in the literature.  
 
C-Reactive Protein  C-reactive protein (CRP) is an acute phase protein of which the plasma 
levels may rise dramatically, as much as 1000-fold or more, in response to an acute 
inflammatory stimulus. The protein was first identified in patients with pneumonia, and it 
was named after a protein (“C” polysaccharide) derived from the pneumococcal cell wall that 
CRP can precipitate (99). CRP is a reliable marker of non-specific response to inflammation 
because the plasma half-life of CRP is about 19 hours under all conditions, and the plasma 
concentration is determined solely by the hepatic synthesis rate, which reflects the intensity 
of the pathological process(es) stimulating CRP production (100). 
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Without acute inflammatory conditions, plasma CRP levels in normal adults are 
under 3 μg/ml, which was historically regarded as clinically insignificant (99). However, as 
high-sensitivity assays for CRP have recently become commercially available, it is largely 
agreed that the chronic low-level elevations in CRP levels might predict future risk of 
cardiovascular events (101-103).  
While anti-inflammatory activities of CRP appear to exist, proinflammatory activities 
have been more recognized. CRP upregulates the expression of adhesion molecules, inhibits 
endothelial nitric-oxide synthase expression in aortic endothelial cells, stimulates IL-8 
release from several cell types, increases plasminogen activator inhibitor-1 expression and 
activity, and increases the release of IL-1, IL-6, IL-18, and TNF-α (99). IL-6 is also a main 
inducer of CRP mRNA transcription, although the final synthesis of CRP protein undergoes 
further regulation during translation and post-translation processes (104). 
 
Interleukin-6  Interleukin-6 (IL-6) is a cytokine that can act as both pro-inflammatory 
and anti-inflammatory mediators (40).  Since plasma levels of IL-6 increase with age, 
dysregulation of IL-6 has been implicated in the pathogenesis of chronic diseases (105). In 
relation to carcinogenesis,  IL-6 appears to stimulate cell growth, and evade apoptosis  
(106;107). Recently, it was shown that adipose tissue is a major source of IL-6 secretion, 
accounting for up to 40% of the circulating levels (40). This concurs with numerous 
observations that circulating levels of IL-6 are positively correlated with increasing adiposity 
(89). It can be hypothesized that obesity as well as aging modifies circulating levels of IL-6 
and induce procarcinogenic changes.  
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Tumor Necrosis Factor – alpha   Tumor necrosis factor – alpha (TNF-α) is a key 
cytokine that orchestrates the array of cytokines during the inflammatory responses (97).  As 
the name implies, TNF-α was first identified as a host-induced substance selectively toxic to 
tumor cells (108). However, it appears that TNF-α kills tumor cells at large, cytotoxic doses, 
and it mostly promotes cellular proliferation and inhibits apoptosis probably by inducing NF-
κB (97). In previous studies, TNF-α mRNA expression was substantially higher in obese 
individuals than lean individuals, and the adipose production of TNF-α was also higher in 
obese individuals (109;110).   
 
C. Evaluation of Risk factors for Colorectal Cancer in the Context of Inflammation 
Several factors have been associated with risk of colorectal cancer and adenomas. As 
a growing body of literature suggests, some of these risk factors for colorectal neoplasia 
might be mediated by inflammation. 
 
Age 
Like many cancers, the incidence of colorectal cancer and the prevalence of 
adenomas both increase with advancing age (7;8;111). Although it is well accepted that aging 
affects immune response, it remains unknown how the modified immunity contributes to the 
increasing occurrence of cancers (112). Hypothetically, age-associated debilitating regulatory 
function of immune response might create a pro-cancer cellular environment (113). With 
recently increasing interest in inflammation as a pathway to many different disease outcomes, 
several inflammation mediators were studied, and CRP and IL-6 were positively associated 
with chronological age or some manifestations of aging such as frailty, muscle and bone 
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mass or anemia (114-116). However, it remains controversial whether the rise of these 
mediators is really the consequence of aging or simply the reflection of underlying health 
conditions that are more common with increasing age (117).  
 
Body mass index/obesity 
High BMI and obesity are known to increase risk of colorectal cancer and adenomas 
(118;119). As discussed in detail in the section titled “Obesity and Colorectal Neoplasia,” 
two main hypotheses - hyperinsulinemia (120;121) and inflammation (122) - have been 
proposed to explain an effect of obesity on colorectal neoplasia.   
The inflammation pathway was suggested based on the data showing that circulating 
levels of the inflammation mediators were elevated in the obese individuals than lean 
individuals (3), and the levels of the inflammation mediators decreased after weight loss 
among the same subjects (86;123). It is now known that adipose tissue produces and secretes 
inflammatory cytokines such as TNF-α and IL-6, and the amount of the proinflammatory 
cytokines released from adipose tissue is increased in proportion to adipocyte number and 
volumes (42).   
 
Physical Activity 
According to Nicklas et al.’s recent review (124), high level of physical activity and 
fitness were associated with decreased levels of CRP and proinflammatory cytokines 
including IL-6 and TNF-α, independent of obesity. It is known that a single bout of acute 
exercise stimulates proinflammatory cytokine production. On the contrary, regular long-term 
exercise might reduce levels of inflammation mediators, particularly IL-6 production from 
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skeletal muscle (125). It could be a potential mechanism by which a physically active 
lifestyle plays a protective role against colorectal adenomas and cancer (34;126;127).  
 
Smoking 
Smoking has been associated with increased risk of colorectal adenomas (128), 
whereas it has been less consistently associated with colorectal cancer (15). It was shown that 
smoking increased circulating levels of CRP (129-131) and the effect of smoking on the 
inflammation mediators appeared to persist for several years after smoking cessation (132). 
Smoking was also associated with elevated IL-6 (129). However, it is not determined 
whether elevated inflammation mediators were due to tissue damage smoking might have 
caused, or via affecting coagulation factors (132).  
 
Non Steroidal Anti-Inflammatory Drugs (NSAIDs) and selective COX-2 inhibitors 
Aspirin and a class of drugs known as non-steroidal anti-inflammatory drugs 
(NSAIDs) have been consistently associated with reduced risk of colorectal adenomas and 
cancer and in observational studies (133-140) and randomized clinical trials (141;142). COX-
2, an inducible form of cyclooxygenase is a well-known pharmacological target of the 
NSAIDs (143). The selective COX-2 agent, celecoxib was shown to reduce polyp burden in 
familial adenomatous polyposis patients compared to a control group (144). COX-2 is 
overexpressed in colon cancer cells (143) and it has been suggested that COX-2 is implicated 
in carcinogenesis through several mechanisms including inhibition of apoptosis, modulation 
of cellular adhesion and motility, promotion of angiogenesis, and immunosuppression (145). 
Cytokines are involved in many of these mechanisms possibly via NF-κB, a transcription 
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factor regulating various inflammatory, apoptotic and oncogenic genes. TNF-α as well as 
COX-2 is one of the key inducers of NF-κB (146). There is indirect evidence for the 
involvement of inflammation in the pharmacologic mechanism of NSAIDs. In the analysis of 
a randomized placebo-controlled trial, aspirin appeared to provide greater risk reduction for 
colorectal adenomas among obese patients than lean patients (147). This agrees with a 
significantly greater risk reduction for myocardial infarction in patients with higher CRP 
compared to lower CRP by aspirin (103).  
 
Apoptotic activity  
Given that tumors arise from an imbalance between cell proliferation and apoptosis, it 
is expected that such an imbalance between proliferation and apoptosis could explain the 
adenoma to carcinoma sequence. Several studies have reported decreased apoptosis 
associated with increased risk of adenoma occurrence (134) and adenomas with villous 
architecture (148). Increased apoptotic activity was also correlated with regression of polyps 
among Familial Adenomatous Polyposis patients (16).  However, it is poorly understood how 
apoptosis is modified in the sequence of colon tumor development. COX-2-mediated 
mechanism might play a role in suppression of apoptotic capability in colon carcinogenesis. 
Increased apoptotic activity by NSAIDs(149;150) and the selective COX-2 inhibitor, 
celecoxib (16) have been reported. Cytokines also can influence apoptotic capability in 
epithelial cells. TNF-α shares NFκB-mediated mechanism with COX-2 (146). 
 
D. Epidemiologic Studies of Inflammation Mediators and Colorectal Cancer 
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Based on accumulating evidence suggesting the involvement of inflammation in 
colorectal carcinogenesis, several studies directly examined effects of systemic inflammation 
on pathogenesis of colon tumor. Four epidemiologic studies have been published on the 
associations of CRP with incident colorectal cancer, and provided mixed results, summarized 
in the table 1.6.   
A study by Erlinger et al. (151) was a nested case-control study in the CLUEII cohort 
of 22,887 adults after the maximum of 11 years of follow-up period. Based on 172 colorectal 
cancer cases and 342 controls matched by age, sex, race and date of blood draw, they found a 
significantly higher odds ratio of 2.55 (95% CI: 1.34-4.88) for colorectal cancer among the 
highest quartile of CRP (> 3.69mg/L) at baseline compared to the lowest quartile (<0.92 
mg/L) after adjustment for age, sex, smoking status, BMI, hormone use, and use of aspirin 
and NSAIDs. The finding was supported by two other nested case-control studies. In a case-
control study nested in the Alpha Tocopherol, Beta Carotene (ATBC) Cancer Prevention 
Study cohort of male smokers, the relative risk of developing colorectal cancer in the highest 
quartile (>4.9 mg/L) compared to the lowest quartile (<1.4 mg/L) was 2.9 (95% CL: 1.4-6.0) 
(152). Similarly, higher levels of CRP at baseline were associated with elevated risk of 
incident colorectal cancer in the Japan Public Health Center cohort (OR = 1.6, 95% CI:1.1-
2.5) (153). 
On the other hand,  Zhang et al. (154) did not find statistically significant associations 
between CRP and incident colorectal cancer among female participants in the Women’s 
Health Study.  After adjusting for randomized treatment assignment (low dose aspirin and 
vitamin E) and other covariates, the hazard ratio for distal colon was estimated to be 1.27 
(95% CI: 0.59-2.73) for CRP>3mg/L compared to CRP<1.0mg/L at baseline. The highest 
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level of CRP was inversely related to proximal colon (HR=0.44: 95% CI: 0.22-0.89) and 
rectum cancers (HR=0.44: 95% CI: 0.18-1.08). The relative risk of the highest serum CRP 
levels at baseline was 1.18 (95% CI: 0.68-2.06) for colorectal cancer and 1.42 (95% CI: 0.73-
2.74) for colon cancer in the Japan Collaborative Cohort Study (155). 
 Contradictory findings in the current literature are hard to reconcile. The discrepant 
results might be attributed to gender distribution of the study populations. Several earlier 
studies on CRP in relation to cardiovascular events reported the association only in men, but 
not in women. A recent meta-analysis has shown a stronger association between CRP and 
cardiovascular disease in men compared to women (101). Alternatively, the associations of 
CRP with colorectal cancer might vary by tumor location. It is possible that CRP level was 
positively, albeit statistically not significantly, associated with risk of colon cancer in the 
studies by Zhang et al (156)  and Ito et al. (155), whereas there appeared to be no association 
of serum CRP with rectal cancer.  
One study examined IL-6 and TNF-α in relation to cancer. Among older adults (aged 
70-79 years) participating in the Health Aging and Body Composition  study (157), higher 
levels of IL-6 and TNF-α as well as CRP were associated with increased risk of incident 
cancer and cancer deaths. Although the authors did not present cancer site-specific estimates 
of the associations due to small samples, it was suggested that serum levels of IL-6 and CRP 
were positively associated with colorectal cancer.  
 
E. Markers of Inflammation 
As with other biomarkers, one time measurement of plasma levels of inflammation 
mediators may not represent an individual’s overall inflammatory status. Given that the 
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inflammatory response is a dynamic process that involves a complex interaction between 
inflammation mediators in response to non-specific stimuli, the biologic nature of the 
inflammatory system as well as measurement errors are thought to affect levels of 
inflammatory cytokines (158). 
 
Reproducibility over Time 
 CRP can be a reliable marker of systemic inflammation over time. In a longitudinal 
analysis of healthy blood donors (159), blood was drawn 3-5 times over 6 months from 26 
individuals, and drawn up to 12 times over 7 weeks from 4 individuals for CRP assay. The 
study showed that CRP levels are tightly regulated over 6 months, and relatively stable for 7 
weeks despite the presence of short-term fluctuations.    
 
Factors Affecting Circulating Levels of Inflammation Mediators 
Seasonal Variation Increased incidence of cardiovascular events during winter months 
lead to research concerning higher levels of inflammation mediators during those times. 
However, there was no significant intra- and inter-individual seasonal variation in CRP level. 
That is, plasmas taken in winter did not have systematically higher or lower levels of CRP 
compared to plasmas taken at other months (160). 
  
Diurnal Variation Both in vivo and ex vivo studies have shown that the IL-6 level is low 
in the morning and high just before bedtime possibly due to feedback inhibition by 
endogenous cortisol, which is subject to circadian variation (161). Given that IL-6 is a main 
inducer of circulating CRP (105), it is plausible that CRP can follow the circadian variation 
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of IL-6. In one environment-controlled study of 13 healthy subjects, however, CRP levels 
showed a remarkable stability throughout the course of the 24 hours of a day (161). 
  
Fat-rich Diet High intake of saturated fat, trans fat, and cholesterol is positively associated 
with increased concentrations of CRP and IL-6 (162). Ingestion of fat meal also leads to a 
substantial increase in circulating IL-6 and a transient decrease in TNF-α. On the other hand, 
ingestion of the fat meal did not lead to any significant variation in plasma CRP levels (163).  
 
Stress-level Chronic activation of stress system can suppress immune response by 
activation of corticotrophin-releasing hormone (164). On the other hand, a stressful event 
might induce a short-term increase in plasma levels of CRP, IL-6 and TNF-α (165). 
 
 
1.2.4 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND COLORECTAL CANCER 
A. Introduction 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used of 
all therapeutic agents. They are indicated for arthritis, fever, injuries, or menstrual cramps 
due to their analgesic, anti-pyretic, and anti-inflammatory properties (166). NSAIDs, 
particularly aspirin, have also shown anti-thrombotic activity. Primary and secondary 
prevention of cardiovascular events with aspirin have been well documented (167). In 
addition, a wide range of studies indicates chemopreventive potential of NSAIDs. This 
section evaluates several aspects of NSAIDs to be considered as a chemopreventive agent 
against colorectal neoplasia. 
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B. Non-Steroidal Anti-Inflammatory Drugs 
Definition of NSAIDs 
NSAIDs is a collective term to indicate drugs used to relieve inflammation, swelling, 
stiffness, and fever. As the name implies, they are distinguished from steroidal anti-
inflammatory drugs like glucocorticoids (166). NSAIDs comprises a variety of drugs 
including some common medications like aspirin, sulindac, ibuprofen, naproxen and 
piroxicam (168). 
NSAIDs have diverse chemical structures, and they vary in their strength, duration of action, 
and the way in which they are eliminated from the body. However, NSAIDs share similar 
therapeutic properties, and depending on the dose, they share similar adverse effects profiles 
(169).  
 
Prostaglandin Pathway 
The common therapeutic actions of NSAIDs are driven through inhibition of 
prostaglandin pathway either by competing with arachidonic acid for binding or by 
modifying structure of COX enzyme(170). Prostaglandins (prostanoids) are eicosanoids, and 
they acts as autocrine and paracrine lipid mediators to signal changes within the immediate 
environment. Prostaglandins are not stored but are produced by various cells.  
The prostaglandin synthesis starts with the oxidative cyclization of arachidonic acid, 
which is released by phospholipase A2 from the cell membrane. Arachidonic acid is an 
essential fatty acid consumed in the diet, or derived from dietary linoleic acid (171). The free 
arachidonic acid is then catalyzed by cyclooxygenase (COX) enzymes to intermediate 
prostaglandin H2 (PGH2). And depending on cell types and physiological conditions like 
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level of COX, the PGH2 is converted to various prostaglandins involved in diverse functions 
including blood clotting, ovulation, initiation of labor, bone metabolism, nerve growth and 
development, wound healing, kidney function, blood vessel tone, or immune responses 
(170;172). For example, endothelial cells primarily produce PGI2, whereas platelets mainly 
produce (TX)A2. Human colonic mucosa is known to be capable of synthesizing all of the 
PGE2, PGF2α, PGI2 and thromboxane (TX)A2, while tumors produce PGE2 most commonly 
compared with the surrounding normal mucosa (171). PGE2 concentration is increased in 
colon cancer tissues where COX-2 is overexpressed (143).  
 
Cyclooxygenase 
Cyclooxygenase (COX) is the enzyme catalyzing formation of prostaglandin from 
arachidonic acid. COX was identified as a pharmacologic target of NSAIDs in early 1970s 
which was soon after the prostaglandin synthesis pathway became known (170).  
There are two types of COX enzymes.  COX-1 is constituitively expressed, and is 
responsible for maintaining gut lining, and therefore, the inhibition of COX-1 is related to 
unwanted side effects of NSAIDs. COX-2 is an inducible form of cyclooxygenase, and it was 
identified later in 1990s. Since its discovery, the therapeutic effects of NSAIDs have been 
attributed to COX-2. COX-2 is known to be responsible for the synthesis of prostaglandins 
that mediate inflammation (172;173). COX-2 is expressed in response to proinflammatory 
and mitogenic stimuli, such as growth factors (epidermal growth factor, vascular endothelial 
growth factor, fibroblast growth factor) and cytokines (TNF-α, IL-1α and 1β), and certain 
mutations such as v-src, v-Ha-ras, HER-2/neu, and Wnt (173;174). COX-2 is also activated 
by nitric oxide through heme oxidation, or indirectly through the production of peroxynitrile 
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and hydroxyl radical, leading to increased lipid peroxidation(143). On the other hand, APC 
(175), and IL-13, IL-10 and IL-4 (143;173) were shown to downregulate COX-2.  
 
C. Chemopreventive Efficacy of NSAIDs 
Several studies have reported overexpression of COX-2 in cancer cells (173). COX2 
mRNA and protein both were expressed in up to 90% of colon cancer, and 40% of adenomas, 
but less or not expressed in hyperplastic polyps or normal mucosa. Expression level has also 
been positively correlated with tumor recurrence in advanced cancer (176). Together with the 
fact that COX-2 is a pharmacological target of NSAIDs, these data support the role of the 
COX2 in carcinogenesis, in particular of colon, and have lead to various investigations of 
NSAIDs as an anti-cancer agent. 
 
Animal Studies 
The effects of NSAIDs on colorectal cancer growth have been tested in three different 
animal models including Apc min mouse, azoxymethane-treated rat, and the nude mouse 
xenograft assay. In the Apc min mice that are predisposed to develop multiple adenomas of 
the gastrointestinal tract, the number of polyps decreased when the Apc mice were bred with 
a COX knockout mouse, or treated with COX-2 inhibitor, suggesting that COX-2 plays a key 
role in the adenoma formation (177). Likewise, other NSAIDs such as indomethacin, aspirin, 
and piroxicam proved to be potent suppressors of colorectal cancer cell growth by reducing 
the number and size of colon tumors of azoxymethane-treated rodents as well as colon cancer 
cells of athymic mice in a dose-dependent manner (172;173). 
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Studies of Patients with FAP 
In humans, the anti-cancer activities of NSAIDs were first noted in patients with 
familial adenomatous polyposis (FAP). When sulindac was given to FAP patients, the 
number and size of rectal polyps were dramatically reduced (178). The efficacy of sulindac 
in regression of polyp burden was established in the several randomized, placebo-controlled 
trials (173).  
 
D. Epidemiologic Studies of NSAIDs and Colorectal Neoplasia 
Since the late 1980s numerous epidemiologic studies have reported that those who 
regularly take NSAIDs have a lower incidence of colorectal adenomas, invasive colorectal 
cancer, and death attributed to colorectal cancer compared with non-users. Results from 
observational epidemiologic studies and randomized controlled trials are summarized and 
discussed in this section. 
 
Observational Studies of NSAIDs and Colorectal Cancer 
Thirty six potentially relevant references were identified through PubMed Search and 
a recent review (170) of this topic. Out of 24 studies, two were excluded because they 
examined the association of sulfasalazine (5-aminosalicylate) intake with colorectal cancer 
among patients with ulcerative colitis (179) or inflammatory bowel disease (180). Since 
sulfasalazine acts as a bacteriostatic agent as well as an anti-inflammatory agent in the 
intestine (179), it is not relevant to include the studies in this summary. Additionally, two 
studies were excluded because they attempted to suggest an inverse association between 
 33
NSAIDs and colorectal cancer by reporting a lower incidence of colorectal cancer among 
patients with arthritis than in the general population (181;182).  
A total of 20 studies directly evaluated the association between NSAIDs and colon 
cancer and are presented in tables 1.7 and 1.8. In most of the studies NSAIDs were 
collectively evaluated as a single exposure in relation to colorectal cancer except for aspirin. 
Most studies defined regular use as at least 2-3 times of use per week, and the 
regular/consistent users were defined as an exposed group. However, the duration of the 
consistent usage was not uniformly defined among studies; it ranged from 1 month (183) to 
more than 1 year (184-186), or was otherwise unspecified (187).   
Overall, regular use of NSAIDs was inversely associated with risk for colon cancer 
with the exception of one study conducted in a California retirement community (187). 
However, the study was distinguished from others in that it was composed of an elderly 
population with median age of 73. During a defined time period, more frequent (186;188) 
and high dosage (189) was more strongly associated with risk reduction in colon cancer. On 
the other hand, longer duration of usage was not associated to stronger risk reduction. Dose-
response relation is difficult to assess in observational studies. This is particularly true for 
NSAIDs, which are often intermittently used to relieve pain due to dysmenorrhea, headaches, 
and injuries (190).  
Although the direction of the association between NSAIDs and colon cancer is 
amazingly consistent in the epidemiologic literature, there is considerable variation in 
magnitudes of risk reduction among studies. For example, aspirin taken more than 3 times 
per week was associated with an odds ratio (OR) for colon cancer of 0.08 (95% CI: 0.02-
0.59) in one study (191), but 0.7 (95% CI: 0.6-0.8) in a different study (183). Such variation 
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could be due to characteristics of the study population, site of cancer, or more detailed 
classification of exposure.  
In terms of population characteristics, regular use of NSAIDs has been shown to be 
similarly protective in both sexes (183;186), although women were shown to benefit more 
from NSAIDs compared with men in one case-control study (184). On the other hand, it 
cannot be easily determined at this time whether NSAIDs act differently depending on 
anatomic site of cancer. An Italian study (192) found reduced risk for rectal cancer (OR = 0.4, 
95% CI: 0.2-0.9) with regular use of aspirin, but not for colon cancer. Stronger inverse 
association with rectal cancer was also reported by Collet and collegues (190). However, the 
findings were not confirmed in the other two studies (189;193;194).     
 There has been an attempt to compare strength of association among individual 
NSAIDs. Except for aspirin, however, small numbers of users of each drug, and the 
subsequent loss of statistical power (185) have made it difficult to evaluate individual change. 
One of the earliest studies (193) has reported slightly higher point estimates with non-aspirin 
NSAIDs compared with aspirin, and yet, the 95% confidence intervals of two estimates 
mostly overlapped. Later, two pharmacy records-based studies evaluated aspirin separately 
from non-aspirin NSAIDs. However, results from the two studies contradict each other. 
While Peleg and collegues (191) reported stronger association with aspirin compared with 
non-aspirin NSAIDs, risk reduction was only observed with non-aspirin NSAIDs in the other 
study (195). Such inconsistency is not unexpected, taking consideration of various dosage 
and forms of drugs grouped into NSAIDs or aspirin.  
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Alternatively, different magnitudes of association found in the literature could be 
explained by differences in exposure assessment, definition/classification of exposure, 
prevalence of exposure in the study population, and selection of adjustment variables.     
Exposure assessment is potentially critical in determining variation in study results, 
given that it subsequently affects other differences between studies. In the literature, 
information on NSAID use was collected using questionnaire (either via interview or self-
administration) or pharmacy records. In general, exposure assessment based on questionnaire 
suffers from recall bias in both retrospective and prospective studies, whereas the recall bias 
would not systematically differ by case status in the prospective studies. On the other hand, 
drug claims data provide more accurate information on timing, dosage, and duration of 
NSAID use. However, since not all the prescriptions are filled, and not all the filled 
prescriptions are really taken, the information based on drug claims data might reflect 
indication of prescription of certain drugs rather than usage of the drugs. Moreover, the 
database includes only prescription drugs, which are often taken in higher doses compared 
with over-the-counter drugs. 
On the other hand, use of the same method does not ensure the same quality in 
exposure assessment. For example, Schreinemachers’s study (196) is based on NHANES, 
and its representativeness of the U.S. population could be an important strength to this study. 
However, aspirin exposure was assessed using a single question asking ever use of aspirin 
during 30 days prior to the interview. Since such a definition of the exposed group 
encompasses a wide variety of frequencies, and is not likely to reflect regular use of aspirin 
over years, the validity of the study is questionable. In fact, the proportion of exposure group 
may have been overestimated in this study with prevalence of aspirin users of 59% (196).  
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 Lastly, the selected effect measure will affect the magnitude of association. At a 
glance, odds ratio estimates from case-control studies summarized in table 1 are generally 
further away from the null compared to those from cohort studies in table 2. Odds ratios are 
further away from the null compared with risk ratios and rate ratios using the same dataset.  
In summary, despite the wide range of strength in the association, epidemiologic 
literature provides consistent inverse association between NSAIDs and colorectal cancer in 
diverse populations.  
 
Observational Studies of NSAIDs and Colorectal Adenomas 
Colorectal adenomas are well-established precursors of colorectal cancer (197). 
Evaluation of the associations between NSAIDs and colorectal adenomas would shed light 
on whether or not an early step of colon carcinogenesis is also interrupted by NSAIDs.  
Using a PubMed Search and one of the most recent review papers on this topic (170), 
twelve epidemiologic studies were found as to the association between NSAIDs and 
colorectal adenomas.  However, one study (135) was excluded because its definition of 
outcome included hyperplastic polyps as well as adenomatous polyps. Hyperplastic polyps 
are traditionally considered to be non-neoplastic (198). Although more recent studies have 
identified hyperplastic polyps with evidence of the epithelial dysplasia (also known as 
serrated adenomas), it is not likely that the serrated adenomas follow the same carcinogenic 
pathway as adenomatous polyps (199).  
Features of the selected 11 studies are presented in tables 1.9 and 1.10. In most of the 
studies, presence or absence of adenomas was ascertained using colonoscopy only (134;200-
202), sigmoidoscopy only (133;140;203), or colonoscopy or sigmoidoscopy (139;204). On 
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the other hand, another three studies (137;188;205) defined cases based on a diagnosis of 
polyps from medical records, and absence of adenomas was not verified among controls. 
Given that adenomas are very common in the adult population with a prevalence estimated to 
be up to 30-50 percent (7;8), these three studies could not be free from validity issues due to 
potential false negatives among controls.  
In general, studies agreed on the inverse association between use of aspirin and other 
NSAIDs and the occurrence of colorectal adenomas. Using results from the studies that 
evaluated colorectal adenomas and cancer within a single setting, the strength of the 
associations with NSAIDs could be compared between adenomas and cancer. Suh (188) and 
Giovannuci (133) reported a stronger association of NSAIDs with colorectal cancer 
compared with adenomas. Garcia-Rodriguez (137) also found a similar result in non-aspirin 
NSAIDs, but not in aspirin. Some studies also assessed the association with advanced 
adenomas, separately from any adenomas. Although one sigmoidoscopy-based screening 
trial in Norway (203) did not find a stronger association of NSAIDs with distal advanced 
adenomas compared with any distal adenomas, in a secondary analysis of the Polyp 
Prevention Study I after 3 years of follow-up, Tangrea and colleagues (202) observed 
stronger associations of NSAIDs and aspirin with advanced adenomas (defined as lesions that 
had a maximal diameter of at least 1 cm or at least 25 percent villous elements or evidence of 
high-grade dysplasia, including carcinoma). It is likely that NSAIDs could have anti-
carcinogenic activity in both initiation and promotion/progression stages of colon 
carcinogenesis.    
 
Randomized Placebo-Controlled Trials  
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Although NSAIDs have been consistently associated with reduced risk of colorectal 
cancer and adenomas in observational epidemiologic studies, there has been concern that the 
risk reduction with use of NSAIDs might reflect the effect of lifestyle or health behaviors of 
the NSAID users rather than the medication itself (206). A recent study attempted to resolve 
this issue by showing a null association between paracetamol (acetaminophen) use and colon 
cancer (195). However, it is not likely that paracetamol users share the same or similar 
baseline characteristics with NSAID users, given that cardioprotection with NSAIDs, 
especially aspirin, has been publicized for almost a decade.  
 Without convincing evidence from randomized placebo-controlled trials, NSAIDs 
could not be utilized as a chemopreventive agent in the general public in the near future. To 
date, there have been five randomized trials of aspirin or aspirin derivative, and two trials of 
selective COX-2 inhibitors to prevent colorectal neoplasia in population-based subjects 
(Tables 1.11 & 1.12).  
Two studies have examined effects of aspirin on colorectal cancer in a randomized 
placebo-controlled setting. The Physicians’ Health Study (207) was a study of 325 mg of 
aspirin on alternate days in association to self-reported colorectal adenomas or 
incidence/death rates from colorectal cancer, and the Women’s Health Study (208) was a 
study of 100 mg of aspirin on alternate days. However, the two studies did not find any 
statistically significant risk reduction in colorectal cancer. The conflicting results with the 
findings of observational epidemiologic studies has promoted active discussion. First, 
duration of aspirin treatment could be relatively short to modify risk of colorectal cancer 
(194;209). Second, 325 mg of aspirin every other day as well as 100 mg might be lower than 
the dose employed by regular aspirin users defined in most of the epidemiologic literature 
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(207). Third, the physicians and women health professionals in these trials might have been 
compliant with risk-reducing life-styles including better utilization of screening procedures 
(205), and might not have benefit from any further chemopreventive agent. Additionally, it 
should be noted that in these trials information about polyps or cancer at baseline and at the 
end of the trial was not systematically collected  (170;209), and the participating individuals 
were not uniformly examined with colonoscopy. 
The other five studies evaluated effects of aspirin or selective COX-2 inhibitors on 
colorectal adenomas because it is not feasible to conduct chemoprevention clinical trials 
employing colon cancer as an endpoint due to the lengthy process of colorectal cancer 
development, and the availability of endoscopic polypectomy as an effective cancer 
prevention measure for screened populations (178). In all the five trials, study subjects 
underwent polypectomy before randomization to treatment.  
In a trial of patients with previous colorectal cancer (210), risk of colorectal 
adenomas was significantly reduced with 325 mg of daily aspirin use during an interim 
analysis after an average of 12.8 months of treatment. The significant risk reduction in the 
intervention group led to the early termination of the trial. On the other hand, no statistically 
significant risk reduction was observed with the same dose of aspirin in Baron’s study based 
on 1,121 post-polypectomy patients, while 81mg of aspirin was shown to render up to 20% 
of risk reduction in colorectal adenomas (209). In this trial, the magnitude of risk reduction 
was stronger with advanced adenomas as an endpoint, compared with any adenomas. 
Likewise, one year treatment with lysine acetylsalicylate was associated with stronger risk 
reduction in advanced adenomas compared with any adenomas, although none of the 
associations reached statistical significance (211).  
 40
Recently, there were trials of selective COX-2 inhibitors (coxibs) in preventing 
colorectal adenomas, given gastrointestinal toxicity of non-selective NSAIDs through 
inhibition of COX-1, which is responsible for maintaining gut mucosa. Both celecoxib and 
refecoxib have been shown to be protective in preventing colorectal adenomas, and also, 
there was a stronger protection in preventing advanced adenomas (212;213).  
 
E. Suggested Mechanisms of Action of NSAIDs 
Several mechanisms have been proposed to explain protection from NSAIDs in the 
development of colon cancer. Most popular is so-called COX-dependent mechanism, which 
involves the blockage of the cyclooxygenase (COX) enzymes.  
There are several lines of evidence linking COX-2 to mechanisms of malignant 
change of the colon. Firstly, although there is variation in the proportion of COX-2 positive 
cells in clinical colon cancer samples estimated to be 40-100% (143), numerous studies 
established markedly increased expression of COX-2 protein in human colorectal cancer 
cells in comparison with normal colonic tissues (173). Secondly, studies have shown that 
COX-2 induces angiogenesis, which is essential for tumor growth (143). Co-localization of 
angiogenesis factors, such as VEGF, PDGF, basic fibroblast growth factor, and tumor growth 
factor-β (TGF-β) with COX-2 was evidenced in immunihistochemical staining studies (143). 
The use of in vitro models of colon cancer cells showed that overexpression of COX-2 
produced angiogenesis factors, and stimulated endothelial migration and tube formation. The 
angiogenesis was effectively suppressed by by NS-398 (a selective COX-2 inhibitor), and by 
aspirin (214). Another procarcinogenic potential of COX-2 overexpression includes 
resistance to apoptosis (176). Using the rat intestinal epithelial cells, Tsujii and Dubois 
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showed that overexpression of COX-2 resulted in increased adhesion to extracellular matrix, 
and a resistance to butyrate-induced apoptosis, which was mediated by increased expression 
of the anti-apoptotic factor BCL-2 and TGF- β (215). 
 While knowledge about the COX-2 mediated anti-carcinogenic actions of NSAIDs is 
expanding, evidence supporting COX-2 independent mechanisms is also emerging at the 
same time. Such mechanisms involve leukocyte lipid-formation mediated by the inhibition of 
NF-κB (176), or are mediated by interfering with the binding of PPARδ to DNA (23). 
However, in a strict sense, the newly suggested mechanisms may not be called COX-2 
independent,  and also they often utilize concentrations of NSAID (100-100μM) that are 
difficult to achieve in humans without severe toxic side effects (176). Therefore, COX-2 will 
remain as a hot topic in studies of anti-carcinogenic actions of NSAIDs for a while.    
 
F. Adverse Effects of NSAIDs 
Before closing this section, potential risk associated with preventive usage of 
aspirin/NSAIDs should be discussed. Gastrointestinal disorders are the most common and 
potentially serious side effects related to NSAIDs: at least 10-20% of patients taking an 
NSAID experience dyspepsia at some points during the treatment (216). In general, 
gastrointestinal toxicity is considered to be dose-dependent. However, even with low (174) 
doses of aspirin, the incidence of serious gastrointestinal bleeding was increased by two 
times compared with placebo (217). In addition, given a large proportion of population who 
would get exposed to NSAIDs during a lifetime, the risk of NSAID-related gastrointestinal 
bleeding, and subsequent cost cannot be ignored.  
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Recently, selective COX-2 inhibitors received attention as a novel agent with fewer 
gastrointestinal complication without compromise in the efficacy of NSAIDs (174;217-219). 
However, the selective COX-2 inhibitors turned out to have specific adverse effects such as 
increased risk of myocardiac infarction and stroke due to imbalance between prostacyclin 
and (TX)A2 (220). COX-2 is a major source of prostacyclin, which is an antithrombotic 
prostaglandin that inhibits platelet aggregation, vasoconstriction and vascular proliferation. 
By contrast, (TX)A2, the most important COX-1 product of platelets, induces 
vasoconstriction (220). 
In addition to efficacy profiles of NSAIDs as a chemopreventive agent in colon 
carcinogenesis, it is critical to carefully examine the safety profiles. Such effort will also help 
to identify a group of the population who potentially might take best advantage of NSAIDs 
as chemopreventive agent. 
 
G. Summary 
  NSAIDs are the most widely used class of drugs, with more than 70 million 
prescriptions and more than 30 billion over-the-counter tablets sold annually in the United 
States (216). Numerous epidemiologic studies have shown strongly consistent inverse 
associations between regular use of NSAIDs and colorectal cancer and adenomas. Although 
the mechanism of actions for NSAIDs in colon carcinogenesis remains unclear, the anti-
carcinogenic potential of NSAIDs is generally agreed. Recently, results from a few 
randomized placebo-controlled trials of aspirin ad Coxibs have become available, and yet, 
the benefits of the medications as a chemopreventive agent against colorectal cancer are far 
from convincing, especially given the recognized complications, and very low margin for 
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toxicity in the administration of prophylactic drugs (170).  Nevertheless, aspirin and NSAIDs 
are among the most promising chemopreventive agents (5;23). It is not likely that 
aspirin/NSAIDs will prevent colorectal cancers in all patients. By examining variation of 
chemopreventive efficacy and agent toxicity by subgroup of the population as well as 
evaluating preventive effects of NSAIDs in combination with other preventive measures 
(178), potential target population for this promising agent could be identified. 
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1.4 Table 
Table 1.1 Case-control studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure 
assessment 
Exposure definition Relative risk (95% CI) Adjustment variables 
Graham 
1988 (60) 
NY USA Case 205; 
controls 205 
Height/weight self-
reported 
BMI (Q4 vs. Q1) 
Cecum/ascending 
  Men 
  Women 
Transverse/descending 
  Men 
  Women 
Sigmoid 
  Men 
Women 
 
 
 
2.29 (0.94-5.56) 
1.88 (0.79-4.48) 
 
2.64 (1.05-6.62) 
1.52 (0.54-4.31) 
 
2.13 (0.98-4.62) 
2.21 (1.06-4.61) 
Age, education, and 
intakes of fat calories and 
dietary fiber 
West 1989 
(221) 
Utah, USA Cases 231; 
controls 391 
 BMI (Q5 vs. Q1) 
   Men 
   Women 
 
2.1 (1.0-4.6) 
2.3 (1.1-4.9) 
 
Age, dietary fiber intake 
and energy intake 
Kune 1990 
(222) 
Australia Cases 715; 
controls 727 
 
Height/weight self-
reported 
BMI  (≥ 31 vs. 20-25) 
   Men 
   Women 
 
1.7 (0.8-3.6) 
0.71 (0.4-1.4) 
 
Age, intakes of dietary 
fiber/vegetables/crucifero
us vegetables/vitamin 
C/pork/fish and other 
meats, milk drinks, fats 
and beef 
 
Dietz 1995 
(59) 
Women only, 
WI, US 
Cases 779; 
controls 2,315 
Height/weight 5 
years prior to 
diagnosis self-
reported 
 
Weight (Q4 vs. Q1) 
Left colon 
Right colon 
Rectal 
 
OR 
2.2 (1.4-3.5) 
0.9 (0.8-2.0) 
1.1 (0.7-1.7) 
Age, family history of 
colorectal cancer, 
screening sigmoidoscopy 
history, and height 
Slattery 
1997 (35) 
USA Cases 2,073; 
Controls 2,466 
Height measured; 
weight self-
reported 
BMI (Q5 vs. Q1) 
  Men 
  Women 
 
 
1.94 (1.49-2.54) 
1.45 (1.08-1.94) 
 
Age, energy intake, 
family history of 
colorectal cancer, aspirin 
and other NSAIDs use, 
physical activity, and 
dietary intake of fiber and 
calcium 
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Table 1.1 (cont.) Case-control studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure assessment Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Le 
Marchand 
1997(223) 
Multiethnic 
population, 
Hawaii, US 
 
Cases 1,192;  
controls 1,192 
Height/weight at 5 
years ago self-
reported 
BMI (Q4 vs. Q1) 
Men 
Women 
 
2.2 (1.5-3.2) 
1.2 (0.8-1.9) 
Age, family history of 
colorectal cancer, 
alcohol intake, smoking, 
egg, dietary fiber, 
caloric intake, and 
physical activity 
 
Russo 1998 
(31) 
Hospital-based; 
Italy 
Cases 1,217;  
controls 4,136 
Height/weight self-
reported 
BMI (Q5 vs. Q1) 
  Men 
  Women 
OR 
1.68 (1.25-2.27) 
0.87 (0.65-1.17) 
Age, study center, 
education, physical 
activity and caloric 
intake 
 
Caan 
1998(224) 
 Cases 1983;  
controls 2400 
Height/weight 
measured 
BMI (Q3 vs. Q1) 
  Men 
Women  
 
OR 
7.76 (2.6-23.1) 
4.85 (2.33-10.12) 
 
Boutron-
Rualt 2001 
(68) 
France Cases 171;  
controls 309 
 BMI (Q5 vs. Q1) 
   
 
1.1 (0.6-2.1) Age 
Slattery 
2003 (66) 
USA Cases 1,972;  
controls 2,386 
Height/weight self-
reported 
BMI  (>30 vs. <23) 
  Men 
  Women 
 
1.88 (1.29-2.74) 
1.45 (1.09-1.92) 
 
 
  Rectal cancer cases 
1,447 
 BMI 
Men: 
 < 25 
≥ 25-29 
≥ 30 
Women: 
 < 25 
≥ 25-29 
 ≥ 30 
 
 
1. 
1.41 (1.15-1.71) 
1.75 (1.35-2.28) 
 
1. 
1.28 (1.02-1.61) 
1.5 (1.11-2.02) 
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Table 1.1 (cont.) Case-control studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Pan 2004 
(225) 
Canada Controls 5,039; 
Colon cancer cases 
1,727 
 
 BMI 
Men: 
 < 25 
≥ 25-29 
≥ 30 
Women: 
 < 25 
≥ 25-29 
 ≥ 30 
 
OR 
 
1. 
1.54 (1.27-1.86) 
2.16 (1.68-2.78) 
 
1. 
1.22 (0.98-1.52) 
1.77 (1.35-2.32) 
Age, province of residence, 
education, pack-years of 
smoking, alcohol drinking, 
total caloric intake, vegetable 
intake, dietary fiber intake, 
and recreational physical 
activity 
Hou 
2006(65) 
China Cases 931; controls 
1,552 
Height/weight self-
reported 
BMI  
Men: 
< 19.2 kg/m2 
19.2-20.3 kg/m2 
20.4-21.3 kg/m2 
21.4-22.8 kg/m2 
   > 22.8 kg/m2 
Women: 
< 19 kg/m2 
19.0-20.5 kg/m2 
20.6-21.9 kg/m2 
22-23.6 kg/m2 
   > 23.6 kg/m2 
 
OR 
 
1. 
1.0 (0.7-1.4) 
1.0 (0.7-1.4) 
1.2 (0.9-1.8) 
1.7 (1.1-2.4) 
 
1. 
1.2 (0.8-1.7) 
0.9 (0.6-1.3) 
1.1 (0.8-1.7) 
1.4 (1.0-2.1) 
Age, family history, 
education, monthly family 
income, marital status, total 
energy intake, intake of red 
meat, carotene and fiber, and 
number of pregnancies 
(women) 
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Table 1.2 Cohort studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure assessment Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Le Marchand 
1992 (61) 
Nested Case-
control study; 
Hawaii, US 
Total N. 
52,539; 
Cases 885; 
controls 
3,363 
Height/weight 
retrieved from 
Registry Records 
BMI (Q3 vs. Q1) 
Cecum/ascending 
Transverse/descending 
Sigmoid  
Rectosigmoid 
Rectal 
 
OR 
0.9 (0.5-1.6) 
1.4 (0.8-2.5) 
2.1 (1.4-3.2) 
1.3 (0.7-2.2) 
0.7 (0.6-1.4) 
Socioeconomic status 
Lee 1992 
(226) 
Prospective cohort 
study; Male 
Harvard alumni, 
US 
Total N. 
17,595; 
cases 302 
Height/weight at 
college entry 
retrieved from the 
University archives 
 
BMI (≥26 vs. <22.5) 
 
1.52 (1.06-2.17) Age, physical activity, and 
parental history of cancer 
Must 1992 
(71) 
Prospective cohort 
study; adolescents 
13-18 years at 
baseline, US 
 
Total N. 
508; Cases 5 
(All males) 
Height/weight at age 
13-18 measured 
Overweight vs. lean at 
age 13-18 
 
 
5.6 (0.6-57.5) Adult BMI 
Bostick 1994 
(227) 
Prospective cohort 
study; women aged 
55-69 years, Iowa, 
US 
Total N. 
35,215 
(167,447 PY 
over 5 
years); colon 
cases 212 
Height/weight self-
reported 
Q5 vs. Q1 
Height  
BMI  
 
HR 
1.23 (0.83-1.84) 
1.41 (0.9-2.23) 
Age, total energy intake, 
height (for BMI), parity, total 
vitamin E intake, total vitamin 
E intake by age interaction 
term, and vitamin A 
supplement intake 
Moller 1994 
(228) 
Prospective cohort; 
Those diagnosed 
with obesity from 
Dansih hospitals, 
Denmark 
 
Total N. 
37,957; 
cases 195 
Diagnosis of obesity 
(ICD=277) 
Colon 
Men 
Women 
Rectal 
Men 
Women 
 
SIR 
1.3 (1.0-1.7) 
1.1 (1.0-1.4) 
 
1.0 (0.7-1.4) 
1.2 (0.9-1.5) 
Age and period (in 5-year 
group) 
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Table 1.2 (cont.) Cohort studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Giovannucci 
1995 (127) 
Prospective cohort 
study; Male Health 
Professionals, US 
Total N. 
47,723; cases 
249 
Height/weight and 
waist/hip 
circumferences self-
measured 
Q5 vs. Q1 
BMI  
WHR 
 
HR 
1.48 (0.89-2.46) 
3.41 (1.52-7.66) 
Physical activity, age, history 
of endoscopic screening or 
polyp diagnosis, parental 
history of colorectal cancer, 
pack-years of smoking, 
aspirin use, and intake of 
folate, methione, alcohol, 
dietary fiber, red meat, and 
total energy 
 
Martinez 
1997 (57) 
Prospective cohort 
study; Female 
nurses, US 
Total N. 
89,448; cases 
396 
Height/weight self-
reported and 
waist/hip 
circumferences self-
measured 
BMI (≥29 vs.  <21) 
WHR (>0.833 vs. 
<0.728) 
 
1.45 (1.02-2.07) 
1.48 (0.88-2.49) 
Age, cigarette smoking, 
family history of colorectal 
cancer, leisure-time physical 
activity, postmenopausal 
hormone use, aspirin use, 
intake of red meat, and 
alcohol consumption 
 
Ford 
1999(229) 
Prospective study; 
NHANES I 
 
Total N. 
13,420; 
Cases 222 
 
Height/weight 
measured 
BMI (<22 vs. ≥ 30) 
 
2.79 (1.22-6.35) 
 
Age, sex, race, education, 
smoking, serum cholesterol, 
recreational exercise, and 
non-recreational exercise 
Schoen 1999 
(230) 
Prospective cohort 
study; 
Cardiovascular 
Health Study 
cohort (Aged 65+), 
USA 
 
Total N. 
5,849; Cases 
102 
Height/Weight and 
Waist/Hip 
circumferences 
measured 
Q4 vs. Q1 
Waist circumference 
(cm) 
BMI 
WHR 
HR 
2.2 (1.2-4.1) 
1.4 (0.8-2.5) 
2.6 (1.4-4.8) 
Age, sex, and physical 
activity 
Wolk 
2001(231) 
Prospective cohort 
study; Patients 
with a diagnosis of 
obesity, Sweden 
Total N. 
28,129 
(283,337 PY); 
cases 142 
Diagnosis of 
obesity (ICD7 = 
287.00, 287.09; 
ICD8 = 277.99; 
ICD9 = 278A) 
 
All cohort 
Those without diabetes 
Those with diabetes 
SIR 
1.3 (1.1-1.5) 
1.1 (0.9-1.4) 
1.7 (1.3-2.3) 
Standardized by age (in 5-
year groups), sex, and 
calendar year-specific cancer 
incidence rates 
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Table 1.2 (cont.) Cohort studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure assessment Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Terry 2001 
(232) 
Prospective cohort 
study; women aged 
40-76), Sweden 
Total N. 61,463 
(588,270 PY); 
Cases 450 
Height/weight self-
reported 
BMI (<22 vs ≥ 26.7) 
Ages (40-54) 
Ages (55-76  
 
HR 
1.74 (1.05-2.87) 
1.07 (0.78-1.47) 
Age, education level, intakes 
of energy, alcohol, red meat, 
total fat, folate, vitamin D, 
vitamin C and calcium 
 
Terry 2002 
(58) 
Prospective cohort 
study; Breast 
screening program 
cohort (women 
aged 40-59 at 
baseline), Canada 
Total N. 89,835 
(936,433 PY); 
Cases 527 
Height/weight self-
reported 
BMI (<25 vs. ≥ 25)   
Premenopausal 
Postmenopausal  
  
 
HR 
1.88 (1.24-2.86) 
0.73 (0.48-1.1) 
5-year age group, smoking, 
educational level, vigorous 
physical activity, oral 
contraceptive use, HRT, and 
parity 
Lin 2004 
(67) 
Prospective cohort 
study; Female 
health 
professionals 
Total N. 37,671 
(mean follow-up 
of 8.7 years); 
cases 202   
Height/weight self-
reported 
BMI (<23 vs. ≥30) 
All women 
Postmenopausal 
women  
HR 
1.67 (1.08-2.59) 
1.99 (1.23-3.21) 
 
Age, randomized treatment 
assignment, family history, 
history of colon polyps, 
physical activity, smoking 
status, baseline aspirin use, red 
meat intake, alcohol 
consumption, menopausal 
status, and baseline 
postmenopausal hormone use 
Moore 
2004(53) 
Prospective cohort 
study; Framingham 
Study Cohort 
- Aged 30-54y: 
Total N. 3,764; 
cases 157  
-Aged 55-79y: 
Total N. 3,802; 
Cases 149 
Height/weight 
measured 
BMI (<25 vs. ≥30) 
Aged 30-54y: 
    Men 
    Women 
Aged 55-79y: 
     Men 
    Women 
 
HR 
 
2.0 (0.98-4.2) 
1.3 (0.65-2.7) 
 
3.7 (1.7-8.1) 
1.9 (0.98-3.5) 
Education, age, height, alcohol 
intake, cigarettes per day, and 
physical activity 
Samanic 
2004 (233) 
Retrospective 
cohort study; Male 
U.S. Veterans 
Total N. 
4,500,700 (12 
years of follow-
up); Cases 22, 
214  
Clinical diagnosis of 
obesity (ICD8=277, 
ICD9=278.0) 
Non-obese vs. obese 
   White men 
   Black men 
1.47 (1.39-1.55) 
1.45 (1.28-1.64) 
Age and calendar year 
 70
Table 1.2 (cont.) Cohort studies of the association between obesity and incident colorectal cancer 
Authors Setting/location Sample size  Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
MacInnis 
2004 (234) 
Prospective cohort 
study; Australia; 
Men mostly 
(99.3%) aged 40-
69 
Total N. 16,556; 
cases 153 
 
Height/Weight 
and Waist/Hip 
circumferences 
measured; 
bioimpedance 
analysis 
 
Waist (<87 vs.>99.3) 
BMI (<24.8 vs.>29.2) 
WHR (<0.88 vs.>0.96) 
 
2.1 (1.3-3.5) 
1.7 (1.1-2.8) 
2.1 (1.3-3.4) 
Age at attendance, country of 
birth, and highest level of 
education 
Kuriyama 
2005 (235) 
Prospective cohort 
study; Japan 
Total N. 27,539 
(208,138 PY); 
Cases 115 
 
Height/weight 
self-reported 
BMI (<25 vs. ≥30) 
Men 
   Women 
 
HR 
1.3 (0.32-5.37) 
2.08 (0.88-4.9) 
 
 
Oh 2005 
(236) 
Prospective cohort 
study; Males, 
Korea 
Total N. 781,283 
(10 years of 
follow-up); Cases 
colon 953, 
Rectosigmoid 
1,563  
Height/weight 
measured 
BMI (18.5-22.5 vs. 
≥30) 
Colon  
Rectosigmoid 
 
 
1.92 (1.15-3.22) 
1.08 (0.56-2.1) 
Age, smoking status, average 
amount of alcohol consumed 
per day, frequency of regular 
exercise for more than 30 
minutes during a week, 
family history of cancer, and 
residency area at baseline 
 
Pischon 2006 
(64) 
Prospective cohort 
study; EPIC 
cohort, Europe 
Total N. 368,277 
(2,254,727 PY; 
6.1 years of 
follow-up); Cases 
colon 984, 
Rectum586 
 
Height/weight 
and waist/hip 
circumferences 
measured 
Colon: 
BMI (Q5 vs. Q1) 
  Men 
   Women 
WHR (Q5 vs. Q1) 
  Men 
  Women  
Rectum: 
   Men 
   Women: 
WHR (Q5 vs. Q1) 
  Men 
  Women 
 
 
1.55 (1.12-2.15) 
1.06 (0.79-1.42) 
 
1.51 (1.06-2.15) 
1.52 (1.12-2.05) 
 
1.05 (0.72-1.55) 
1.06 (0.71-1.58) 
 
1.93 (1.19-3.13) 
1.2 (0.81-1.79) 
Age, center, smoking status, 
education, alcohol intake, 
physical activity, fiber intake, 
and consumption of red and 
processed meat, fish and 
shellfish, and fruits and 
vegetables; WHR further 
adjusted for height 
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Table 1.3 Case-control studies of the association between obesity and colorectal adenomas 
Authors Setting/location Outcome Sample size  Exposure definition Relative risk (95% CI) Adjustment variables 
Davidow 
1996 (237) 
Patients with a 
previous history of 
adenomas, USA 
Recurrent 
adenomas 
Cases 198; 
controls 347 
BMI (1st quintile: Ref.) 
2nd quartile 
 3rd quartile 
 4th quartile 
 
 
2.3 (1.1-4.5) 
1.9 (0.9-4.1) 
1.9 (0.9-4.0) 
Age at diagnosis, age-at-
highest-weight, activity level, 
pack-years of smoking and 
energy intake 
Bird 
1998(238) 
Subjects with a 
history of 
sigmoidoscopy, USA  
Rectal 
adenomas 
Cases 483; 
controls 483 
BMI (1st quintile: Ref.) 
2nd quartile 
3rd quartile 
4th quartile 
 
OR 
1.7 (1.0-2.8) 
1.8 (1.1-2.9) 
2.1 (1.4-2.3) 
 
Boutron-
Rualt 2001 
(68) 
France Small 
adenomas 
(<10 mm) 
Cases154; 
controls 427 
 
BMI (1st quintile: Ref.) 
   
2nd quintile 
 3rd quintile 
 4th quintile 
 5th quintile 
 
OR 
1.3 (0.7-2.5) 
1.2 (0.7-2.3) 
0.9 (0.5-1.7) 
1.7 (1.0-3.1) 
Age 
  Large 
adenomas 
(≥10 mm)  
Cases 208; 
controls 427 
BMI (1st quintile: Ref.) 
2nd quintile 
 3rd quintile 
 4th quintile 
 5th quintile 
 
OR 
1.3 (0.7-2.2) 
1.1 (0.6-2.0) 
1.0 (0.6-1.8) 
2.1 (1.2-3.5) 
 
Lieberman 
2003(239) 
USA Advanced 
neoplasia 
Cases 329; 
Controls 1,441 
BMI 
Per 5 units 
 
OR 
1.06 (0.94-1.2) 
Age, smoking, alcohol, 
physical activity, NSAIDs, and 
diet 
 
Larsen 
2006(69) 
Cross-sectional study 
of colorectal cancer 
screening trial, 
Norway 
Low-risk 
adenomas 
Total N=6,961 
Low risk 
adenomas 443;  
BMI (self-reported) 
< 25 
≥ 25-29 
≥ 30 
 
 
1. 
1.11 (0.88-1.41) 
1.57 (1.13-2.18) 
  Advanced 
neoplasia 
Advanced 
adenomas 108 
BMI 
< 25 
≥ 25-29 
≥ 30 
 
1. 
0.94 (0.60-1.48) 
1.37 (0.72-2.58) 
Gender, age, smoking habits, 
total score for exercise, total 
consumption of vegetables, 
fruit and berries, boiled 
potatoes, poultry, other meat 
than poultry and fatty fish 
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Table 1.4 Cohort studies of the association between obesity and colorectal adenomas 
Authors Setting/ location Outcome Sample size  Exposure definition Relative risk (95% CI) Adjustment variables 
Giovannucci 
1995 (127) 
Male Health 
Professionals, 
USA 
Small adenoma Total N. 47,723; 
cases 568 (in 
distal 
colorectum); 455 
(distal colon)  
Waist circumference  
2nd quintile 
 3rd quintile 
 4th quintile 
 5th quintile 
HR 
0.47 (0.27-0.81) 
1.12 (0.73-1.74) 
1.04 (0.6-1.62) 
0.77 (0.48-1.23) 
  Large adenoma    
2nd quintile 
 3rd quintile 
 4th quintile 
 5th quintile 
 
2.68 (1.2-5.98) 
2.86 (1.3-6.34) 
2.98 (1.36-6.56) 
3.42 (1.57-7.47) 
Physical activity, age, 
history of endoscopic 
screening or polyp 
diagnosis, parental history of 
colorectal cancer, pack-years 
of smoking, aspirin use, and 
intake of folate, methionine, 
alcohol, dietary fiber, red 
meat, and total energy 
 
Giovannucci 
1996(33) 
Female nurses, 
USA 
Small adenoma Total N. 13,057; 
Cases (distal 
colon adenoma) 
330  
BMI (<21 : Ref.) 
  21-22 
  23-24 
  25-28 
  ≥ 29 
 
0.94 (0.61-1.43) 
0.98 (0.63-1.52) 
0.69 (0.41-1.16) 
1.44 (0.86-2.38) 
  Large adenoma    21-22 
  23-24 
  25-28 
  ≥ 29 
 
0.74 (0.39-1.39) 
1.67 (0.96-2.9) 
1.69 (0.95-3.01) 
2.21 (1.18-4.16) 
Age, prior endoscopy, 
family history of colorectal 
cancer, smoking, aspirin, 
and intakes of animal fat, 
dietary fiber, folate, 
methionine, and alcohol 
 
Morimoto 
2002(240) 
National Polyp 
Study, 
Minneapolis 
(MN),  USA 
Any adenomas Cases 437; 
controls 708 
 
BMI  
Men (<24.2 : Ref.) 
24.2 – 26.4 
26.5 – 29.6 
 29.7+  
 
. 
1.2 (0.7-2.1) 
2.2 (1.3-3.7) 
1.6 (1.0-2.8) 
Age, BMI, HRT (yes/no), 
smoking (pack-years), and 
alcohol, where appropriate 
    Women (<22.7 : Ref.) 
< 22.7  
22.7 – 25.8 
25.9 – 29.8 
29.9+   
 
 
0.7 (0.4-1.2) 
0.8 (0.5-1.4) 
0.8 (0.5-1.3) 
 
Sass 2004 (9) USA Any adenomas Total N. 119; 
cases 60 
VAT (cm3, CT scanned) 
2nd quartile 
3rd quartile 
 4th quartile 
OR 
0.4 (0.1-1.3) 
0.3 (0.1-0.9) 
1.0 (0.3-3.3) 
Age, gender, remote prior 
adenomas, and 
randomization group 
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Table 1.5 Epidemiologic studies of the association between obesity and colon cancer deaths 
Authors Design/Setting Sample size  Exposure 
assessment 
Exposure definition Relative risk (95% CI) Adjustment variables 
Phillips 1985 
(70) 
Prospective 
cohort study; 
Seventh-Day 
Adventists, US 
Total N. 25,493 
(21 years of 
follow-up); cases 
189 (M 111, F 
71)  
Weight measured % desirable weight (241) 
(100-19% :  Ref.) 
Colon cancer (M) 
85-99 
110-124 
≥ 125 
Colon cancer (F) 
85-99 
110-124 
≥ 125 
 
HR 
 
 
1.3 (0.5-3.6) 
2.3 (1.0-5.5) 
3.3 (1.3-8.4) 
 
1.2 (0.6-2.2) 
0.9 (0.5-1.7) 
1.0 (0.6-2.0) 
 
Age and sex 
Must 1992 
(71) 
Prospective 
cohort study; 
adolescents 13-18 
years at baseline, 
US 
Total N. 508; 
Deaths 10 (Males 
6; Females 4) 
Height/weight at 
age 13-18 
measured 
Overweight vs. lean at age 
13-18 
Men 
Women 
 
HR 
 
9.1 (1.1-77.5) 
1.0 (0.1-7.0) 
 
Adult BMI 
Murphy 
2000 (242) 
Prospective 
cohort study; 
Cancer Prevention 
Study II, US 
Total N. (12 
years of follow-
up) M 379,167, F 
496,239; deaths 
M 1,792, F 1,616 
Height/weight 
self- reported 
BMI (<25 : Ref.) 
Men 
  25-29.9 
  ≥ 30 
Women 
   25-29.9 
  ≥ 30 
HR 
 
1.34 (1.21-1.48) 
1.75 (1.49-2.05) 
 
1.08 (0.96-1.20) 
1.25 (1.06-1.46) 
Age, race, education, 
smoking status, exercise, 
alcohol, parental history of 
colon cancer, fat intake, 
vegetable and fiber intake, 
estrogen replacement 
therapy, and aspirin use 
 
Calle 2003 
(73) 
Prospective 
cohort study; 
Cancer Prevention 
Study II, US 
Total N. (16 
years of follow-
up) M 404,576, F 
495,477; deaths 
M 3,494 F 3,012 
Height/weight 
self- reported 
BMI (<25 : Ref.) 
Men  
  25.0-29.9 
  30.0-34.9 
  35.0-39.9 
Women  
  25.0-29.9 
  30.0-34.9 
  35.0-39.9 
  ≥40.0 
HR 
 
1.2 (1.12-1.3) 
1.47 (1.3-1.66) 
1.84 (1.39-2.41) 
 
1.1 (1.01-1.19) 
1.33 (1.17-1.51) 
1.36 (1.06-1.74) 
1.46 (0.94-2.24) 
Age, education, smoking 
status and number of 
cigarettes smoked, physical 
activity, alcohol use, 
marital status, race, aspirin 
use, estrogen-replacement 
therapy (women), fat 
consumption, and vegetable 
consumption 
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Table 1.6 Published studies of the association between circulating levels of CRP and colorectal cancer  
Authors Setting Sample size   Median (mg/L) Exposure: CRP Relative risk 
(95% CI) 
Adjustment variables 
Erlinger 
2004(151) 
Nested case-control 
study of a cohort of 
22,827, USA 
Cases 172; controls 342 
(frequency matching by 
age, sex, race, date of 
blood draw, and time 
since last meal  
 
2.44 (Cases) 
1.94 (Controls) 
Q1 (<0.92) 
Q2 (0.92-1.93) 
Q3 (1.92-3.69) 
Q4 (>3.69) 
1. 
1.16 (0.65-2.09) 
1.42 (0.82-2.46) 
2.0 (1.16-3.46) 
 
 
 
Zhang 
2005(243) 
Prospective cohort 
study of 27,913 
apparently healthy 
women 
USA 
 
Cases 169 
Total N. 27.913 
 
2.02 (Total) 
1.77 (Cases) 
<1 
1-3 
>3 
1. 
0.77 (0.53-1.11) 
0.67 (0.46-0.97) 
 
Age and treatment 
(aspirin and vitamin E) 
 
Ito 
2005(153) 
Nested case-control 
study of a cohort of 
39,242 
Japan 
 
Cases 141; controls 327 
(matched by sex and 
age) 
 
0.37 (Cases) 
0.45 (Controls) 
T1 (<0.26) 
T2 (0.27-0.8) 
T3 (>0.81) 
1. 
0.93 (0.52-1.65) 
0.91 (0.50-1.66) 
Smoking, alcohol 
consumption and BMI 
Otani 
2006(155) 
Nested case-control 
study of a cohort of 
38,373 
Japan 
 
Cases 375; controls 750 
 
0.55 (Cases) 
0.45 (Controls) 
Q1 (<0.24) 
Q2 (0.24-0.45) 
Q3(0.45-0.95) 
Q4(>0.96) 
1. 
1.5 (0.99-2.2) 
1.3 (0.85-2.0) 
1.6 (1.1-2.5) 
 
Smoking, alcohol 
consumption, BMI, 
physical exercise, and 
family history of 
colorectal cancer   
 
Gunter 
2006(152) 
Nested case-control 
study of 29,133  
male smokers  
Finland 
Cases 130; controls 260 3.4 (Cases) 
2.6 (Controls) 
Q1 (0.2-1.4) 
Q2 (1.5-2.6) 
Q3(2.7-4.8) 
  Q4(4.9-49.5) 
1. 
1.9 (1.0-3.8) 
1.2 (0.6-2.6) 
2.9 (1.4-6.0) 
 
Age, smoking duration 
(years), number of 
cigarettes smoked per 
day, and prior daily use 
of aspirin, BMI 
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Table 1. 7 Case-control studies of the association between NSAIDs and colorectal cancer  
Authors Setting Sample size   Exposure 
assessment 
Exposure definition Relative risk (95% CI) Adjustment variables 
Kune 
1988(193) 
Melbourne, Australia Cases 715; controls 
727 
(frequency matching 
by age and sex) 
 
Interview Aspirin 
NSAIDs 
OR = 0.53 (0.40-0.71) 
OR = 0.77 (0.60-1.01) 
 
 
Age, sex, and history of 
arthritis 
Rosenberg  
1991(244) 
Drug surveillance 
 
Cases 1,326 
 (802 colon; 524 
rectum);  
Controls 4,891 
Interview NSAIDs 
≥4days/wk for ≥3 
month 
OR= 0.5 (0.4-0.8) 
 
 
 
Age, sex, race, religion, 
consumption of alcohol 
and coffee, family history 
of colorectal cancer/ 
cholecystectomy, and 
education  
 
Thun 
1991(186) 
Nested Case-control 
study in the Cancer 
Prevention Study II 
cohort 
:Volunteers (>30 yrs 
old) from all across 
the U.S. 
 
N = 662,424 
Cases 598; controls 
3,058 
(matched by sex and 
age) 
 
Self-
administered 
questionnaire 
Aspirin 
≥ 16 per months for 
≥ 1 year 
 
 
M: OR = 0.6 (0.4-0.89) 
F:  OR = 0.58 (0.37-
0.9)  
 
*Outcome: colon 
cancer deaths 
 
 
 
Age, BMI, physical 
activity, family history, 
total fat intake, and intake 
of vegetables, citrus fruit, 
and high fiber grains 
Suh 
1993(188) 
Hospital-based study 
Buffalo, NY 
Cases 490 (colon) 
and 340 (rectum); 
Controls 524 
(hospital patients1) ; 
1,138 (healthy 
population2) 
 
Self-
administered 
questionnaire 
Aspirin 
2+ per day 
OR1 = 0.44 (0.18-1.10) 
OR2 = 0.33 (0.15-0.72) 
 
Adulthood lifetime 
duration of aspirin use, 
sex, age, residence and 
education 
Peleg et al. 
1994(191) 
Hospital-based study 
Mostly blacks 
Atlanta, GA 
Cases 97;  
controls 388  
 
Pharmacy and 
medical records 
 
Aspirin 
>3day/wk  
non-aspirin NSAIDs 
1-3 day/wk 
 
OR = 0.08 (0.02-0.59) 
 
OR = 0.34 (0.15-0.77) 
Age and sex 
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Table 1.7 (cont.) Case-control studies of the association between NSAIDs and colorectal cancer  
Authors Setting Sample size   Exposure 
assessment 
Exposure definition Relative risk (95% CI) Adjustment 
variables 
Muscat 1994 
(184) 
Hospital based study 
NY and OH, U.S. 
Cases 511; 
Controls 500  
 
Interview NSAIDs 
≥3 times per 
week for 
≥12 months 
 
M:OR = 0.64 (0.42-
0.97)  
F: OR = 0.32 (0.18-
0.57)  
Age, sex, and 
month of 
interview 
Peleg 
1996(205) 
Hospital based study 
Atlanta, GA, US. 
Cases 93; controls 186 Pharmacy and 
medical records 
NSAIDs 
≥ 5 years  
 
OR = 0.12 (0.04-0.39) Age and sex 
La Vecchia 
1997(136) 
Hospital based study 
Italy 
Cases 860 (colon)  and 
497 (rectum); Controls 
1,891 
Structured 
questionnaire  
 
Aspirin 
≥4days/wk  
for >6 months 
 
OR = 0.7 (0.5-1.0) 
Colon: 0.9 (0.6-1.4) 
Rectum: 0.4 (0.2-0.9) 
Education, 
physical 
exercise, and 
selected dietary 
factors 
Rosenberg 
1998(245) 
MA, U.S. Cases 1,201;  
Controls 1,201  
 
Interview NSAIDs 
≥4 days/week for ≥ 3 
months 
OR=0.7 (0.5-0.8)  Age and sex 
Friedman 
1998(183) 
MN and northern 
CA, US 
Cases 1,993; controls 
2,410  
Interview 
(reference date 
was about 2 years 
before the 
diagnosis/index 
date) 
 
Aspirin/NSAIDs 
≥ 3 times/week for at 
least 1 month 
OR = 0.7 (0.6-0.8) 
 
Sex, age, race, 
family history of 
colon cancer, 
BMI, daily 
intake of 
calories, fiber 
and calcium, 
physical activity, 
cigarette 
smoking and 
alcohol use 
 
Collet 
1999(190) 
Nested case-control 
study 
Saskatchewan, 
Canada 
 
Colon cancer cases 
3,844; controls 15,373 
 
Rectal cancer cases 
1,971; controls 7,882 
4 controls per case  
Data Linkage; 
Saskatchewan 
Prescription Drug 
Plan (SPDP) 
NSAIDs 
Highest level of use 
11-15 years before 
diagnosis 
 
Colon: 
IRR = 0.57 (0.36-0.89)  
 
Rectum: 
IRR = 0.26 (0.11-0.61) 
Age, gender, and 
index date 
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Table 1.7 (cont.) Case-control studies of the association between NSAIDs and colorectal cancer  
Authors Setting Sample size   Exposure assessment Exposure definition Relative risk (95% CI) Adjustment variables 
Langman 
2000(189) 
Nested case-
control study 
U.K. 
Cases 990 (colon) 
and 441(rectum); 
controls 4,089 
General Practice 
Research Database 
 
NSAIDs 
≥ 7 prescriptions 
(during 13-36 months 
prior to cancer  
diagnosis) 
 
Colon  
OR = 0.76 (0.58-1.00) 
 
Rectum  
OR = 0.75 (0.49-1.14) 
 
Age and smoking 
Garcia-
Rodriguez  
2001(195) 
Nested case-
control study  
U.K. 
 
Cases 2002; controls  
10,000  
 
General Practice 
Research Database 
 
Non-aspirin NSAIDs* 
Aspirin* 
≥ 6 months  
 
OR=0.5 (0.4-0.9) 
 
OR=0.9 (0.8-1.1) 
Age and sex 
Coogan 
2000(246) 
Hospital based 
study 
Boston, MA 
 
Cases 1526; controls 
10,628  
 
Interview NSAIDs  
≥ 4 times/week for at 
least 3 months  
 
 OR=0.5 (0.4-0.7) 
 
Age, sex, race, education, 
cholecystectomy, 
consumption of alcohol, 
coffee, religion, center, 
year of interview, and 
number of previous 
hospitalization 
 
 
Coogan 
2000(246) 
MA, US Cases 1,201; 
controls 1,201 
Interview NSAIDs  
≥ 4 times/week for at 
least 3 months  
OR=0.7 (0.6-0.9)  
Sansbury 
2005(247) 
 Cases 638; controls 
1,048 
Interview NSAIDs 
≥ 3 times/week for at 
least 3 months 
 
OR = 0.42 (0.29-0.65) 
Age, race, sex, smoking 
history, physical activity, 
total energy, regular 
vitamin/mineral use, red 
meat intake, body mass 
index, fat intake, family 
history, and sampling 
probability offsets. 
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Table 1.8 Cohort studies of the association between NSAIDs and colorectal cancer  
Authors Setting Sample size   Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Paganini-Hill 
1989(187) 
White, affluent and 
well educated 
retirement 
community  
CA, US 
 
N = 13,987 over 
average 6.5 years of 
follow-up 
 
Self-administered 
questionnaire 
 
Aspirin  
(≥ 1/day) 
IRR = 1.5 (1.1-2.2) Age and sex 
Schreinemac
hers 
1994(196) 
NHANES I and 
NHEFS (NHANES 
1 Epidemiologic 
Follow-up Studies) 
 
N = 12,668 (average 
follow-up: 12.4 
pereson-years) 
Cases: 1,257 
 
NHANES I 
 
Aspirin 
Ever use during 30 
days prior to the 
interview  
IRR = 0.85 (0.63-
1.15) 
Age 
Giovannucci 
1994(248) 
Male health 
professionals 
N = 47,900 
Cases 251 
Self-administered 
questionnaire 
Aspirin 
≥ 2 times per week 
RR = 0.68 (0.52-
0.92) 
 
Age, polyp, endoscopy, 
smoking, family history, 
BMI, physical activity, 
red meat, Vit. E, and 
alcohol use 
 
Giovannucci 
1995(249) 
Female nurses N = 89,446 
Cases 331; Total PY 
551,651  
Self-administered 
questionnaire 
Aspirin  
≥2 aspirin 
tablets/week for more 
than 20 years 
IRR = 0.56 (0.36-
0.90) 
 
 
Family history, smoking 
history, BMI, physical 
activity level, alcohol 
consumption, alcohol, 
dietary intake of red 
meat, methionine, folate, 
fiber, calcium and 
vitamin D 
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Table 1.8 (cont.) Cohort studies of the association between NSAIDs and colorectal cancer  
Authors Setting Sample size   Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Sturmer 
1998 (250) 
Physician’s Health 
Study (Follow-up of 
RCT of aspirin) 
N =  22,071 (12 
years of follow-up); 
Cases 341 
Random assignment 
and self-
administered 
questionnaire 
Aspirin 
≥3 aspirin/week after 
aspirin treatment in 
the RCT 
 
IRR = 1.07 (0.67-
1.70) 
Sturmer 1998 (250) 
 Smalley 
1999(194) 
Retrospective 
cohort study based 
on Tennessee 
Medicaid program 
(aged 65 or older) 
N = 104,217 
(447,065 PY) 
Cases 1,277 
Medicaid Pharmacy 
Claim File 
Time since last use of 
NSAIDs  
<1yr and cumulative 
use of nsaids in past 5 
yrs 
>12mo. 
Combined: 
IRR = 0.61(0.48-
0.77) 
 
Rectum: 
IRR= 0.81 (0.49-
1.32) 
Left colon: 
IRR = 0.77 (0.55-
1.08) 
Right colon: 
IRR = 0.48 (0.34-
0.68) 
 
Age, sex, race, calendar 
year, and NSAID-
exposure category 
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Table 1.9 Case-control studies of the association between NSAIDs and colorectal adenomas 
Authors Procedure/Setting Sample size   Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Logan et al. 
1993(139) 
FOBT and follow-
up 
colonoscopy/sigmoi
doscopy among 
FOBT positive 
patients 
U.K.  
 
Cases 147;  
Controls 153 
(negative controls); 
Positive controls 
176 
 
Interview Aspirin 
≥ 3 months  
Other NSAIDs 
≥ 3 months 
 
OR = 0.57 (0.3-1.0) 
 
OR = 0.5 (0.3-1.0) 
*Compared with 
negative controls 
Age, sex and social class 
 
Suh et al. 
1993(188) 
Hospital records 
Buffalo, NY 
Cases 212; 
Controls 524 
(hospital) and 1,138 
(healthy)  
 Aspirin 
≥ 2 per day 
OR1 = 0.53 (0.19-
1.49)  
OR2 = 0.61 (0.26-
1.4)  
 
Adulthood lifetime 
duration of aspirin use, 
sex, age, residence and 
education 
 
Martinez 
1995 (135) 
Endoscopy, TX, 
USA 
Cases 157; controls 
480 
Interview NSAIDs 
≥ 1 time/day 
 
OR = 0.36 (0.2-
0.63) 
 
Peleg 
1996(205) 
Medical records 
Atlanta, GA, U.S. 
Cases 113;  
Controls 226 
Pharmacy and 
medical records 
data 
NSAIDs (prescription 
only) 
   ≥5 years  
 
OR = 0.25 (0.08-
0.79) 
 
Age and sex 
Sandler 
1998(200) 
Colonoscopy  
NC, U.S. 
Cases 210;  
Controls 169 
Interview NSAIDs 
>15 times/ month 
 
OR = 0.56 (0.34-
0.92) 
 
Age, sex, race, and BMI 
 
Breuer-
Katschinski 
2000(204) 
Endoscopy 
Germany 
Cases 185; 
Hospital controls 
181; 
Community 
controls 184 
 
Interview NSAIDs  
>5 years 
Vs. Hosp. Controls 
 
Vs. Comm. Controls 
 
 
OR =0.2 (0.04-
1.04)  
 
OR = 0.21 (0.04-
0.99)  
 
Energy, fat, fiber, beta 
carotene, folic acid, 
calcium, red meat, relative 
weight, smoking and 
social class 
 
 
 81
Table 1.9 (cont.) Case-control studies of the association between NSAIDs and colorectal adenomas 
Authors Procedure/Setting Sample size   Exposure 
assessment 
Exposure definition Relative risk  
(95% CI) 
Adjustment variables 
Garcia-
Rodriguez 
2000(251) 
 
Medical records of 
the diagnosis of 
colorectal polyps 
U.K. 
 
Cases 1,864; 
controls  10,000  
 
General Practice 
Research Database 
 
Non-aspirin NSAIDs 
Aspirin 
OR=0.8 (0.7-01.0) 
 
OR = 0.8 (0.7-1.0) 
Age, sex, ischemic heart 
disease, and constipation 
Martin 
2002(134) 
Colonoscopy 
NC, U.S. 
 
Cases 226; controls 
493 
Interview NSAIDs 
Tertile 1 (mean use 
per month: 3.4) 
Tertile 2 (14.3) 
Tertile 3 (47.3) 
 
 
OR = 0.83 (0.5-1.4) 
 
OR = 0.51 (0.3-0.9) 
OR = 0.5 (0.3-0.8) 
Age, sex, BMI, and race 
Gondal 
2005(203)  
flexible 
sigmoidoscopy, 
Norway  
Cases 2,154; 
Controls 10,806  
Interview NSAIDs/ASA 
> 5 years 
Distal adenomas: 
 
 
Advanced adenomas: 
 
M:OR = 0.62 (0.38-
1.00) F: OR = 0.73 
(0.38-0.41) 
 
M: OR =0.69 (0.32-
1.51) 
F:  OR = 1.40 
(0.56-3.51) 
Smoking, alcohol, BMI, 
age, and HRT (in women) 
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Table 1.10 Cohort studies of NSAIDs and the risk for colorectal adenomas 
Authors Procedure/Setting Sample size   Exposure 
assessment 
Exposure 
definition 
Relative risk (95% CI) Adjustment variables 
Greenberg 
1993(138) 
Colonoscopy 
based;  
Polyp Prevention 
Study I (1 year of 
follow-up) 
U.S. 
 
Total N=793 
Cases 259 
Self-
administered 
questionnaire 
Aspirin  
 
OR = 0.52 (0.31-0.89) Age, sex, number of prior 
adenomas, study center, 
treatment group 
(antioxidant vitamins) 
Giovannucci 
1994(133) 
Self-reported 
diagnosis of 
adenomas on distal 
colon and rectum 
among those who 
underwent 
endoscopy 
 
N = 47,900 
Cases 251 
Self-
administered 
questionnaire 
Aspirin 
≥ 2 per week 
OR = 0.77 (0.63-0.95) 
 
Age, polyp, endoscopy, 
smoking, family history, 
BMI, physical activity, 
red meat, Vit. E, and 
alcohol use 
 
Tangrea 
2003(202) 
Colonoscopy 
based;  
Polyp Prevention 
Study I (3 year of 
follow-up) 
U.S. 
Total N = 1,905; 
Cases 754 (39.5%) 
 
Interview 
 
NSAIDs 
 
 
 
 
Aspirin 
Any adenomas: 
OR = 0.77 (0.63-0.95) 
Advanced adenomas: 
OR = 0.51 (0.33-0.79) 
 
Any adenomas: 
OR = 0.82 (0.65-1.02) 
Advanced adenomas: 
OR = 0.64 (0.40-1.04) 
 
Age, gender, BMI, 
intervention assignment, 
and the gender and 
intervention interaction 
term 
Chan 
2004(140) 
Self-reported 
diagnosis of 
adenomas on distal 
colon and rectum 
among those who 
underwent 
endoscopy 
N = 22,077 
1,368 cases of 
confirmed distal 
colorectal adenomas 
Self-
administered 
questionnaire 
Aspirin 
≥ 2 per week 
OR = 0.75 (0.66-0.84) 
 
 
Age, smoking, BMI, 
exercise, family history 
of CRC, hormone use, 
multivitamin use, and 
energy-adjusted folate 
and calcium intake 
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Table 1.11 Randomized, double-blinded, placebo-controlled trials of aspirin and colorectal cancer 
Authors Sample size/location Daily interventions Outcome assessment Endpoint Relative risk (95% CI) 
Gann 
1993(207) 
22,071 male 
physicians, USA 
Aspirin 325 mg and/or 
beta-carotene 59 mg 
every other day 
Duration: 5 years 
 
Self-report, pathology, 
medical records 
Invasive cancers 
Adenomas 
1.15 (0.8-1.65) 
0.86 (0.68-1.10) 
Cook 2005 
(208) 
39,876 female health 
care professionals, 
USA 
Aspirin 100 mg and/or 
Vitamin E 600 IU every 
other day 
Duration: 10 years 
 
Self-report, pathology, 
medical records 
Invasive cancers 0.97 (0.77-1.24) 
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Table 1.12 Randomized, double-blinded, placebo-controlled trials of aspirin/selective COX-2 inhibitors and colorectal adenomas 
Authors Sample size/location Daily interventions Outcome assessment Endpoint Relative risk (95% CI) 
Benamouzig 
2003 (211) 
272 post-
polypectomy patients, 
France 
Lysine 
acetylsalicylate 160 
mg or 300 mg  
Duration: Planned for 
4 years, and one year 
result reported 
 
Colonoscopy at baseline 
and at 1 year 
New adenomas 
Advanced adenomas 
0.73 (0.52-1.04) 
0.55 (0.24-1.27) 
Sandler 2003 
(210) 
635 patients with 
colorectal cancer (low 
risk of recurrent 
disease), USA 
 
Aspirin 325 mg 
Duration: planned for 
3 years, terminated at 
1 year 
 
Colonoscopy at baseline 
and at 1 year 
New adenomas 0.64 (0.43-0.94) 
Baron 2003 
(209) 
1,121 post-
polypectomy patients, 
USA and Canada 
Aspirin 325 mg or 81 
mg and/or folic acid 
1 mg 
Duration: 3 years 
Colonoscopy at baseline, 
year 1 and 3 
New adenomas ASA 81 mg: 
0.83 (0.7-0.98) 
 
ASA 325 mg: 
0.95 (0.8-1.12) 
 
Arber 2006 
(212) 
1,561 post-
polypectomy patients, 
32 countries on six 
continents 
 
Celecoxib 400mg 
Duration: 3 years 
Colonoscopy at baseline, 
year 1 and 3 
New adenomas 
Advanced adenomas 
0.64 (0.56-0.75) 
0.49 (0.33-0.73) 
Baron 
2006(213) 
 
2,587 post-
polypectomy patients,  
Rofecoxib 25 mg 
Duration: 3 years 
Colonoscopy at baseline, 
year 1 and 3 
 
New adenomas 
Advanced adenomas 
0.76 (0.69-0.83) 
0.70 (0.58-0.86) 
  
 
 
 
 
 
 
2. STUDY HYPOTHESIS AND SPECIFIC AIMS 
2.1 Study Hypotheses 
 
The overall goal of the proposed dissertation research was to explore the associations 
between obesity, inflammation and colorectal neoplasia using data and plasma specimens 
from three completed, epidemiologic studies.   
 
Two major hypotheses for this dissertation research were as follows: 
1.  Circulating levels of proinflammatory cytokines will be positively associated with the 
risk of colorectal neoplasia 
 2.  Inverse associations between NSAID use and risk of colorectal neoplasia will be 
more pronounced in those with high BMI compared to those with low BMI  
 
Hypothesis 1 was tested using data and plasma specimens from the Diet and Health 
Study III and IV, and was summarized in paper 1. Hypothesis 2 was examined using two 
different datasets: (1) phase II of the North Carolina Colon Cancer Study (NCCCS), a 
population-based case-control study of sigmoid/rectosigmoid/rectal cancer, and (2) the 
Cancer and Leukemia Group B 9270 study (CALGB9270), a randomized, double-blind, 
placebo-controlled trial of aspirin 325 mg to prevent colorectal adenomas in patients with a 
history of colorectal cancer. This resulted in two separate papers.  
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2.2 Specific Aims 
2.2.1 CIRCULATING CYTOKINES AND RISK OF COLORECTAL ADENOMAS 
 
Aim 1:  To evaluate the associations between levels of inflammation markers such as CRP, 
IL-6, and TNF-α and risk factors for colorectal neoplasia such as older age, high BMI, and 
long-term smoking, and protective factors like physical activity, use of NSAIDs and high 
levels of apoptosis in rectal mucosa 
 
Aim 2: To determine whether circulating levels of CRP, IL-6, and TNF-α are positively 
associated with increased occurrence of colorectal adenomas 
 
Aim 3: To compare distributions of circulating levels of inflammation markers among 
patients with polyps by adenoma characteristics such as villous histology, size, and 
multiplicity  
 
 
2.2.2 POTENTIAL EFFECT MODIFICATION BY BMI OF THE ASSOCIATION BETWEEN 
NSAIDS AND DISTAL  LARGE BOWEL CANCER  
 
Aim 1: To examine the association between regular NSAID use and distal large bowel cancer 
(i.e., sigmoid, rectosigmoid, and rectal cancer)  
 
Aim 2: To investigate whether the association between regular NSAID use and distal large 
bowel cancer is different between African Americans and whites  
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Aim 3: To explore subsite-specific associations with regular NSAID use and distal large 
bowel cancer  
 
Aim 4: To determine whether the association between regular NSAID use and distal large 
bowel cancer is modified by BMI  
 
 
2.2.3 POTENTIAL EFFECT MODIFICATION OF ASPIRIN ON INCIDENT COLORECTAL 
ADENOMAS BY BMI  
 
Aim 1: To examine whether high BMI is a risk factor for incident colorectal adenomas in 
patients with a history of colorectal cancer 
 
Aim 2: To determine whether the protective effect of aspirin in preventing colorectal 
adenomas is more pronounced in patients with higher BMI than lower BMI 
 
 
 
 
 
 
 
  
 
 
 
 
3. MATERIALS AND METHODS 
 
3.1 Diet and Health Study 
3.1.1 OVERVIEW 
In order to investigate the role of circulating inflammatory cytokines in colon 
carcinogenesis, we conducted an ancillary study using stored plasma samples and data 
collected for the Diet and Health Study III (DHS III) and IV (DHS IV). The DHS was a 
colonoscopy-based cross-sectional study of colorectal adenomas conducted at the University 
of North Carolina Hospitals in Chapel Hill, North Carolina. In this study all subjects 
underwent complete colonoscopic examination, and the presence and characteristics of 
colorectal adenomas were reviewed by a single study pathologist to minimize missing data 
and misclassification of the study outcome. Also, the DHS contains detailed information on 
diet and lifestyle collected by trained interviewers, which allowed a full assessment of 
potential confounding factors. Given that the adenoma-carcinoma sequence is a major 
pathologic pathway to colon cancer in average-risk populations (1), and that colorectal 
adenomas largely share risk factors with colorectal cancer (2), the proposed study could 
effectively examine the proposed study question, and would contribute to our current 
understanding of the role of systemic inflammation in colon carcinogenesis.  
 
 
3.1.2 STUDY POPULATION
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Study participants were drawn from consecutive patients who underwent 
colonoscopy at the UNC Hospitals for a variety of indications or screening between 
August 1, 1998 and March 4, 2000 (for the DHS III), or November 5, 2001 and 
December 20, 2002 (for the DHS IV), respectively. UNC Hospitals is a public, academic 
medical center offering health care for residents from all 100 counties in North Carolina 
and several surrounding states, with about 30 percent of patients from surrounding 
counties. Patients were eligible to participate in the study if they were 30 years of age or 
older, had cognitive and English language proficiency to provide informed consent and 
complete a telephone interview, and had no known history of polyposis (>100 polyps), 
colon resection, colorectal cancer, colitis, or colorectal adenomas. Patients who had 
incomplete colonoscopic examinations (cecum not reached) were excluded. Eligible 
participants were asked to provide a rectal biopsy and blood sample, and to complete a 
telephone interview.   
There were 2,162 patients (926 for the DHS III and 1,236 for the DHS IV) who 
met eligibility criteria (Table 3.1). Overall, 84.3% of the eligible patients were asked to 
participate; of these, 93.4% of DHS III and 86.3% of DHS IV participants agreed. 
Information on diet and lifestyle risk factors as well as demographic information was 
available for 75.5% subjects who consented to participate. Apoptosis was measured in 
rectal biopsies from 1,002 participants, and plasma samples for cytokine assays were 
adequate for 873 participants. 
Because the proposed cytokine assays were performed in a subset of the entire 
study participants, we compared selected characteristics of study participants with and 
without cytokine assays (Table 3.2). Subjects who provided bloods were slightly younger, 
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more likely to be male, white and obese, and consumed more daily calories than 
participants who did not provide bloods. However, smoking status and use of NSAIDs 
did not vary by availability of a blood specimen.  
 
3.1.3 DATA COLLECTION 
A. Colonoscopy and Pathology Review: Colorectal Adenomas 
Colonoscopies were performed by attending gastroenterologists and supervised 
gastroenterology fellows. All elevated lesions were biopsied or removed. Biopsy specimens 
were placed in formalin and submitted directly to pathology for sectioning and staining. A 
single experienced study pathologist examined all pathologic specimens and recorded the 
number of polyps and the maximum diameter (in millimeters), location, histologic type and 
atypia grade of each polyp on a standardized form. Any polyp with tubular, tubulovillous or 
villous pathology was classified as an adenoma, as well as any polyp with mixed 
adenomatous and hyperplastic characteristics.  
 
B. Telephone Interview 
Interviews were conducted over the telephone within 8 weeks of the colonoscopy 
using a structured questionnaire designed to obtain information about dietary and lifestyle 
exposures and family history. Interviewers were blinded to the results of the colonoscopy or 
laboratory studies. Interviewers recorded the responses on scannable forms developed for the 
DHS. Interviewers rated 91% of interviews with eligible subjects as being of adequate 
quality.  
   
 91
Physical activity Level of physical activity was assessed with a series of questions 
developed for the DHS in collaboration with Dr. Barbara Ainsworth (an exercise 
epidemiologist who has extensively evaluated commonly used physical activity 
questionnaires). The questionnaire asked about the duration and the intensity of various 
occupational and non-occupational activities during typical days in the previous year. The 
activity items were drawn from the Compendium of Physical Activities (3). Weekly energy 
expenditure was derived from multiplication of the body weight in kilograms, the number of 
hours engaged in each of the activities, and the number of METS (Metabolic Equivalents – a 
standard measure of activity) for each activity. For example, MET = 1 is equivalent to 60 
minutes of “sleeping, relaxing, self care,” and MET = 10 is equivalent to 60 minutes of “very 
hard activity.”  
 
Smoking Information on current and past smoking history was obtained using the main 
questionnaire. Subjects were asked about the age they started smoking, current smoking 
status, whether they had stopped smoking, and the number of cigarettes smoked per day.  
 
NSAIDs The main questionnaire included a series of questions on NSAID use during 
the past five years. Prespecified medications included aspirin, acetaminophen, pain 
medications or anti-inflammatory medications such as ibuprofen, Advil (Whitehall Robins, 
Madison, NJ), Motrin (McNeil Consumer, Fort Washington, NJ), Nuprin (Bristol Myers, 
New York, NY), and Aleve (Bayer Consumer, Morristown, NJ). Subjects were also asked 
about reasons for using the medications and frequency of use (regular: 3 days or more/week; 
occasional: less than 3 days/week; or rare: less than once/month).  
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C. Anthropometric measurement 
DHS research staff weighed all subjects and measured their height, waist and hip 
circumferences prior to colonoscopy. The direct measurements could enable us to avoid 
misclassification of obesity status based on body mass index (BMI) and waist circumference. 
BMI is widely used and is known to have a relatively good correlation with body fatness (4). 
Waist circumference is a measure of central adiposity with high correlation with BMI and 
total body fat, but not with height (5). A validation study has shown that waist circumference 
is superior to waist-to-hip ratio as a measure of regional adiposity (6).    
 
3.1.4 LABORATORY ANALYSIS 
A. Overview 
For the DHS, consenting subjects had blood samples drawn prior to their colonoscopy. 
Plasma was prepared from the blood samples and stored in aliquots at - 80ºC to avoid 
repeated freezing and thawing. For this project, eligible samples were thawed and placed in 
96-well plates and sent to the Center for Gastrointestinal Biology and Disease (CGIBD) 
Immunotechnologies Core lab for ELISA (Enzyme-Linked Immunosorbent Assay) assays. 
Plasma levels of cytokines were quantified using commercially available ELISA kits. 
  
B. Principle of Sandwich Enzyme-Linked Immunosorbent Assay  
ELISA cytokine assays are enzymatic sandwich type immunoassays. First, standards, 
controls and unknown samples are incubated in 96 well plates coated with primary antibodies 
specific to each cytokine. After incubation and washing, the wells are treated with a second 
specific antibody (usually labeled with biotin) followed by streptavidin bound horseradish 
 93
peroxidase (HRP). After removal of unbound streptavidin HRP, substrate is added. The 
degree of enzymatic turnover of the substrate is determined by absorbance at 450 nm and is 
directly proportional to the amount of each specific cytokine in the sample.  
It should be noted that the amounts of cytokine measured by the immunoassays are 
not absolute mass values, but are experimental values related to a specific, stated method of 
determination (7). Because different assay methods and/or standards assign mass to protein 
preparations in varying ways, measured cytokine levels will not be directly comparable to the 
ones reported by other studies. Therefore, results of cytokine immunoassays will be used to 
compare relative concentrations of each cytokine in relation to the outcome of interest 
(colorectal adenomas), rather than to examine dose-dependent biophysiological effects of the 
cytokines on the occurrence of disease. 
 
C. Quality control  
ELISA cytokine immunoassays are easy and relatively quick to perform (8). The 
Center for Gastrointestinal Biology and Disease (CGIBD) Immunotechnologies Core 
routinely performs immunoassays for researchers at UNC using ELISA kits from reputable 
commercial sources.  
There is no gold-standard method for cytokine immunoassays. Therefore, the quality 
of each immunoassay is determined based on its precision, which is defined as the ‘measure 
of the degree of repeatability of an assay under normal operation’ (9), and is assessed by 
intra-assay and inter-assay variability. For the present study, we chose to use commercially 
available ELISA kits from Biosource (Carlsbad, CA) for hIL-6 and hTNF-α, and Diagnostic 
System Laboratories Inc. (Webster, TX) for hCRP. The selected assay kits are highly 
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sensitive: the minimum detection levels are 1.6 ng/ml for CRP, 0.09 pg/ml for TNF-α and 
0.104 pg/ml for IL-6. In addition, these assay kits have generated reliable results in DHS 
samples. In a pilot study of a random sample of 50 cases and 50 controls, the intra-assay and 
inter-assay coefficients of variation for IL-6 were 3.5% and 5.4%, respectively. For CRP, the 
intra assay and inter assay coefficients of variation were 2.1% and 6.5%, respectively.  In 
general, an assay is considered valid if the inter- and intra-assay coefficients of variation are 
less than 10%.  
Intra- and inter-assay coefficients of variation were also determined for the present 
study. For intra-assay variability, each sample was assayed in duplicate. To assess inter-assay 
variability, a quality control sample with known concentrations of each cytokines was 
included in every run. Samples with intra-assay coefficients of variation greater than 20% 
were reassayed to resolve whether source of the high variation was due to poor sample 
quality or the assay procedure. 
It has been tested and confirmed that immunoassay measurements of plasma CRP 
concentrations are consistent over multiple freezing and thawing cycles (10). Nevertheless, 
samples freezing and thawing was minimized by sending the Immunotechnologies Core lab 
enough plasma to perform all three immunoassays at once. Technicians were blinded to 
presence of the quality control samples and the case/control status of each study sample. 
 
3.1.5 STATISTICAL ANALYSIS 
A. Study variables 
Outcome of Interest  
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Cases were patients who had adenomatous polyps confirmed by the study pathologist. 
Subjects who were free from adenomatous polyps were classified as controls. For the present 
study, the histologic grade of adenomas was dichotomized as tubular or tubulovillous/villous 
(including polyps with any villous architecture). Adenomas with maximum diameter ≥ 10 
mm were classified as large adenomas, and otherwise were classified as small adenomas.  
 
Exposure of Interest 
 Circulating plasma levels of each inflammation marker were categorized into 
tertiles based on distributions among controls, and were coded using indicator variables in 
multivariate logistic regression models.   
 
Major Covariates 
Age at colonoscopy is age in years on the date of colonoscopic examination. It was modeled 
as a continuous variable.  
 
Obesity was classified based on body mass index (BMI; kg/m2) and waist circumference (in 
centimeters). BMI were categorized based on World Health organization (WHO) definitions 
(11): obesity was defined as BMI ≥ 30 kg/m2, overweight as BMI 25-29 kg/m2 and normal 
weight or underweight of BMI < 25 kg/m2.  According to the criteria for abdominal obesity 
made by the American Diabetes Association, waist circumference has sex-specific cutoff 
points: action level 1: men ≥ 94 cm, women ≥ 80 cm; and action level 2: men ≥102 cm, 
women, ≥ 88 cm) (12). For multivariate modeling of the associations between inflammatory 
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cytokinies and colorectal adenomas, both BMI alone and BMI combined with waist 
circumferences were entered as a categorical covariate.  
 
Physical activity has been estimated from weekly energy expenditure in METs (Metabolic 
Equivalents – a standard measure of activity). The variable was recoded as a categorical 
variable (tertiles) in the multivariate models of the associations between inflammatory 
cytokines and colorectal adenomas. Tertile cut points were determined based on the 
distribution among controls. 
 
Smoking status was classified into three categories: current smoker, former smoker and never 
smoker.  
 
Use of NSAIDs was represented as a binary variable. Regular users were defined as those 
who used any anti-inflammatory agents (prescribed or over-the-counter) for 3 days or more 
per week in the past 5 years. Participants who reported using NSAIDs less than 3 days per 
week were classified as occasional or non-users.  
 
B. Analytic Methods Related to Specific Aims  
All statistical analyses were performed using Stata version 9.0 (Texas Station, TX). 
 
Aim 1:  To evaluate the associations between levels of inflammation markers such as CRP, 
IL-6, and TNF-α and risk factors for colorectal neoplasia such as older age, high BMI, and 
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long-term smoking, and protective factors like high level of physical activity and use of 
NSAIDs.  
 
Logistic regression was used to evaluate associations between risk factors for 
colorectal neoplasia and elevated inflammatory cytokines (CRP, IL-6 and TNF-α), after 
adjustment for age and sex. Levels of each inflammatory cytokine CRP and TNF-α were 
classified as having high CRP or TNF-α if their measured level was higher than the value of 
the 66th percentile (the cut point for the upper tertile) among controls. IL-6 levels were below 
the detection limit in 65% of controls. Therefore, participants with levels below the detection 
limit were assigned a value of zero for IL-6, and participants with IL-6 levels above the 
median value of the IL-6 distributions among controls with detectable IL-6 (0.3571 pg/ml) 
were classified as having high IL-6.   
 Selected risk factors evaluated for associations with inflammatory cytokines included 
age (≥ 65 years or < 65 years), regular use of NSAIDs (yes or no), smoking status (current, 
former, or never), obesity (measured by BMI alone or BMI combined with waist 
circumference), physical activity (tertiles), and daily caloric and fat intakes (tertiles).  
 
Aim 2: To determine whether circulating levels of CRP, IL-6, and TNF-α are positively 
associated with increased occurrence of adenomas 
 
Odds ratios (ORs) and 95% confidence intervals for occurrence of colorectal 
adenomas by three levels of each of inflammation marker were estimated using unconditional 
logistic regression models. Based on a directed acyclic graph (DAG) (13), age, sex, BMI, 
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physical activity, smoking status, use of NSAIDs, comorbidity, and daily caloric and fat 
intakes were considered as potential confounding factors. To determine which covariates 
should be entered in the final multivariate models, we constructed a full model with all 
potential confounders, and assessed change in beta coefficients for high levels of 
inflammatory cytokines versus the reference categories in relation to occurrence of colorectal 
adenomas. Covariates which resulted in more than a 10% change in the beta coefficient were 
included in the final multivariate models, along with age and sex.  
 
Aim 3: To compare distributions of circulating levels of inflammatory cytokines among 
patients with polyps by adenoma characteristics such as histologic grade and size 
 
Cases were classified into two groups based on adenoma characteristics such as 
histologic grade and size. If more than one adenoma was found in a single person, the most 
advanced polyp characteristic (histology and size) was used for classification. Because the 
distributions of inflammatory cytokine measurements were skewed on both raw and log-
transformed scales, Mann Whitney U-tests were used to compare medians of circulating 
levels of inflammatory cytokines between the two groups of cases.  
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3.2 North Carolina Colon Cancer Study  
3.2.1 OVERVIEW 
Using data from phase II of the North Carolina Colon Cancer Study (NCCCS-II), we 
examined associations between NSAIDs and distal large bowel cancer (i.e., sigmoid, 
rectosigmoid and rectal cancer) in African Americans and whites. Potential effect 
modification by BMI of the association between NSAIDs and distal large bowel cancer was 
also examined. The NCCCS-II is a population-based case-control study in 33 counties in the 
central and eastern part of North Carolina. 
  
3.2.2 STUDY POPULATION 
Between October 1, 2001 and May 31, 2006, patients with a first diagnosis of 
invasive adenocarcinoma in sigmoid, rectosigmoid, and rectum were identified through the 
rapid ascertainment system of the North Carolina Central Cancer Registry. The procedure for 
case ascertainment and its effectiveness has been described in detail elsewhere (14). Cases 
were eligible for the study if they were residents of the selected counties, aged between 40 
and 80 years, African American or white race, had a North Carolina driver’s license or 
identification card, and were able to complete an interview in English. Controls were 
randomly selected from North Carolina Division of Motor Vehicle records, based on 
sampling probabilities within blocks defined by 5-year age group, sex and race, using the 
technique of randomized recruitment (15).  
The final dataset for analysis included 1,057 cases and 1,019 controls. The study was 
approved by the Institutional Review Board at University of North Carolina School of 
Medicine, and all subjects provided written informed consent. 
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3.2.3 DATA COLLECTION 
A. Confirmation of Diagnosis by Pathological Review 
In order to confirm the diagnosis of invasive adenocarcinoma of sigmoid, 
rectosigmoid, or rectum, pathology reports were obtained and reviewed.  
 
B. Interview 
Data for this study were collected by in-person interviews, conducted in the subject’s 
home or in another convenient location, by trained nurse interviewers.  The study 
questionnaire was based on two questionnaires: the Health Habits and History Questionnaire 
(HHHQ) (for data concerning risk factors) and the Patient Experiences Questionnaire (PEQ) 
(for data concerning social ties, coping, health care access and other issues that might relate 
to both incidence and mortality.)  
  
NSAID use 
Use of NSAIDs was queried in relation to five large categories: 1) over-the-counter 
aspirin (e.g, Bufferin, Anacin, ExcedrinTM, BC or Goody’s powder, or Alka SeltzerTM); 2) 
over-the-counter non-aspirin pain medications (e.g., AdvilTM, MortrinTM, AleveTM); 3) 
prescription pain medications (e.g., MortrinTM, DayproTM, NaprosynTM, FeldeneTM); and 4) 
prescription selective COX-2 inhibitors (e.g., VioxxTM or CelebrexTM). For each NSAID 
category, respondents who reported NSAID use were asked about frequency, duration, and 
their use at 1 year before interview (for controls) or diagnosis (for cases).  
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Obesity 
Weight and height 1 year prior to diagnosis and 5 years prior to diagnosis were asked 
at the time of interview, and current weight and height at the time of interview were 
measured. Self-reported weight and height 1 year before diagnosis were used to calculate 
BMI in all subjects, because occurrence and treatment of colorectal cancer might have 
affected the current weight of cases.  
 
Other covariates  
Nutrient intake from diet and supplements in the year prior to diagnosis (for cases) 
and the year preceding the interview date (for controls) were assessed with the Diet History 
Questionnaire, developed and evaluated at the National Cancer Institute (16). 
 Physical activity was assessed with a series of questions developed for the DHS. 
Study participants were asked about the amount of time spent in various activities during the 
previous year during typical week/work days and weekend/non-work days to estimate their 
weekly energy expenditure.  
The study questionnaire also included questions pertaining to demographic 
information, socioeconomic indicators such as years of education, income level, and 
occupation history, smoking habits, family history of cancer, and other potential risk factors 
for colorectal cancer.  
 
3.2.4 STATISTICAL ANALYSIS 
A. Study Variables 
 Outcome of Interest 
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 The outcome of interest was incident distal large bowel cancer (i.e., sigmoid, 
rectosigmoid, and rectal cancer). We included cancers of the sigmoid and rectosigmoid 
because a) there were not sufficient numbers of rectal cancer to support detailed analysis; b) 
there is misclassification between anatomic sites in the distal colon particularly between 
rectum and rectosigmoid. 
 
Exposures of Interest 
Use of NSAIDs was defined based on self-reported use of any NSAIDs in the past 5 years. 
Depending on the frequency of use, subjects were categorized as non-regular users (less than 
3 times per week), and regular users (≥ 3 times/week). Duration of use was examined among 
regular users. In addition, we examined whether associations with incident distal large bowel 
cancer varied by type of NSAID based on classification of NSAIDs into 4 categories: 1) 
over-the-counter aspirin; 2) over-the-counter non-aspirin NSAIDs; 3) selective COX-2 
inhibitors (COXibs); and 4) non-COXib prescription NSAIDs.  
 
BMI at 1 year prior was modeled as a categorical variable. Subjects were classified into three 
groups based on the World Health organization (WHO) definitions (11): obesity (BMI ≥ 30 
kg/m2), overweight (BMI 25-29.9 kg/m2) and normal weight or underweight (BMI < 25 
kg/m2).  
 
Other Covariates 
Major covariates for multivariable models included age, sex, race, age, level of 
physical activity, total caloric and fat intake, family history of colorectal cancer, regular use 
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of calcium, smoking status, annual household income, years of education and comorbid 
conditions such as arthritis, diabetes, hypertension and heart problems.  
Sex and race were modeled as binary variables. Age was categorized in 10-year 
intervals (40-49, 50-59, 60-69 or 70+). As with age, total caloric and fat intake, and level of 
physical activity were modeled as categorical variables with 3 groups (tertiles based on 
distributions among controls). Use of calcium supplements was modeled as a binary variable, 
with participants that used supplements ≥ 1 per week defined as regular users.  
Family history of colorectal cancer was represented as a binary variable: at least one 
first-degree family member diagnosed with colorectal cancer, or no first-degree family 
history. Comorbid conditions such as arthritis, diabetes and heart problems were defined as 
presence or absence of each condition, and were represented as three separate binary 
variables. Smoking status was categorized as never smoker, former smoker, and current 
smokers at 1 year before diagnosis. Annual household income was grouped into 4 categories 
(≤$15,000, $15,000-20,000, $20,000-25,000, $25,000-50,000, or >$50,000 per year), and 
years of education was grouped into 3 categories (≤9, 10-12, or >12 years).  
 
B. Analytic Methods Related to Specific Aims 
For all analysis, p-values were two-sided, and a p-value of 0.05 or less was 
considered statistically significant. All statistical analyses were performed using Stata 
version 9.0 (Texas Station, TX). 
 
Aim 1: To examine the association between regular NSAID use and distal large bowel cancer  
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Odds ratios (OR) and 95% confidence intervals for the association between regular 
use of NSAIDs and distal large bowel cancer were estimated from unconditional logistic 
regression models. Regular use was defined as taking NSAIDs at least 3 times per week. 
Subjects who reported no use or use of NSAIDs less than 3 times per week were classified as 
“non-regular users”, and served as the referent group. In addition, we examined recency of 
use (defined as use in the past year or not), duration of use (categorized as ≥ 1 year, or < 1 
year), and use of different types of NSAIDs (any over-the-counter NSAIDs, over-the-counter 
aspirin, over-the-counter non-aspirin NSAIDs, any prescription NSAIDs, prescription COX-
2 inhibitors (COXibs), and other prescription NSAIDs) among regular users. All logistic 
regression models included age (continuous), sex, race and an offset term to adjust for 
sampling probability. Other potential covariates assessed for inclusion in multivariable 
models were: years of education (<12, 12-15, or ≥ 16 years), annual household income 
(<15,000, 15,000-25,000, 25,000-50,000, or ≥ 50,000 dollars), smoking status (current, past, 
or never) at the time of diagnosis (for cases) or interview (for controls), family history of 
colorectal cancer (having at least 1 first degree family member with colorectal cancer, or not), 
comorbidity (having at least one of the following conditions: arthritis, hypertension, heart 
attack, or diabetes) prior to diagnosis (for cases) or at the time of interview (for controls), 
body mass index (BMI) 1 year ago (normal or underweight: < 25, overweight: 25-29.9, or 
obese: ≥ 30 kg/m2), physical activity 1 year ago (tertiles based on the distribution among 
controls), calcium supplement use during the past 5 years (yes or no), and dietary intakes of 
energy and fat during the past year (tertiles based on the distributions among controls). To 
determine which covariates should be entered in the final multivariable models, we 
constructed a full model with all potential confounders, and assessed the change in beta 
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coefficients for regular use versus non-regular use of NSAIDs in relation to distal large 
bowel cancer when covariates were removed. Only BMI 1 year prior resulted in more than a 
10% of change in the beta coefficient, and was included in the final multivariable models in 
addition to matching factors (age, sex, race and a sampling probability offset term). 
 
Aim 2: To investigate whether the association between regular NSAID use and distal large 
bowel cancer is different between African Americans and whites  
To address aim 2, we examined the association between regular use of NSAIDs and 
incident colorectal cancer stratified by race. A possible interaction between regular use of 
NSAIDs and race was assessed using log likelihood ratio tests comparing models with and 
without interaction terms. A significant result indicates that the models fit the data 
significantly better with interaction terms between regular NSAID use and race than without 
the interaction terms, i.e., that the odds ratios are not homogeneous between racial groups.  
 
Aim 3: To explore subsite-specific associations with regular NSAID use and distal large 
bowel cancer  
 We used multinomial logistic regression to simultaneously estimate odds ratios and 
95% confidence intervals for sigmoid, rectosigmoid, and rectal cancers, compared with 
controls. Wald statistics were used to assess statistical difference in effect estimates for the 
association with NSAID use between cancer subsites. 
 
Aim 4: To determine whether the association between regular NSAID use and distal large 
bowel cancer is modified by BMI  
 106
We assessed significant departure from the null for multiplicative interaction between 
BMI (< 25, 25-29, or ≥ 30) and use of NSAIDs (regular versus ‘not regular’) using the log 
likelihood ratio test in the multivariable logistic regression analysis. A significant result 
indicates that the logistic regression model fits the data significantly better with interaction 
terms between BMI and use of NSAIDs compared with the model without the interaction 
terms.  
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3.3 Cancer and Leukemia Group B Study 
3.3.1 STUDY DESIGN 
The Cancer and Leukemia Group B Study (CALGB 9270) was a randomized, double-
blind, placebo-controlled trial of daily use of 325 mg of aspirin against the occurrence of new 
colorectal adenomas among patients with a history of colorectal cancer.  
Study participants were aged 30-80 and in good health, and had history of CRC with 
a low risk of recurrence (defined as Duke’s stage A or B1, or stage B2 or C). All subjects had 
to undergo a complete colonoscopy, and have all polyps removed, within the 4 months prior 
to study entry. 
Major exclusion criteria were as follows: (a) a history of familial polyposis; (b) 
invasive cancer other than nonmelanoma skin cancer within 5 years before the intake 
appointment; (c) cardiovascular disease of functional class III or IV, as defined by the New 
York Heart Association; (d) a history of inflammatory bowel disease; (e) possible 
contraindications to the administration of aspirin; and (f) a high likelihood of requiring 
NSAID use. 
Between May 15, 1993, and January 10, 2000, 719 participants were registered for 
the trial, and 635 completed the run-in period and underwent randomization (317 to aspirin 
group and 318 to placebo). Within four months before study entry patients had to have 
undergone colonoscopy to the cecum (or small-bowel anastomosis) and had all polyps 
removed. The primary end point of the study was the detection of adenomas in the large 
bowel during follow-up colonoscopic or sigmoidoscopic examinations after randomization. 
Overall, 517 out of 635 randomized patients (81%) had at least one colonoscopic 
examination after randomization (258 in the placebo group and 259 in the aspirin group) after 
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an average of 12.8 months of treatment. Body weight and height at baseline were available 
for 93.2% (n = 482) of subjects that completed follow-up colonoscopic examinations.  
Colonoscopic examinations were performed by each patient’s gastroenterologist or 
surgeon as a part of their usual follow-up. Endoscopists were instructed to remove all raised 
lesions, and biopsy specimens were submitted to local pathologists for review. The study 
chair reviewed a copy of the colonoscopy and pathology reports to verify the adequacy and 
extent of the examination and the size, location, and pathological findings of any lesions. The 
trial was originally planned for three years of follow-up, but was terminated during an 
interim analysis due to significant risk reduction of colorectal adenomas with 325 mg of daily 
aspirin use.  
 
3.3.2 STATISTICAL ANALYSIS 
A. Study Variables 
 Development of colorectal adenomas at follow-up was the primary outcome, and it 
was represented as a binary variable in the analysis. Aspirin treatment was a binary variable: 
subjects were randomly assigned to either aspirin 325 mg per day or placebo group in the 
parent study. 
Body mass index (BMI) was calculated based on height and weight measured at 
baseline in 482 subjects; 7 subjects were missing information on either height or weight, and 
28 subjects had implausible height (defined as <130 or >220 centimeter), or weight (defined 
as > 200 kilograms) values. On the basis of BMI, subjects were categorized into normal 
(BMI<25 kg/m2), overweight (BMI 25-29.9 kg/m2), or obese (BMI ≥ 30 kg/m2)(11).  
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B. Analytic Method Related to Specific Aim 
For all analysis, p-values were two-sided, and a p-value of 0.05 or less was 
considered statistically significant. All statistical analyses were performed using Stata 
version 9.0 (Texas Station, TX). 
 
Aim 1: To examine whether high BMI is a risk factor for incident colorectal adenomas in 
patients with a history of colorectal cancer 
A Poisson model with robust error variance was used to estimate risk ratios and 95% 
confidence intervals for detection of colorectal adenomas by aspirin treatment because the 
conventionally employed log-linear models failed to converge (17).  We also assessed 
whether the association between BMI and incident colorectal adenomas was modified by sex, 
using multivariable analysis including product terms between sex and three categories of 
BMI in the model. Multivariable models included the following covariates; age (30-49, 50-59, 
60-69, or ≥ 70 years), sex, treatment assignment, cancer stage (Dukes’ A or B1, or Dukes’ 
B2 or C), number of years since diagnosis, time to the first colonoscopy (continuous), time to 
the last colonoscopy, and number of colonoscopic examinations (1, 2, 3, or 4+) in the 
multivariable analysis.   
 
Aim 2: To determine whether the protective effect of aspirin in preventing colorectal 
adenomas is more pronounced in patients with higher BMI than lower BMI 
We evaluated evidence of Interaction between BMI (3 categories: < 25. 25-29 and ≥ 
30) and assignment of aspirin treatment (aspirin vs. placebo) using a “chunk test” of two 
interaction terms between aspirin treatment and two levels of BMI (BMI 25-29.9, and BMI≥ 
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30 kg/m2). A significant p-value for the interaction coefficients indicates differences in risk 
ratios for colorectal adenomas depending on BMI. 
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3.5 Tables 
Table 3.1 Participation rates and biospecimen availability for eligible subjects 
 
 
DHS III 
(8/1/1998-3/4/2000) 
DHS IV 
(11/5/2001-12/20/2002) 
Total 
Eligible subjects 926 1,236 2,162 
Subjects recruited 860 (92.9%) 962 (78.1%) 1,822 (84.3%) 
Subjects who consented to participate 803 (93.4%) 830 (86.3%) 1,633 (89.6%) 
Subjects who completed a main 
questionnaire 
756 (94.1%) 701 (87.3%) 1,457 (89.2%) 
Subjects who completed both Main 
and diet questionnaires 
662 (82.4%) 571 (68.8%) 1,233 (75.5%) 
Subjects who gave adequate biopsy 539 (67.1%) 463 (55.8%) 1,002 (81.3%) 
Subjects who gave bloods 457 (56.9%) 613 (73.9%) 1,070 (65.5%) 
Samples that will be analyzed for the 
proposed cytokine assays 
327 (43.3%) 546 (77.9%)    873 (59.9%) 
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Table 3.2 Major characteristics of study participants by inclusion in the cytokine assay  
 Subjects included in the 
cytokine assay 
Subjects not included p-value 
 (N=873) (N=583)  
Mean age, years (SD) 55.6 (10.6) 56.6 (10.8) 0.0954 
Women (%) 479 (54.9) 352 (60.3) 0.041 
White (%) 670 (76.8) 429 (73.5) 0.153 
Smoking status (%)    
Current 113 (14.1) 96 (17.6) 0.135 
Former 296 (39.9) 180 (32.9)  
Never 394 (49.1) 296 (49.5)  
Mean daily calories, kcal (SD) 1764.8 (673.6) 1588.1 (626.5) <0.0001 
Mean BMI, kg/m2 (SD) 27.3 (5.7) 28.1 (6.6) 0.0085 
Mean monthly use of NSAIDs (SD) 12.1 (23.87) 12.4 (30.3) 0.1578 
 
 
 
 
 
 
3 RESULTS PAPER 1: CIRCULATING LEVELS OF INFLAMMATORY 
CYTOKINES AND RISK OF COLORECTAL ADENOMAS 
 
4.1 Abstract 
The association between obesity and colorectal neoplasia may be mediated by 
inflammation. Circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor 
necrosis factor-α (TNF-α) are elevated in the obese. Adipose tissue can produce and release 
inflammatory cytokines that are potentially procarcinogenic. We examined circulating levels 
of CRP, IL-6, and TNF-α in relation to risk factors and the prevalence of colorectal 
adenomas. Plasma levels of CRP, IL-6, and TNF-α were quantified in 873 participants in a 
colonoscopy-based cross-sectional study conducted between 1998 and 2002. Multivariable 
logistic regression was used to estimate associations between levels of inflammatory 
cytokines, colorectal adenomas, and known risk factors. Several known risk factors for 
colorectal neoplasia were associated with higher levels of inflammatory cytokines such as 
older age, current smoking, and increasing adiposity. The prevalence of colorectal adenomas 
was associated with higher concentrations of IL-6 and TNF-α, and to a lesser degree, with 
CRP.  For IL-6, adjusted odds ratios for colorectal adenomas were 1.69 (95% confidence 
interval [CI]: 1.13-2.54) for the second highest plasma level, and 1.80 (95% CI: 1.22-2.66) 
for the highest level compared with the reference level. A similar association was found with 
TNF-α, with adjusted odds ratios of 1.51 (95% CI: 1.01-2.27) and 1.59 (95% CI: 1.06-2.40), 
respectively. Our findings suggest that systemic inflammatory cytokines might be involved in 
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the early development of colorectal neoplasia, and support the hypothesis that inflammation 
might mediate the association between colorectal cancer and obesity and other risk factors.  
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4.2 Introduction 
Previous studies have shown that obesity is positively associated with colorectal  
adenomas and cancer (1). Possible mechanisms for the positive association between obesity 
and colorectal neoplasia include the obesity-induced insulin-related pathway (1), and 
inflammation (2;3). Adipose tissue is now recognized as an endocrine organ rather than a 
simple fat storage site, and a wide range of inflammatory cytokines are released from adipose 
tissue, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)  (4;5). Circulating 
levels of C-reactive protein (CRP), TNF-α, and IL-6 are elevated in the obese (6), and 
decrease after weight loss among the same subjects (7;8). Based on growing evidence 
suggesting procarcinogenic effects of the proinflammatory cytokines (9-11), we hypothesized 
that systemic inflammation might mediate the association between obesity and colorectal 
neoplasia. The aims of the present study were (1) to examine associations of levels of CRP, 
IL-6 and TNF-α and colorectal cancer risk factors (older age, high BMI, and smoking) and 
protective factors (high physical activity and use of NSAIDs), and (2) to determine whether 
circulating levels of CRP, IL-6 and TNF-α were positively associated with prevalent 
colorectal adenomas.  
 
 118
4.3 Materials and Methods 
4.3.1 STUDY POPULATION 
Study participants were drawn from consecutive patients who underwent colonoscopy 
at the UNC Hospitals (Chapel Hill, NC) for a variety of indications or screening between 
August 1, 1998 and March 4, 2000 (Diet and Health Study (DHS) III), or November 5, 2001 
and December 20, 2002 (DHS IV), respectively. Patients were eligible to participate in the 
study if they were 30 years of age or older, could provide informed consent and complete a 
telephone interview, and had no known history of polyposis (>100 polyps), colon resection, 
colorectal cancer, colitis, or colorectal adenomas. Patients were excluded if they had 
inadequate preparation, or incomplete colonoscopic examinations (cecum not reached). At 
the time of colonoscopy all elevated lesions were biopsied or removed. Biopsy specimens 
were placed in formalin and submitted directly to pathology for sectioning and staining. A 
single experienced study pathologist (J.T.W) examined all pathologic specimens and used a 
standardized form to record the total number of polyps and the maximum diameter (in 
millimeters), location, histologic type and atypia grade of each polyp. Any polyp with tubular, 
tubulovillous or villous pathology, or that had mixed adenomatous and hyperplastic 
characteristics, was classified as an adenoma. 
 
4.3.2 DATA COLLECTION 
DHS research staff weighed all subjects and measured their height, waist and hip 
circumferences prior to colonoscopy. Information about demographic characteristics, 
education, medical history, NSAID use, smoking and other lifestyle exposures was collected 
by telephone interview within 12 weeks of the colonoscopy using a structured questionnaire. 
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Dietary intake was assessed using the Block food frequency questionnaire (DHS III) (12) and 
the NCI quantitative food frequency questionnaire (DHS IV) (13). Physical activity was 
estimated by computing weekly energy expenditure in METs (Metabolic Equivalents – a 
standard measure of activity) based on the duration and intensity of various occupational and 
non-occupational activities during typical days in the previous year. This study was approved 
by the institutional review board at the University of North Carolina School of Medicine. 
 
4.3.3 SAMPLES FOR ANALYSES 
There were 2,162 patients (926 for the DHS III and 1,236 for the DHS IV) who met 
the eligibility criteria described above. Overall, 84.3% of the eligible patients (N = 1,822) 
were asked to participate in the study; of these, 89.6% (N = 1,633) agreed. Telephone 
interviews were completed with 75.5% of the subjects who consented to participate (N = 
1,233). The final study sample consisted of 873 participants (327 for the DHS III and 546 for 
the DHS IV) with plasma samples for cytokine assays.  There were slightly more men in the 
final study sample (45% vs. 40%, p < 0.04), compared with those who were interviewed but 
not included in cytokine assays. However, there were no significant differences in other 
demographic characteristics such as age and race. 
 
4.3.4 LABORATORY METHODS 
Specimen collection and handling conditions were similar for DHS III and IV. 
Plasma was extracted from blood samples and stored in aliquots at −80ºC until analyses. 
Plasma concentrations of inflammatory cytokines were quantified using commercially 
available ultrasensitive ELISA kits for human CRP (Biosource, Carlsbad, CA), and human 
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IL-6 and TNF-α (Diagnostic System Laboratories Inc., Webster, TX). Minimum detection 
levels were 1.6 ng/ml for CRP, 0.104 pg/ml for IL-6, and 0.09 pg/ml for TNF-α, according to 
the manufacturers. All assays were run in duplicate, and levels were classified according to 
the average of each pair of measurements. The intra- and inter-assay coefficients of variation 
were 2.8% and 0.19% for CRP at 100 ng/ml; 11.3% and 16.9% for IL-6 at 0.16 pg/ml; and 
5% and 11.2% for TNF-α at 1 pg/ml, respectively. 
 
4.3.5 STATISTICAL ANALYSIS 
Selected characteristics were compared between cases and controls, and chi-square 
tests were used to assess differences in proportions. Median and interquartile ranges for each 
inflammatory cytokine were calculated according to case/control status. Levels of 
inflammatory cytokines were not normally distributed on raw or log-transformed scales; 
therefore, Hodges-Lehmann estimators (14) and Mann-Whitney U test p-values were 
calculated to evaluate the difference in circulating levels of each inflammatory cytokine by 
case/control status. 
Logistic regression was used to evaluate associations between risk factors for 
colorectal neoplasia and high levels of inflammatory cytokines (CRP, IL-6 and TNF-α, 
dichotomized as described below), after adjustment for age (30-49, 50-64, ≥65 years) and sex. 
Subjects were classified as having high CRP or TNF-α if their measured levels were greater 
than or equal to the value of the 66th percentile in the distribution of each cytokine among 
controls. For IL-6, 630 subjects (50% of cases and 65% of controls) had values below the 
detection limit; therefore, we classified subjects as having high IL-6 if their levels were 
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greater than or equal to the median value among controls with detectable values (0.3571 
pg/ml).  
Risk factors for colorectal neoplasia that were evaluated for associations with 
inflammatory cytokines were age at colonoscopy (30-49, 50-64, ≥65 years), sex, regular use 
of NSAIDs (use ≥ 3 times per week during the past 5 years), smoking status (current, former, 
or never), physical activity (average levels in the prior year categorized into tertiles based on 
the distribution among controls), average daily total energy and fat intakes in the prior year 
(tertiles based on distribution among controls), and obesity (measured by body mass index 
[BMI] alone or BMI combined with waist circumference). BMI was categorized based on the 
World Health organization (WHO) definitions (15) as obese  (BMI ≥ 30 kg/m2), overweight 
(BMI 25-29 kg/m2), and normal weight or underweight (BMI < 25 kg/m2).  Waist 
circumference was categorized according to the American Diabetes Association criteria for 
abdominal obesity as action level 1 (men ≥ 94 cm, women ≥ 80 cm), action level 2 (men 
≥102 cm, women, ≥ 88 cm) or normal (16).  
Odds ratios (ORs) and 95% confidence intervals for associations between colorectal 
adenomas and each inflammatory cytokine were estimated using unconditional logistic 
regression models. CRP and TNF-α were categorized based on tertile distributions among 
controls, with the lowest tertile serving as the referent exposure category for each cytokine. 
For IL-6, subjects with values below the detection limit in the assay were the referent 
exposure category, and the remaining subjects were categorized into two groups using the 
median IL-6 level among controls with detectable values (0.3571 pg/ml) as a cut point.  
Based on a directed acyclic graph (DAG) (17), age (30-49, 50-64, ≥65 years), sex, 
smoking status, regular use of NSAIDs, comorbidity (defined as presence of arthritis, 
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diabetes, hypertension, or heart attack), study phase (DHS 3, or DHS 4), daily total energy 
and fat intakes, physical activity and  BMI were considered as potential confounding factors. 
To determine which covariates should be entered in the final multivariate models, we 
constructed a full model with all potential confounders, and assessed change in beta 
coefficients for high levels of inflammatory cytokines versus the reference categories in 
relation to occurrence of colorectal adenomas. Age and sex were included in all models, and 
other covariates were retained if the beta coefficient for any cytokine changed by more than 
10% when they were removed. Final models for each inflammatory cytokine included age 
(30-49, 50-64, or ≥65), sex and obesity (assessed by BMI combined with waist 
circumference: BMI <25; BMI 25-29.9 kg/m2 and action level 1 abdominal adiposity; BMI 
25-29.9 kg/m2 and action level 2 abdominal adiposity; BMI ≥ 30 kg/m2 and action level 1 
abdominal adiposity; or BMI ≥ 30 kg/m2 and action level 2 abdominal adiposity).  
Levels of each inflammatory cytokine were compared between case subgroups 
defined according to villous histology (villous or non-villous), the size of the largest 
adenoma (<10 mm or ≥ 10 mm in diameter), and the presence of multiple adenomas (1, or ≥ 
2 adenomas). Participants with more than one adenoma were classified based on the most 
advanced or largest adenoma, respectively. Hodges-Lehmann estimators (14) and Mann-
Whitney U tests were used to assess median differences in cytokine levels between case 
subtypes.  
All statistical tests were two-sided. All analyses were performed using Stata version 
9.0 (Texas Station, TX).  
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4.4 Results 
Selected characteristics of colorectal adenoma cases and controls are shown in Table 
4.1. The median age was 58 years in cases and 54 years in controls. Compared with controls, 
cases were more likely to be male, and were less likely to have used NSAIDs regularly in the 
past 5 years. Cases were also more likely to self-report comorbid conditions (arthritis, 
hypertension, heart attack or diabetes.) Although associations did not reach statistical 
significance, cases were also more likely to be current smokers, obese (based on both BMI 
and waist circumference), and less physically active, and to have had higher total energy and 
fat intakes than controls.  
The median difference in TNF-α levels between cases and controls was 0.2149 
(Hodges-Lehmann estimate, 95% CI: 0.0707-0.3586; Mann-Whitney U test, p < 0.0034) 
(Table 4.2). For CRP, the median concentration was 7,582.4 ng/ml (interquartile range: 
2,376.9 – 16,823.3) in cases and 5,699.04 ng/ml (interquartile range: 2,066.3 – 15,646.4) in 
controls. The median difference in CRP levels was not statistically significant (p = 0.2547). 
Median IL-6 levels were zero in both cases and controls; however, the Mann-Whitney U test 
p-value was highly significant (p < 0.001), indicating that the IL-6 concentration of a 
randomly selected case was higher than would be expected by chance alone, compared with 
the IL-6 concentration of a randomly selected control.  
Many known risk factors for colorectal neoplasia were positively associated with high 
levels of CRP, IL-6 and TNF-α (Table 4.3). Older age, current smoking, and higher adiposity 
were positively associated with prevalence of high levels of the inflammatory cytokines. 
When considered in combination with action level 2 abdominal adiposity, BMI ≥ 30 (kg/m2) 
appeared to be more strongly related to high levels of inflammatory cytokines than when 
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considered alone, particularly for CRP (OR = 5.36, 95% CI: 3.61-7.96 for BMI ≥ 30 [kg/m2], 
and OR = 6.26, 95% CI: 4.04-9.68 for BMI ≥ 30 [kg/m2] and action level 2 abdominal 
adiposity). This association did not vary between men and women (p for interaction between 
obesity and sex in relation to high levels of CRP = 0.8115). 
Subjects in the highest tertiles of total energy and fat intakes were more likely to have 
high CRP than those in the lowest tertiles of intakes. Subjects in the highest tertile of fat 
intake were also more likely to have high IL-6 and TNF-α than those in the lowest tertile of 
fat intake. Prevalence of high CRP and TNF-α was inversely associated with physical 
activity above the reference level. Although regular use of NSAIDs is a generally-accepted 
protective factor for colorectal neoplasia, regular users of NSAIDs in this study had a slightly 
increased prevalence of high levels of inflammatory cytokines relative to non-regular users. 
Finally, women were more likely to have high CRP than men, although there was no 
association between sex and IL-6 or TNF-α.   
Table 4.4 shows crude and adjusted odds ratios and 95% confidence intervals for 
associations between colorectal adenomas and plasma levels of inflammatory cytokines. 
Overall, the prevalence of colorectal adenomas was positively associated with IL-6 and TNF-
α above reference levels. Specifically, for IL-6, adjusted odds ratios for colorectal adenomas 
were 1.69 (95% CI: 1.13-2.54) for the second highest category, and 1.80 (95% CI: 1.22-2.66) 
for the highest category compared with the reference category. A similar association was 
found with TNF-α, for which adjusted odds ratios for the second and third highest levels 
were 1.51 (95% CI: 1.01-2.27) and 1.59 (95% CI: 1.06-2.40), respectively. The prevalence of 
colorectal adenomas was also slightly increased in association with the highest category of 
circulating CRP only (adjusted OR = 1.34, 95% CI: 0.88-2.04).  
 125
To evaluate whether higher levels of circulating inflammatory cytokines were 
associated with advanced pathological features of colorectal adenomas, we performed 
separate analyses comparing adenoma subtypes. Out of 242 adenoma cases, 22 (9%) had 
adenomas with villous histology, 56 (23%) had adenomas ≥10 mm in diameter, and 48 (20%) 
had more than 1 adenoma. The median CRP level was 11,480.34 ng/ml (interquartile range: 
5,760.25, 25,263.24) for adenoma with villous histology, and 7,050.6 ng/ml (interquartile 
range: 2,302.28, 16,504.8) for adenomas with no villous component (Hodges-Lehmann 
estimate, 4,166.17 ng/ml [95% CI: 253.85 – 9,261.75]; Mann-Whitney U test, p < 0.0391). 
There was no significant difference in median concentrations of IL-6 and TNF-α according to 
villous histology. In addition, levels of inflammatory cytokines were not associated with 
large adenomas or multiple adenomas. 
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4.5 Discussion  
In this colonoscopy-based cross-sectional study of colorectal adenomas, circulating 
levels of IL-6 and TNF-α, and to a lesser degree CRP, were positively associated with the 
prevalence of colorectal adenomas. Several known risk factors for colorectal neoplasia also 
were associated with high levels of inflammatory cytokines, specifically older age, current 
smoking, increasing adiposity, physical inactivity, and higher caloric and fat intake.  
Previous studies have not evaluated associations between cytokine levels and 
colorectal adenomas, but several have evaluated associations with colorectal cancer, with 
mixed results. Our findings for adenomas are in agreement with results for colorectal cancer 
from a nested case-control study in the CLUEII cohort, in which Erlinger et al.(18) found a 
positive association with the highest quartile of CRP at baseline compared to the lowest 
quartile. Two prospective studies based on a Japanese population (19) and a cohort of Finish 
male smokers (20) also support an association between CRP and colorectal cancer, but there 
was no clear relationship between CRP and colorectal cancer in the Women’s Health Study 
(21), or in the Japan Collaborative Cohort Study (22). Few studies have evaluated plasma 
levels of IL-6 or TNF-α in relation to colorectal neoplasia.  Among older adults (aged 70-79 
years) participating in the Health Aging and Body Composition study, IL-6 and TNF-α as 
well as CRP were positively associated with incident cancers and cancer deaths (23). 
However, cancer site-specific estimates of associations with each cytokine were not 
presented.  
Accumulating evidence suggests that systemic inflammation might be a plausible 
mechanism for colon carcinogenesis. Studies have shown that genetic variations in 
inflammation-related genes such as IL-6, IL-8 and IL-10 are associated with susceptibility to 
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colorectal cancer and adenomas (3;9). IL-6 appears to stimulate cell growth, and inhibit 
apoptosis  (2;11). TNF-α is a key cytokine that is involved in the regulation of cytokines 
during inflammatory responses (10).  Although TNF-α was first identified as a host-induced 
substance that is selectively toxic to tumor cells at high doses (24), at physiologic levels 
TNF-α promotes cellular proliferation and inhibits apoptosis, at least partly by inducing NF-
κB (10). CRP upregulates the expression of adhesion molecules, and increases the release of 
IL-1, IL-6, IL-18, and TNF-α from mononuclear phagocytes (25). 
With regard to associations between inflammatory cytokines and risk factors for 
colorectal neoplasia, our findings are largely in agreement with previous studies. Obesity is a 
known risk factor for colorectal neoplasia, and has recently been characterized as a state of 
low-grade systemic inflammation (6). Circulating levels of inflammatory cytokines were 
elevated in obese individuals compared with lean persons (26), and levels have been shown 
to decrease after weight loss (7;27). It is now recognized that adipose tissue can synthesize 
and release cytokines such as TNF-α and IL-6 (28). Strong positive associations between 
obesity and levels of the proinflammatory cytokines in our study were consistent with 
expectations given that adipose tissue is a source of cytokines. CRP and IL-6 levels increase 
with chronological age (29;30), but it remains unclear whether this occurs as a consequence 
of aging or is simply a reflection of underlying health conditions that are more common with 
increasing age (31). Smoking also has been associated with elevated levels of CRP and IL-6 
(32-34). Although the effect of smoking on inflammatory cytokines appeared to persist for 
several years after smoking cessation in one study (33), only current (not past) smoking was 
associated with high levels of inflammatory cytokines in our study. In addition, high levels of 
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physical activity have been associated with decreased concentrations of CRP, IL-6 and TNF-
α, independent of obesity (35).   
Weak positive associations between regular use of NSAIDs and high levels of 
inflammatory cytokines were contrary to our expectations. This could have been due to 
confounding by indication because comorbidity was related both to regular use of NSAIDs 
and to high levels of inflammatory cytokines. However, adjustment for comorbidity did not 
change the direction of associations, although the strength of the associations was slightly 
attenuated. Alternatively, inflammatory cytokines measured at the time of colonoscopy may 
not have reflected typical levels among regular NSAID users, since it is recommended that 
patients abstain from NSAID use for one week prior to colonoscopy. In a placebo-controlled 
trial serum CRP levels had returned to near baseline levels 14 days after aspirin treatment 
was discontinued (36); therefore, a positive association between NSAIDs and cytokines 
might be evident if cytokine levels among regular users are elevated relative to non-users in 
the absence of NSAID use.  Finally, the protective effect of NSAIDs might not be exerted via 
modifying circulating cytokines, as we hypothesized. 
Our study has several strengths. First, colorectal adenomas were completely 
ascertained by colonoscopy to the cecum, and were reviewed by a single experienced 
pathologist. Also, detailed information on exposure history enabled the assessment of a wide 
range of potential confounding factors as well as the evaluation of relations between 
inflammatory cytokines and risk factors for colorectal neoplasia.  
The temporal ambiguity inherent in a cross-sectional study is a limitation, but it is 
unlikely that adenomas themselves would cause a systemic increase in inflammatory 
cytokines. In our study, the median size of the largest adenoma was only 5 millimeters, and  
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macrophage infiltration, which is uncommon in adenomas in general, is particularly rare in 
small adenomas (37). We recognize that a one time measurement of circulating inflammatory 
cytokines may not represent an individual’s inflammatory status during the development of 
adenomas, and that measured levels may be influenced by diurnal or stress induced variation. 
For example, patients in our study could have experienced a short-term increase in plasma 
levels of CRP, IL-6 and TNF-α given that they were awaiting colonoscopy, which may be a 
stressful event.  However, stress-induced activation of cytokines (38) would have not differed 
by case/control status. In addition, while there is a report that TNF-α is significantly lower in 
the morning than in the evening (39), CRP (40) and IL-6 (39) are tightly regulated over time, 
and are not affected by circadian variation (39). Lastly, our finding that IL-6 levels were 
below the detection limit in about 50% of cases and 65% of controls was consistent with 
expectations, since it has been recognized that IL-6 is generally undetectable in healthy 
individuals without infection, trauma or other inflammatory conditions (41).  
We have shown associations between the prevalence of colorectal adenomas and 
increased levels of IL-6 and TNF-α, and, to a lesser degree, CRP. These findings suggest that 
systemic inflammation might be involved in the early development of colorectal neoplasia, 
and support a hypothesis that inflammation might mediate the association between colorectal 
cancer and obesity and other risk factors. 
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4.8 Tables 
Table 4.1. Selected characteristics of colorectal adenoma cases and controls, Diet and Health 
Study, 1998-2002 
Characteristics Cases (N = 242) Controls (N = 631) Χ2 –p 
VALUE  NO. % NO. %  
Age (years)      
30–49 45 18.6 173 27.5  
50-64 125 51.7 335 53.2  
≥ 65 72 29.8 122 19.4 0.001 
Median age 58  54   
Sex      
Male 144 59.5 250 39.6  
Female 98 40.5 381 60.4 <0.001 
Regular use of NSAIDs      
Yes 100 45.3 323 55.3  
No 121 54.8 261 44.7 0.011 
Smoking status      
Never 95 43.4 299 51.2  
Past smokers 88 40.2 208 35.6  
Current smokers 36 16.4 77 13.2 0.13 
Body mass index (kg/m2)      
< 25 80 33.6 248 40.6  
25 – 29.9 90 37.8 213 34.9  
≥ 30 68 28.6 150 24.6 0.131 
Median body mass index 26.84  26.15   
Abdominal obesity†      
Normal  34 19.2 131 25.8  
Level 1  47 26.6 116 22.9  
Level 2 96 54.2 260 51.3 0.187 
      
Comorbidity‡      
Yes 144 65.2 336 57.6  
No 77 34.8 247 42.4 0.052 
      
Physical activity (MET/MIN/DAY)      
1st tertile (<2400) 76 39.8 175 32.5  
2nd tertile (2400 – 15269) 65 34.0 183 34.0  
3rd tertile (≥ 15270) 50 26.2 180 33.5 0.104 
Median physical activity 2670  2973   
      
Total energy intake (KCAL/DAY)     
1st tertile (1389.11) 61 29.5 183 33.3  
2nd tertile (1389.11 – 1935.63) 64 30.9 183 33.3  
3rd tertile (≥ 1935.64) 82 39.6 184 33.5 0.279 
Median energy intake 1757.72  1598.18   
      
Total fat intake (G/DAY)       
3rd tertile (47.05) 64 30.9 183 33.3  
2nd tertile (47.05 – 72.88) 60 29.0 183 33.3  
3rd tertile (≥ 72.89) 83 40.1 184 33.5 0.223 
Median fat intake 63.85  59.57   
†Defined based on waist circumference. In women, <80 (cm) defined as normal, 80-87.9 as action 
level 1, and ≥ 88 as action level 2 abdominal obesity. In men, <94 defined as normal, 94-101.9 as 
action level 1, and ≥102 as action level 2 abdominal obesity. 
‡Defined as presence of arthritis, diabetes, hypertension, or heart attack 
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Table 4.2. Median differences in inflammatory cytokines between cases and controls, Diet and 
Health Study, 1998-2002 
 Case 
Median (IQR†) 
Control 
Median (IQR†) 
HL estimator‡  
(95% CI) 
p-value* 
CRP (ng/ml) 7,582.4 
(2,376.9-16,823.3) 
5,699.04 
(2,066.3-15,646.4) 
468.43 
(-3,046.9-1,359.98) 
0.2547 
     
IL-6 (pg/ml) 0 
(0-0.041) 
0 
(0-0.11) 
0  
(0-0) 
<0.001 
     
TNF-α (pg/ml) 1.9619 
(1.419-2.771) 
1.8427 
(1.199-2.47) 
0.2149 
(0.0707-0.3586) 
0.0034 
†Interquartile ranges 
‡Hodges-Lehmann estimator 
*P-values are based on Mann-Whitney U tests 
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Table 4.3. Multivariable† associations of risk factors for colorectal neoplasia and high levels of 
inflammatory cytokines, Diet and Health Study, 1998-2002 
 OR (95% CI) 
Risk factors CRP 
(≥12013.1ng/ml) 
IL-6 
(≥0.3571pg/ml) 
TNF-α 
(≥2.2358pg/ml) 
Age (years)    
50-64 1.39 (0.97-2.0) 1.6 (1.02-2.5) 1.16 (0.82-1.65) 
≥ 65 1.62 (1.06-2.48) 2.17 (1.31-3.59) 1.94 (1.29-2.91) 
    
Female sex 2.25 (1.67-3.04) 0.85 (0.61-1.19) 0.94 (0.71-1.25) 
    
Regular use of NSAIDs  1.19 (0.88-1.62) 1.47 (1.03-2.12) 1.34 (1.0-1.81) 
    
Smoking status    
Current  2.05 (1.31-3.23) 2.59 (1.6-4.2) 1.23 (0.79-1.91) 
Past  0.85 (0.61-1.2) 1.01 (0.67-1.51) 0.93 (0.67-1.29) 
    
Obesity    
  BMI 25 – 29.9 (kg/m2) 1.94 (1.34-2.83) 1.85 (1.22-2.83) 1.46 (1.04-2.05) 
Level 1 abdominal adiposity‡ 1.75 (1.1-2.79) 1.93 (1.17-3.18) 1.44 (0.95-2.2) 
Level 2 abdominal adiposity‡ 2.1 (1.33-3.23) 1.71 (0.83-3.55) 1.46 (0.96-2.22) 
    
   BMI ≥ 30 (kg/m2) 5.36 (3.61-7.96) 2.47 (1.58-3.85) 1.91 (1.32-2.76) 
Level 1 abdominal adiposity‡ 3.54 (1.9-6.6) 1.74 (1.04-2.92) 1.63 (0.89-2.97) 
Level 2 abdominal adiposity‡ 6.26 (4.04-9.68) 2.81 (1.73-4.56) 2.03 (1.35-3.05) 
    
Physical activity (MET-minutes/day)     
2nd tertile* 0.74 (0.5-1.09) 0.71 (0.44-1.14) 0.69 (0.47-1.01) 
3rd tertile* 0.65 (0.43-0.99) 1.09 (0.68-1.74) 0.73 (0.49-1.09) 
    
Daily energy intake (kcal)    
2nd tertile* 1.06 (0.72-1.56) 0.73 (0.45-1.17) 0.80 (0.55-1.16) 
3rd tertile* 1.45 (0.97-2.16) 1.16 (0.74-1.81) 1.02 (0.7-1.49) 
    
Total daily fat intake (g)     
2nd tertile* 1.01 (0.68-1.5) 0.92 (0.57-1.48) 0.86 (0.58-1.25) 
3rd tertile* 1.48 (1.0-2.19) 1.29 (0.82-2.04) 1.24 (0.85-1.81) 
†Adjusted for age (30-49, 50-64, ≥65 years) and sex 
‡Defined based on waist circumference. In women, <80 (cm) defined as normal, 80-87.9 as action 
level 1, and ≥ 88 as action level 2 abdominal obesity. In men, <94 defined as normal, 94-101.9 as 
action level 1, and ≥102 as action level 2 abdominal obesity. 
*Tertiles are based on the distribution among controls.  
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Table 4.4 Crude and adjusted† odds ratios (OR) and 95% confidence intervals (CI) for 
associations between colorectal adenomas and plasma levels of inflammatory cytokines, Diet 
and Health Study, 1998-2002 
 Cases Controls OR (95% CI) Adj. † OR (95% CI) 
 No. % No. %   
CRP       
<2916.03 71 30.34 204 33.28 1. 1. 
2916.03-12013 75 32.05 204 33.28 1.06 (0.72-1.54) 0.97 (0.64-1.45) 
≥12013.1 88 37.61 205 33.44 1.23 (0.85-1.78) 1.34 (0.88-2.04) 
       
IL-6       
0 122 50.83 403 64.86 1. 1. 
<0.3571 54 22.5 110 17.49 1.64 (1.12-2.41) 1.69 (1.13-2.54) 
≥0.3571 64 26.67 111 17.65 1.93 (1.33-2.79) 1.80 (1.22-2.66) 
       
TNF-α       
<1.3877 53 22.36 209 33.28 1. 1. 
1.3877-2.2357 89 37.55 209 33.28 1.68 (1.14-2.48) 1.51 (1.01-2.27) 
≥2.2358 95 40.08 210 33.44 1.78 (1.21-2.63) 1.59 (1.06-2.40) 
†Adjusted for age (30-49, 50-64, ≥65 years), sex and obesity (BMI<25 kg/m2; BMI 25-29.9 kg/m2 and 
action level 1 abdominal adiposity; BMI 25-29.9 kg/m2 and action level 2 abdominal adiposity; BMI 
≥30 kg/m2 and action level 1 abdominal adiposity; or BMI ≥30 kg/m2 and action level 2 abdominal 
adiposity)  
 
 
 
 
 
5. RESULTS PAPER 2: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
AND DISTAL LARGE BOWEL CANCER IN WHITES AND AFRICAN 
AMERICANS 
 
5.1 Abstract 
The inverse association between non-steroidal anti-inflammatory drugs (NSAIDs) 
and colorectal cancer has been well documented; however, relatively few studies have 
focused specifically on rectal cancer, despite the possibility that the etiology and risk factors 
for rectal cancer might differ from colon cancer. We examined the association between 
NSAIDs and distal large bowel cancer in African Americans and whites using data from a 
population-based case-control study in North Carolina. Patients with a first diagnosis of 
invasive adenocarcinoma in sigmoid, rectosigmoid, and rectum were identified between 2001 
and 2006 through the North Carolina Central Registry. Regular NSAID use was inversely 
associated with distal large bowel cancer in whites, but not in African Americans (for regular 
vs. non-regular use, whites: OR = 0.51, 95% CI: 0.39-0.66; African Americans: OR = 0.99, 
95% CI: 0.60-1.63). Among whites, the inverse association with distal large bowel cancer 
was evident for all types of different NSAIDs, but was slightly stronger with prescription 
NSAIDs, particularly with COXibs, than with non-prescription NSAIDs. The strength of the 
association among whites was similar for more recent use, longer duration of use, and any 
regular use. Whereas regular NSAID use was inversely associated with all subsites of distal 
large bowel cancer, there was a slightly stronger inverse association with regular NSAID use 
for rectal cancer compared with sigmoid or rectosigmoid cancer. Despite extensive research 
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supporting the chemopreventive potential of NSAIDs, NSAIDs might not be effective in 
preventing all subtypes of colorectal cancer, or in preventing colorectal cancer in all 
populations. Further studies should be directed to identify characteristics of subgroups that 
might most benefit from NSAIDs. 
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5.2 Introduction 
The inverse association between non-steroidal anti-inflammatory drugs (NSAIDs) 
and colorectal cancer has been well documented (1-13); however, relatively few studies have 
focused specifically on rectal cancer, despite the possibility that the etiology and risk factors 
for rectal cancer might differ from colon cancer. The proximal and the distal parts of large 
bowel have different embryonic origins, and physiologic differences in bile salt concentration 
and bacterial populations (14). Different genetic aberrations have been associated with 
specific subsites of the large bowel (15). Moreover, although the anatomic distribution of 
colorectal cancer has been shown to differ between African Americans and whites (16;17), 
there have been few studies of risk factors for colorectal cancer in African Americans. 
The aim of our research was to examine the association between NSAIDs and 
adenocarcinoma in distal large bowel (i.e., sigmoid, rectosigmoid, and rectum) in African 
Americans and whites. We also explored associations with NSAIDs by level of obesity 
(defined by body mass index), since a previous finding suggested a more pronounced effect 
of aspirin in preventing colorectal adenomas among obese versus non-obese individuals (18). 
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5.3 Materials and Methods 
5.3.1 STUDY POPULATION 
We used data from phase II of the North Carolina Colon Cancer Study (NCCCS-II). 
The NCCCS-II is a population-based case-control study in 33 counties in the central and 
eastern part of North Carolina. Between October 1, 2001 and May 31, 2006, patients with a 
first diagnosis of invasive adenocarcinoma in sigmoid, rectosigmoid, and rectum were 
identified through the rapid ascertainment system of the North Carolina Central Cancer 
Registry. The procedure for case ascertainment and its effectiveness has been described in 
detail elsewhere (19). Cases were eligible for the study if they were residents of the selected 
counties, aged between 40 and 80 years, African American or white race, had a North 
Carolina driver’s license or identification card, and were able to complete an interview in 
English. A total of 1,831 potentially eligible cases were identified; of these, 57 (3%) were 
excluded for physician refusal, and 357 (20%) were found ineligible. Of the remaining 1,417 
eligible cases, 118 (8%) were not able to be contacted, 242 (17%) refused to participate, and 
1,057 (75%) completed an in-person interview.  
Controls were randomly selected from North Carolina Division of Motor Vehicle 
records, based on sampling probabilities within blocks defined by 5-year age group, sex and 
race, using the technique of randomized recruitment (20). Initially, 2,345 subjects were 
identified as potentially eligible controls. However, 521 (22%) were found ineligible. Of the 
1,824 eligible controls, 325 (18%) were not able to be contacted, and 483 (26%) refused to 
participate. A total of 1,019 (56% of eligible controls) completed an interview. The final 
dataset for analysis included 1,057 cases and 1,019 controls. The final dataset for analysis 
included 1,057 cases and 1,019 controls. The study was approved by the Institutional Review 
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Board at University of North Carolina School of Medicine, and all subjects provided written 
informed consent. 
 
5.3.2 DATA COLLECTION 
In-person interviews were conducted in the subjects’ home or in another convenient 
location by trained nurse interviewers using a standard questionnaire. The questionnaire 
included information regarding demographic characteristics, socioeconomic indicators (such 
as years of education, income level, and occupation history), medication use, medical history, 
family history of cancer, smoking habits, and level of physical activity and weight 1 year 
prior to diagnosis (for cases) or interview (for controls). Current weight and height at the 
time of interview were also measured.  Dietary intake was assessed with the Diet History 
Questionnaire, developed and evaluated at the National Cancer Institute (21). Cancer stage 
(local, regional, distant, or unknown), tumor location (sigmoid, rectosigmoid, or rectum), and 
other diagnosis-related data were available from the Central Cancer Registry. 
 
5.3.3 ASSESSMENT OF NSAIDS 
 We assessed NSAID use during the past five years (for controls) and five years prior 
to diagnosis (for cases). For the purpose of data collection, NSAIDs were classified into four 
categories:  1) over-the-counter aspirin (e.g, Bufferin, Anacin, ExcedrinTM, BC or Goody’s 
powder, or Alka SeltzerTM); 2) over-the-counter non-aspirin pain medications (e.g., AdvilTM, 
MortrinTM, AleveTM); 3) prescription pain medications (e.g., MortrinTM, DayproTM, 
NaprosynTM, FeldeneTM); and 4) prescription selective COX-2 inhibitors (e.g., VioxxTM or 
CelebrexTM). For each NSAID category, respondents who reported ever use of NSAIDs were 
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asked about frequency, duration, and their use 1 year prior to diagnosis (for cases) or  
interview (for controls). Use of acetaminophen or TylenolTM, which is an antipyretic and 
analgesic with very weak anti-inflammatory activity, was queried separately and was not 
classified as an NSAID in analyses (22). 
 
5.3.4 STATISTICAL ANALYSIS 
We stratified study participants by race to compare distributions of selected 
characteristics between cases and controls. Odds ratios (OR) and 95% confidence intervals 
for the association between regular use of NSAIDs and distal large bowel cancer were 
estimated from unconditional logistic regression models. Regular use was defined as taking 
NSAIDs at least 3 times per week. Subjects who reported no use or use of NSAIDs less than 
3 times per week were classified as “non-regular users”, and served as the referent group. In 
addition, we examined recency of use (defined as use in the past year or not), duration of use 
(categorized as ≥ 1 year, or < 1 year), and use of different types of NSAIDs (any over-the-
counter NSAIDs, over-the-counter aspirin, over-the-counter non-aspirin NSAIDs, any 
prescription NSAIDs, prescription COX-2 inhibitors (COXibs), and other prescription 
NSAIDs) among regular users. All logistic regression models included age (continuous), sex, 
race and an offset term to adjust for sampling probability. Other potential covariates assessed 
for inclusion in multivariable models were: years of education (<12, 12-15, or ≥ 16 years), 
annual household income (<15,000, 15,000-25,000, 25,000-50,000, or ≥ 50,000 dollars), 
smoking status (current, past, or never) at the time of diagnosis (for cases) or interview (for 
controls), family history of colorectal cancer (having at least 1 first degree family member 
with colorectal cancer, or not), comorbidity (having at least one of the following conditions: 
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arthritis, hypertension, heart attack, or diabetes) prior to diagnosis (for cases) or at the time of 
interview (for controls), body mass index (BMI) 1 year ago (normal or underweight: < 25, 
overweight: 25-29.9, or obese: ≥ 30 kg/m2), physical activity 1 year ago (tertiles based on the 
distribution among controls), calcium supplement use during the past 5 years (yes or no), and 
dietary intakes of energy and fat during the past year (tertiles based on the distributions 
among controls). To determine which covariates should be entered in the final multivariable 
models, we constructed a full model with all potential confounders, and assessed the change 
in beta coefficients for regular use versus non-regular use of NSAIDs in relation to distal 
large bowel cancer when covariates were removed. Only BMI 1 year prior resulted in more 
than a 10% of change in the beta coefficient, and was included in the final multivariable 
models in addition to matching factors (age, sex, race and a sampling probability offset term). 
To examine possible effect modification of the association between regular use of NSAIDs 
and distal large bowel cancer, we performed analysis stratified by race, and by three 
categories of BMI 1 year prior. Likelihood ratio tests comparing models with and without 
multiplicative interaction terms were used to assess odds ratio modification (statistical 
interaction). We used multinomial logistic regression to simultaneously estimate ORs and 
95% confidence intervals for sigmoid, rectosigmoid, and rectal cancers, compared with 
controls. Wald statistics were used to assess statistical heterogeneity among the three subsite-
specific effect estimates. 
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5.4 Results 
The study consisted of 1,631 white (790 cases and 841 controls), and 445 African 
American (267 cases and 178 controls) participants (Table 5.1). The proportion of patients 
with rectal cancer was higher among African American cancer cases than white cases (51.3% 
vs. 43.4%, p = 0.014). In both races, cases were younger, less educated, and more reported 
having a family member with colorectal cancer than controls. Cases also had higher intakes 
of energy and dietary fat, and were less likely to use calcium supplements compared to 
controls. Overall, African Americans were overrepresented in low income categories. 
Relative to white controls, African American controls also tended to be current smokers, 
physically less active, and had higher BMI.  
 Approximately 72% cases and 82% controls reported regular use of any NSAIDs in 
the past 5 years (Table 5.2). Overall, compared with non-regular use (i.e., no use or 
infrequent use), regular use of NSAIDs was inversely associated with distal large bowel 
cancer (OR = 0.58, 95% CI: 0.46-0.73) after adjustment for age, sex, race, BMI, and 
sampling probability. The strength of the association with regular NSAID use was similar for 
recent use and use for one year or longer. Associations were also similar with different 
categories of NSAIDs, though inverse associations were slightly stronger for prescription 
than non-prescription NSAIDs, particularly for selective COX-2 inhibitors (COXibs).  
 When stratified by race, inverse associations that were consistent with those estimated 
for the population as a whole were present for whites, but there was little evidence of an 
association between NSAIDs and distal large bowel cancer among African Americans (for 
regular vs. non-regular use, whites: OR = 0.51, 95% CI: 0.39-0.66; African Americans: OR = 
0.99, 95% CI: 0.60-1.63) (Table 5.3). Prescription COXibs and non-COXibs were inversely 
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associated with distal large bowel cancer among African Americans, but the magnitude of the 
associations were weaker than those estimated for whites (OR = 0.71, 95% CI: 0.36-1.38 for 
COXibs; OR = 0.70; 95% CI: 0.37-1.30 for non-COXibs among African Americans). 
Likelihood ratio tests indicated that chance variation was an unlikely explanation for the 
differences observed in odds ratio estimates for African Americans and whites (all p-values ≤ 
0.10).  
In Table 5.4, we show the association between regular NSAID use and sigmoid, 
rectosigmoid, and rectal cancer in the population as a whole. Regular NSAID use was 
inversely associated with all subsites of distal large bowel cancer. However, the strength of 
the association appeared to be slightly higher with rectal cancer, compared to rectosigmoid or 
sigmoid cancer. For example, the multivariable OR associated with regular use of aspirin was 
0.45 (95% CI: 0.32-0.62) for rectal cancer, while the ORs were 0.47 (95% CI: 0.30-0.76) for 
rectosigmoid cancer and 0.74 (95% CI: 0.54-1.01) for sigmoid cancer (p-value for 
heterogeneity = 0.0187). Similarly, the multivariable OR associated with COXibs was 0.32 
(95% CI: 0.21-0.48) for rectal cancer, while the ORs were 0.58 (95% CI: 0.34-0.99) and 0.56 
(95% CI: 0.38-0.81) for rectosigmoid and sigmoid cancers, respectively (p-value for 
heterogeneity = 0.0348). We also examined the subsite-specific associations with NSAIDs by 
race (table not shown). Whereas there was a more pronounced inverse association with rectal 
cancer observed in whites, we did not find difference in the association by tumor location 
among African Americans.  
Lastly, we explored the association between NSAID use and distal colorectal cancer 
stratified by BMI (underweight/normal, overweight, or obese) (Table 5.5). Overall, we did 
not find any evidence supporting effect modification of NSAIDs by BMI. Although there 
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was a significant interaction between regular use of NSAIDs and BMI in African Americans 
(p = 0.0021), the confidence intervals for the estimates were very wide, reflecting a poor 
precision. 
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5.5 Discussion 
We found that regular NSAID use was inversely associated with distal large bowel 
cancer in whites, but not in African Americans. Among whites, the inverse association with 
distal large bowel cancer was evident for all types of different NSAIDs, but was slightly 
stronger with prescription NSAIDs, particularly with COXibs, than with non-prescription 
NSAIDs. The strength of the association among whites was similar for more recent use, 
longer duration of use, and any regular use. We also observed a slightly stronger inverse 
association with regular NSAID use for rectal cancer compared with sigmoid or rectosigmoid 
cancer, although regular NSAID use was inversely associated with all subsites of distal large 
bowel cancer. 
The exact mechanism of the association between NSAIDs and colorectal cancer 
remains unclear; however, the antineoplastic properties of NSAIDs are largely attributed to 
inhibition of cyclooxygenase (COX) enzyme, particularly COX-2 (23). COX-2 is an 
inducible form of COX that is expressed  in response to proinflammatory and mitogenic 
stimuli (24;25). The proportion of COX-2 positive cells in clinical colon cancer samples is up 
to 90%, but less or not expressed in normal colonic tissues (26). NSAIDs suppress COX-2-
induced angiogenesis and resistance to apoptosis in experimental studies (27), and aspirin has 
been associated with a reduced risk of colorectal adenomas, a precursor to colorectal cancer 
in randomized clinical studies (28;29).  
Our results among whites are consistent with previous epidemiologic research that 
has shown that individuals taking aspirin/NSAIDs regularly (2-3 times/week) had a reduced 
risk of colorectal cancer when compared with those who did not (1-13). It has been suggested 
that protection from NSAIDs increases with longer duration of use, and with a higher dosage 
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(30). However, longer duration (defined as ≥ 1 year) of regular use did not confer a greater 
protection compared with less than 1 year of regular use in our study, possibly due to a 
relatively short period of time to define a long-term use in our study.  
The dose of NSAIDs used also has been proposed to be a critical factor in colorectal 
cancer prevention (30). Negative findings from two randomized clinical trials  that treated 
participants with 325 mg (31) , or 100 mg aspirin (32) on alternate days were partly 
attributed to the low dose of NSAIDs used in the interventions, which were less than the dose 
used to define “regular users” in most observational epidemiologic studies (31). For the 
present study, we defined regular users as those who used NSAIDs for at least 3 times per 
week, and combined less frequent users and never users in a single referent group. We also 
assessed different types of NSAIDs in relation to distal large bowel cancer, and observed a 
slightly stronger association with prescription NSAIDs relative to over-the-counter NSAIDs. 
Given that the dose of prescription NSAIDs is generally higher than the dose of non-
prescription NSAIDs (33), this result might suggest that high dose of NSAIDs are more 
effective in preventing colorectal cancer. 
Few studies have included adequate numbers of African Americans to obtain 
meaningful information on NSAID use in relation to colorectal cancer. Our group previously 
reported similar inverse associations between NSAIDs and colon cancer for African 
Americans and whites in North Carolina (34). In the current study of sigmoid, rectosigmoid 
and rectal cancer among North Carolina patients, however, we did not observe an inverse 
association with regular NSAID use in African Americans. We can speculate about the 
reasons for the differences between colon and distal large bowel cancer cases drawn from the 
same population. First, the association with NSAIDs in African Americans might not be as 
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strong as in whites. Non-significant, inverse association only with prescription NSAIDs in 
African Americans in our analysis might support such an explanation. Secondly, the sample 
size of African Americans might not be large enough to reveal an association between 
NSAIDs and distal large bowel cancer. Thirdly, there might be differences in tumor biology 
between African Americans and whites that explain the lack of association between NSAIDs 
and distal large bowel cancer in African Americans. Racial differences in anatomic location 
of colorectal cancer have been noted: compared to whites, African Americans are more likely 
to develop proximal colorectal cancer, suggesting differences in etiology or genetics (16;17).  
For example, emerging data show that the associations between NSAIDs and colorectal 
cancer might vary depending on tumor characteristics or subjects’ genotypes. According to a 
recent study, regular use of aspirin was inversely associated with colorectal tumors 
characterized by modest to strong COX-2 expression, but was not associated with tumors that 
had weak or absent COX-2 expression (35); therefore, differences in COX-2 expression by 
race might result in differences in associations with NSAIDs by race. Finally, several studies 
have reported on polymorphisms of inflammation-related genes and their interactions with 
NSAID use (36-38). Interestingly, the COX-2 V511A polymorphism, which is exclusively 
found in African Americans, (albeit at a low allele frequency [~5%]), appears to be inversely 
associated with colorectal neoplasia like NSAIDs (36). Future studies investigating of racial 
differences in tumor COX-2 expression and associations with NSAIDs according to COX-2 
expression could help clarify whether no association between NSAIDs and distal large bowel 
cancer found in African Americans are truly attributed to racial differences in tumor 
characteristics. 
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Although regular NSAID use was inversely associated with all subsites of large 
bowel cancer in our study, there was a slightly stronger association with NSAIDs for rectal 
cancer compared to sigmoid or rectosigmoid cancer. The literature on this topic is mixed. 
Our results are similar to previous research that has found a stronger association with rectal 
cancer relative to colon cancer (6;13). On the other hand, some studies have reported a more 
pronounced association with colon cancer than with rectal cancer (7;39), and others found no 
difference with respect to tumor location (2;4;9;11;12).  
Unlike our previous finding that aspirin might be more effective in preventing 
colorectal adenomas among obese individuals who presumably have higher levels of 
proinflammatory cytokines compared with non-obese individuals (18), the current study did 
not find a more pronounced inverse association between NSAIDs and colorectal cancer with 
increasing BMI. Although the association between NSAIDs and distal large bowel cancer 
varied according to BMI in African Americans, it is hard to draw meaningful conclusion 
from the finding because of the overall poor precision of the estimates.  
Several potential limitations of our study should be considered. First, we assessed 
NSAID exposure based on self-report data. Although NSAID use may be under-reported by 
participants (40), pharmacy records do not capture over-the-counter NSAID use, which 
comprises the majority of NSAID use. There is little reason to believe that differential 
misclassification of NSAID exposures by cases and controls would explain the observed 
inverse association because we observed no inverse association with acetaminophen use in 
our study population. Second, although we evaluated and adjusted for a range of potential 
confounding factors, our effect estimates for the association might have been biased by 
residual confounding by unknown factors related to the indication for NSAID use. However, 
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to explain the association observed, such a factor would have to be strongly associated with 
both NSAID use and distal large bowel cancer, and be common in our study population (41).  
Strengths of our study relative to previous research include its exclusive focus on 
distal large bowel. Despite anatomic and biologic differences (14), relatively few 
epidemiologic studies have evaluated risk factors for sigmoid, rectosigmoid, and rectal 
cancers specifically. Our study also included a relatively large numbers of African American 
cases and controls. Whereas African Americans have the highest incidence and mortality rate 
for colorectal cancer among racial groups (42), etiologic studies in this population have been 
few. 
Despite extensive research supporting the chemopreventive potential of NSAIDs, 
NSAIDs might not be effective in preventing all subtypes of colorectal cancer, or in 
preventing colorectal cancer in all populations. Further studies should be directed to identify 
characteristics of subgroups that might most benefit from NSAIDs. 
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5.8 Tables 
Table 5.1 Characteristics of distal large bowel cancer cases and controls, by race, North 
Carolina Colon Cancer Study II, 2001-2006 
 Whites  African Americans 
    
 Cases Controls p-value†  Cases Controls p-value† 
 N (%) N (%)   N (%) N (%)  
Total 790 841   267 178  
Location of tumor       0.014* 
Sigmoid 304 (38.5)    100 (37.5)   
Rectosigmoid 143 (18.1)    30 (11.2)   
Rectum 343 (43.4)    137 (51.3)   
Age (years)        
40-49 111 (14.1) 80 (9.5) 0.003  40 (15.0) 21 (11.8) 0.35 
50-59 212 (26.8) 195 (23.2)   77 (28.8) 45 (25.3)  
60-69 230 (29.1) 268 (31.9)   89 (33.3) 59 (33.2)  
70-79 237 (30) 298 (35.4)   61 (22.9) 53 (29.8)  
Median age 60 64   59 63  
Sex        
Male 457 (57.9) 509 (60.5) 0.272  140 (52.4) 92 (51.7) 0.877 
Female 333 (42.2) 332 (39.5)   127 (47.6) 86 (48.3)  
Years of education        
< 12 124 (16.2) 81 (9.8) 0.000  77 (30.1) 40 (23.1) 0.28 
12 – 15 420 (55.0) 403 (48.9)   132 (51.6) 97 (56.1)  
≥ 16 220 (28.8) 340 (41.3)   47 (18.4) 36 (20.8)  
Annual household income ($)        
≤ 15,000 93 (12.8) 79 (10.1) 0.158  85 (37.6) 60 (38.7) 0.976 
15,000 – 25,000 123 (16.9) 120 (15.4)   42 (18.6) 26 (16.8)  
25,000 – 50,000 192 (26.5) 200 (25.6)   47 (20.8) 33 (21.3)  
>50,000 318 (43.8) 382 (48.9)   52 (23.0) 36 (23.2)  
Smoking status        
Never 285 (37.4) 309 (37.8) 0.509  98 (38.3) 75 (43.4) 0.173 
Past smokers 357 (46.8) 396 (48.4)   94 (36.7) 68 (39.3)  
Current smokers 121 (15.9) 113 (13.8)   64 (25.0) 30 (17.3)  
Family history of colorectal 
cancer‡ 
       
Yes 103 (18.5) 93 (15.0) 0.103  33 (18.3) 11 (8.6) 0.016 
No 454 (81.5) 529 (85.1)   147 (81.7) 117 (91.4)  
Comorbid condition§        
Yes 525 (84.4) 607 (85.6) 0.537  198 (95.2) 146 (94.2) 0.673 
No 97 (15.6) 102 (14.4)   10 (4.8) 9 (5.81)  
Body mass index (kg/m2)        
< 25 177 (24.1) 254 (31.7) 0.000  49 (20.3) 34 (20.4) 0.474 
25 – 29.9 278 (37.8) 325 (40.5)   75 (31.1) 61 (36.5)  
≥ 30 281 (38.2) 223 (27.8)   117 (48.6) 72 (43.1)  
Median body mass index 28.1 26.9   29.8 29.1  
†P-values were based on chi-square tests 
*P-value was obtained from comparison between race and tumor location 
‡ Having first degree of family members diagnosed of colorectal cancer 
§Having at least of the following conditions: arthritis, hypertension, heart attack or heart problems, or 
diabetes 
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Table 5.1 (continued) Characteristics of distal large bowel cancer cases and controls, by race, 
North Carolina Colon Cancer Study II, 2001-2006  
 Whites  African Americans 
    
 Cases Controls p-value† Cases Controls p-value† 
 N (%) N (%)   N (%) N (%)  
Calcium supplement use 264 (34.8) 375 (45.7) 0.000  69 (27.1) 55 (32.0) 0.272 
Yes 495 (65.2) 446 (54.3)   186 (72.9) 117 (68.0)  
No        
Physical activity (average 
MET-minutes/day) ‡ 
       
1st tertile (<1,882) 243 (33.2) 260 (32.8) 0.208  93 (38.6) 57 (34.6) 0.041 
2nd tertile (1,882 – 2,078) 212 (29.0) 260 (32.8)   61 (25.4) 61 (37.0)  
3rd tertile (≥ 2,078) 277 (37.8) 272 (34.3)   86 (35.7) 47(28.5)  
Median physical activity 1,968.6 1,974   1,938.9 1,920.9  
Total energy intake 
(kcal/day) ‡ 
       
1st tertile (<1,711) 220 (28.3) 277 (33.1) 0.004  72 (28.2) 60 (34.7) 0.117 
2nd tertile (1,711 – 2,414) 246 (31.7) 292 (34.8)   57 (22.4) 45 (26.0)  
3rd tertile (≥ 2,414) 311 (40.0) 269 (32.1)   126 (49.4) 68 (39.3)  
Median energy intake 2,142.1 1,992.3   2,405.3 2,139.3  
Dietary fat intake (g/day) ‡        
1st tertile (<,64) 203 (26.1) 273 (32.6) 0.000  70 (27.5) 57 (33.0) 0.457 
2nd tertile (64 – 98) 259 (33.3) 302 (36.0)   72 (28.2) 47 (27.2)  
3rd tertile (≥ 98) 315 (40.5) 263 (31.4)   113 (44.3) 69 (40.0)  
Median dietary fat intake 86.7 78.9   86.7 80.0  
†P-values were based on chi-square tests 
‡ Tertiles were based on distributions among controls 
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Table 5.2 Odds ratios and 95% confidence intervals for association between regular use of non-
steroidal anti-inflammatory drug and distal large bowel cancer, North Carolina Colon Cancer 
Study II, 2001-2006 
 Cases Controls OR* Multivariable OR† 
 N (%) N (%) (95% CI) (95% CI) 
Non-regular use 248 (28.3) 163 (18.5) 1. (Referent) 1. (Referent) 
Any NSAIDs 628 (71.7) 717 (81.5) 0.62 (0.49-0.77) 0.58 (0.46-0.73) 
Recent use‡ 512 (58.5) 645 (73.3) 0.56 (0.45-0.71) 0.53 (0.42-0.67) 
Duration of use     
< 1 year 251 (28.7) 242 (27.5) 0.68 (0.52-0.89) 0.61 (0.46-0.80) 
≥ 1 year 377 (43.0) 475 (54.0) 0.58 (0.46-0.75) 0.56 (0.44-0.72) 
By type     
OTC NSAIDs§ 501 (57.1) 571 (64.9) 0.63 (0.50-0.80) 0.59 (0.47-0.76) 
Aspirin  399 (45.6) 480 (54.6) 0.61 (0.48-0.77) 0.57 (0.44-0.73) 
NA-NSAIDs# 188 (21.5) 194 (22.1) 0.66 (0.50-0.88) 0.62 (0.46-0.83) 
Prescription NSAIDs 287 (32.8) 363 (41.3) 0.54 (0.42-0.70) 0.50 (0.38-0.65) 
COXibs 164 (18.7) 235 (26.7) 0.50 (0.37-0.66) 0.46 (0.34-0.61) 
Non-COXibs 174 (19.9) 203 (23.1) 0.57 (0.43-0.76) 0.52 (0.39-0.70) 
* Adjusted for age (continuous), sex, race (African American or White), and sampling probability 
† Adjusted for age (continuous), sex, race (African American or White), sampling probability, and 
BMI (<25, 25-29.9, or ≥30 kg/m2) 
‡ Continuing use in the past year before diagnosis/interview  
§ Over-the-counter NSAIDs  
# Non-aspirin NSAIDs  
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Table 5.3 Associations between regular use of non-steroidal anti-inflammatory drug and distal 
large bowel cancer, by race, North Carolina Colon Cancer Study II, 2001-2006 
 Whites 
(N = 1,631) 
 African Americans 
(N = 445) 
 No. of 
cases/controls OR
† 95% CI  No. of cases/controls OR
† 95% CI 
Non-regular use 190/121 1. Referent  58/42 1. Referent 
        
Any NSAIDs 483/616 0.51 0.39-0.66  145/101 0.99 0.60-1.63 
Recent use‡ 395/554 0.46 0.35-0.61  117/91 0.86 0.51-1.43 
        
Duration of use        
< 1 year 180/197 0.53 0.39-0.73  71/45 0.96 0.54-1.70 
≥ 1 year 303/419 0.49 0.37-0.65  74/56 0.94 0.55-1.63 
        
By type        
OTC NSAIDs§ 386/499 0.51 0.38-0.66  115/72 1.07 0.64-1.80 
Aspirin  308/420 0.49 0.37-0.65  91/60 0.99 0.58-1.69 
NA-NSAIDs# 141/172 0.50 0.36-0.69  47/122 1.53 0.78-2.98 
        
Prescription NSAIDs 225/309 0.45 0.34-0.61  62/54 0.71 0.40-1.24 
COXibs 134/206 0.40 0.29-0.56  30/29 0.71 0.36-1.38 
    Non-COXibs 132/168 0.48 0.34-0.67  42/35 0.70 0.37-1.30 
†Adjusted for age (continuous), sex, race (African American or White), sampling probability, and 
BMI (<25, 25-29.9, or ≥30 kg/m2) 
‡ Continuing use in the past year before diagnosis/interview 
§ Over-the-counter NSAIDs  
# Non-aspirin NSAIDs 
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Table 5.4 Associations between regular use of non-steroidal anti-inflammatory drug and distal large bowel cancer, by tumor location, North 
Carolina Colon Cancer Study II, 2001-2006 
  Sigmoid  Rectosigmoid  Rectum 
 No. of 
controls 
No. of 
cases OR
† 95% CI  No. of cases OR
† 95% CI  No. of cases OR
† 95% CI 
Non-regular use 163 100 1. Referent  40 1. Referent  108 1. Referent 
             
Any NSAIDs 717 306 0.69 0.52-0.93  91 0.54 0.35-0.82  231 0.49 0.37-0.67 
Recent use‡ 645 259 0.66 0.48-0.89  70 0.48 0.30-0.73  183 0.44 0.32-0.59 
             
Duration of use             
< 1 year 242 123 0.71 0.51-1.01  40 0.62 0.37-1.03  88 0.51 0.36-0.73 
≥ 1 year 475 183 0.68 0.49-0.94  51 0.49 0.30-0.78  143 0.49 0.35-0.67 
             
By type             
OTC NSAIDs§ 571 246 0.72 0.53-0.97  70 0.52 0.33-0.81  185 0.51 0.38-0.69 
Aspirin  480 210 0.74 0.54-1.01  52 0.47 0.30-0.76  137 0.45 0.32-0.62 
NA-NSAIDs# 194 88 0.72 0.50-1.04  30 0.59 0.34-1.02  70 0.54 0.37-0.79 
             
Prescription NSAIDs 363 135 0.56 0.40-0.78  51 0.60 0.38-0.97  101 0.41 0.29-0.57 
COXibs 235 83 0.56 0.38-0.81  31 0.58 0.34-0.99  50 0.32 0.21-0.48 
    Non-COXibs 203 80 0.57 0.39-0.83  34 0.69 0.41-1.16  60 0.42 0.28-0.62 
†Adjusted for age (continuous), sex, race (African American or White), sampling probability, and BMI (<25, 25-29.9, or ≥30 kg/m2) 
‡ Continuing use in the past year before diagnosis/interview  
§ Over-the-counter NSAIDs 
# Non-aspirin NSAIDs 
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Table 5.5 Associations of regular use of any non-steroidal anti-inflammatory drugs and body mass index in sigmoid/rectosigmoid/rectal 
cancer in all participants, and by race, North Carolina Colon Cancer Study II, 2001-2006 
 Body mass index (kg/ m2)   
 <25  25-29.9  ≥ 30   
 No. of  
cases/controls OR
† 95% CI  No. of  cases/controls OR
† 95% CI  No. of  cases/controls OR
† 95% CI  p-value
‡ 
Total              
Non-regular  70/65 1. Referent  88/61 1. Referent  79/34 1. Referent  0.647 
Regular  126/194 0.68 0.45-1.02  208/270 0.55 0.38-0.81  266/235 0.52 0.33-0.81   
Whites              
Non-regular  58/47 1.   73/48 1.   52/25 1.   0.907 
Regular  99/185 0.47 0.29-0.74  168/235 0.49 0.32-0.74  197/180 0.54 0.32-0.92   
African 
Americans 
             
Non-regular 12/18 1.   15/13 1.   27/9 1.   0.002 
Regular  27/9 4.93 1.67-
14.60 
 40/35 0.94 0.39-2.28  69/55 0.44 0.19-1.04   
†Adjusted for age (continuous), sex, race (African American or White), sampling probability  
‡ P-values were based on log likelihood ratio tests comparing models with and without interaction term with BMI (<25, 25-29.9, or ≥30 kg/m2) 
 
 
 
 
 
6. RESULTS PAPER 3: OBESITY AND RISK OF COLORECTAL ADENOMAS 
IN PATIENTS WITH CURATIVELY RESECTED COLORECTAL CANCER  
 
6.1 Abstract 
Maintaining healthy weight is generally recommended to cancer survivors for longer 
disease-free survival and quality of life; however, little is known regarding the association 
between obesity and adenoma occurrence in patients with colorectal cancer. We examined 
the association between obesity and risk of incident colorectal adenomas in patients with 
curatively resected colorectal cancer, using data from a randomized controlled trial of aspirin 
325 mg daily to prevent colorectal adenomas. We also investigated whether the effect of 
aspirin treatment in preventing colorectal adenomas was modified by obesity status because a 
previous study suggested that aspirin was more effective in preventing adenomas in obese 
individuals. There was an elevated risk of incident colorectal adenomas in relation to 
increasing BMI in both men and women, but none of the association was statistically 
significant (RR = 1.44 [95% CI: 0.79-2.60] in men, and 1.31 [95% CI: 0.64-2.66] in women). 
We also assessed a possible interaction between aspirin treatment and BMI: however, there 
was no evidence supporting the idea that aspirin treatment was more effective in preventing 
colorectal adenomas in subjects with higher BMI compared with subjects with normal BMI. 
This study suggests that obesity might be a risk factor for incident colorectal adenomas in 
patients with a history of colorectal cancer, and the effect of aspirin was not stronger in obese 
patients compared with non-obese patients. Given that obesity is a modifiable risk factor, 
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patients with curatively resected colorectal cancer should be guided to maintain healthy 
weights. 
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6.2 Introduction 
Colorectal cancer is an important public health problem in the United States with 
153,760 new cases and 52,180 deaths estimated in 2007 (1). It is generally believed that most 
colorectal cancers arise from adenomas (2). Prevention and delay of adenoma occurrence is 
thought to be a good strategy to prevent fatal outcome of colorectal cancers. Screening for 
and surgical or endoscopic removal of adenomas are recommended (3). 
Obesity has been associated with the entire spectrums of colorectal neoplasia: 
increasing obesity has been positively associated with adenomas (4), invasive cancer (5;6) 
and colon cancer deaths (7). Based on the observations, maintaining healthy weight is also 
recommended to cancer survivors for potentially longer disease-free survival and quality of 
life (8). However, there has been limited information regarding the effect of obesity on 
patients with a history of colorectal cancer.  
We examined the association between obesity and risk of incident colorectal 
adenomas in patients with curatively resected colorectal cancer, using data from a 
randomized controlled trial of aspirin to prevent colorectal adenomas. Further, we 
investigated whether effect of aspirin treatment in preventing colorectal adenomas was 
modified by obesity status in order to confirm or refute findings from our previous study that 
suggested that aspirin was more effective in preventing adenomas in obese individuals (9).  
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6.3 Materials and Methods 
6.3.1 CALGB COLORECTAL ADENOMA PREVENTION STUDY 
The design, methods, and primary results of the Cancer and Leukemia Group B 
Colorectal Adenoma Prevention Study (CALGB 9270) have been described in detail (7). 
Briefly, the CALGB 9270 study was a randomized, double-blind, placebo-controlled multi-
institutional trial of daily use of 325 mg of aspirin to decrease the occurrence of new 
colorectal adenomas among patients with a history of colorectal cancer.  
Study participants were aged 30-80, in good health, and had history of CRC with a 
low risk of recurrence (defined as Duke’s stage A or B1, or stage B2 or C with no evidence 
of disease at 5 years). All subjects had to undergo a complete colonoscopy, and have all 
polyps removed, within the 4 months prior to study entry. Patients with a recurrent or a new 
onset of cancer, heart disease, or possible contraindications to aspirin were excluded.  
Between May 15, 1993, and January 10, 2000, 719 participants were registered for 
the trial, and 635 completed the run-in period and underwent randomization (317 to aspirin 
and 318 to placebo). The primary end point of the study was the detection of adenomas in the 
large bowel during follow-up colonoscopic or sigmoidoscopic examinations after 
randomization. Overall, 517 out of 635 randomized patients (81%) had at least one 
colonoscopic examination after randomization (258 in the placebo group and 259 in the 
aspirin group) after an average of 12.8 months of treatment. Body weight and height were 
measured by research staff at baseline.  
Colonoscopic examinations were performed by each patient’s gastroenterologist or 
surgeon as a part of their usual follow-up. Endoscopists were instructed to remove all raised 
lesions, and biopsy specimens were submitted to local pathologists for review. The study 
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chair (R.S.) reviewed a copy of the colonoscopy and pathology reports to verify the adequacy 
and extent of the examination and the size, location, and pathological findings of any lesions. 
The trial was originally planned for three years of follow-up, but was terminated by an 
external Data and Safety Monitoring Committee when a planned interim analysis 
demonstrated significant risk reduction of colorectal adenomas with 325 mg of daily aspirin 
use.  
 
6.3.2 STATISTICAL ANALYSIS 
We compared patient characteristics according to three categories BMI using chi-
square tests for categorical variables (treatment assignment, body mass index, age, sex, race, 
cancer stage, type of surgery, and number of colonoscopic examination after randomization), 
or Kruskal-Wallis tests for continuous variables (time since diagnosis, and time to first and 
last colonoscopy). Body mass index (BMI) was calculated based on height and weight 
measured at baseline in 482 subjects; 7 subjects were missing information on either height or 
weight, and 28 subjects had implausible height (defined as <130 or >220 centimeter), or 
weight (defined as > 200 kilograms) values. On the basis of BMI, subjects were categorized 
into normal (BMI<25 kg/m2), overweight (BMI 25-29.9 kg/m2), or obese (BMI ≥ 30 
kg/m2)(11). Body mass index (BMI) was calculated based on height and weight measured at 
baseline. Based on the calculated BMI, subjects were classified into three groups: obese 
(BMI ≥ 30 kg/m2), overweight (BMI 25-29 kg/m2) and normal weight or underweight (BMI 
< 25 kg/m2).  
The association between BMI and incident colorectal adenomas was examined using 
a Poisson model with robust error variance. We used a modified Poisson model to estimate 
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risk ratios because the conventionally employed log-linear models failed to converge (12).  
We also assessed whether the association between BMI and incident colorectal adenomas 
was modified by sex, using multivariable analysis including product terms between sex and 
three categories of BMI in the model. We then examined potential effect modification of 
aspirin by levels of BMI on incident colorectal adenomas in all subjects and by sex. P-values 
were obtained from “chunk tests” of two interaction terms between aspirin treatment and two 
levels of BMI (BMI 25-29.9, and BMI≥ 30 kg/m2). All tests were two-sided. We used Stata 
version 9.0 (Texas Station, TX) for all analyses. In all analyses we adjusted for age (30-49, 
50-59, 60-69, or ≥ 70 years), sex (except in sex-specific models), treatment assignment, 
cancer stage (Dukes’ A or B1, or Dukes’ B2 or C), number of years since diagnosis, time to 
the first colonoscopy (continuous), time to the last colonoscopy, and number of colonoscopic 
examinations (1, 2, 3, or 4+).  
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6.4 Results 
Table 6.1 presents the characteristics of the 482 study subjects according to three 
categories of BMI. Approximately half of the subjects in each of the three BMI categories 
were assigned to placebo. Distributions of age, race, cancer stage and type of surgery were 
similar in three BMI groups. Compared to men, women subjects were significantly more 
represented in either BMI <25 (kg/m2) or BMI ≥ 30 (kg/m2) categories. Regardless of their 
BMI category assessed at baseline, subjects were followed-up for average 2.5 years, and 
underwent approximately 1-2 colonoscopic examinations during the follow-up period. 
Median time to first colonoscopic examination was 1. 4 years (IQR: 0.8-2.9) in BMI <25 
(kg/m2) group, 1.2 (IQR: 0.8-2.7) in BMI 25-29.9 (kg/m2) group, and 1.3 (IQR: 0.9-2.9) in 
BMI ≥ 30 (kg/m2).  
 Relative to subjects with normal BMI at baseline, obese subjects were at elevated risk 
for colorectal adenomas with risk ratio of 1.42 (95% CI: 0.90-2.24) (Table 6.2). There was no 
increased risk among overweight subjects (RR = 1.10; 95% CI: 0.70-1.72). Since the 
distribution of BMI was significantly different by gender, we also performed stratified 
analysis by gender; however, the association between BMI and incident colorectal adenomas 
appeared similar in both men and women (p for interaction between BMI and gender = 
0.6573). 
 In order to investigate whether aspirin treatment is more effective in preventing 
colorectal adenomas in subjects with higher BMI, we estimated risk ratios for colorectal 
adenomas in aspirin treatment versus placebo, stratified by three levels of BMI (Table 6.3). 
Overall, compared with placebo, aspirin was most effective in the normal BMI group with 
80% risk reduction (RR=0.21, 95% CI 0.08-0.57). Risk reduction associated with aspirin 
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treatment was less pronounced among overweight or obese subjects (RR = 0.86, 95% CI: 
0.49-1.37 for BMI 25-29.9 kg/m2, and RR = 0.77, 95% CI: 0.46-1.31 for BMI ≥ 30 kg/m2). 
The p-value from a chunk test of two interaction terms between aspirin and two categories of 
BMI was borderline significant (p = 0.0522). The relationship of aspirin treatment, BMI, and 
colorectal adenomas was similar in both sexes.   
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6.5 Discussion 
In this study of patients with a history of colorectal cancer we found an elevated risk 
of incident colorectal adenomas in relation to increasing BMI in both men and women, but 
none of the associations were statistically significant. We also assessed a possible interaction 
between aspirin treatment and BMI: however, there was no evidence supporting the idea that 
aspirin treatment was more effective in preventing colorectal adenomas in subjects with 
higher BMI compared with subjects with normal BMI.  
Our finding with respect to BMI is in agreement with a great deal of literature that 
examined the relationship between obesity and risk of colorectal neoplasia. BMI is the most 
widely used indicator of obesity. Overall, higher BMI has been associated with an increase in 
risk of colorectal cancer, and the association has been generally linear (10). Several studies 
have suggested that the positive association between obesity and colorectal cancer appears 
stronger in men than in women (11-15). However, we did not observe such a gender 
difference. Obesity has also been related to an elevated risk of colorectal adenomas, 
particularly large or advanced adenomas, suggesting that obesity might influence growth of 
adenomas rather than their development (16). Obesity increases risk for death attributed to 
colorectal cancer. Several prospective cohort studies have reported an excess number of 
colon cancer deaths among overweight or obese people compared to those with normal 
weight (15;17-19). Obesity might affect the diagnosis or treatment of cancer as well as its 
biologic roles on development and progression of cancer (19).  
Several hypotheses have been proposed to account for the link between obesity and 
colorectal neoplasia. One involves hyperinsulinemia leading to increased bioavailability of 
insulin-like growth factor, which is known to promote proliferation and inhibit apoptosis 
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(20).  Another hypothesis involves inflammation. Adipose tissue is now recognized as an 
endocrine organ rather than a simple fat storage site. A wide range of inflammatory 
mediators such as IL-6 and TNF-α that could promote a procarcinogenic milieu (21) are 
produced and released from adipose tissue (22;23).  
Based on several studies that aspirin treatment could alter levels of inflammatory 
mediators (24;25), we have hypothesized that aspirin might be more protective in preventing 
colorectal adenomas among obese persons compared with non-obese persons. Our previous 
analysis of data from another randomized trial of aspirin to prevent colorectal adenomas was 
in agreement with this hypothesis: a daily 325 mg aspirin provided a greater protection of 
incident colorectal adenomas, particularly advanced adenomas, in subjects with higher BMI 
in both men and women (6). However, in the present study, we failed to find support for our 
previous observation and advanced adenomas were too few to study. The lack of interaction 
between aspirin treatment and obesity could be attributed to insufficient sample size, 
relatively short duration of aspirin treatment, or an altered cytokine environment in patients 
with a history of cancer (26). Alternatively, other biologic mechanism might underlie the 
protective effect of aspirin in preventing colorectal neoplasia.  
There are some limitations in this secondary analysis. First, the sample size of this 
study was not sufficient to test our study hypothesis with precision. Second, as BMI was not 
a key variable in the parent study, some subjects were missing weight or height, or had an 
implausible value. Also, there was no information on physical activity or diet. The study was 
restricted to patients with prior colon cancer.  Because everybody in the study was at high 
risk, there may have been less variability in the outcome variable (adenomas) and we may 
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have failed to detect associations that might have been apparent if the study population were 
more heterogenous. 
In spite of these limitations, our study is unique in that all subjects had curatively 
resected colorectal cancer. The effect of BMI on incident colorectal adenomas has been 
rarely studied in colon cancer survivors, although maintaining a healthy weight is generally 
recommended to prevent second primary cancers and other chronic diseases (8). Also, we 
used data from a randomized placebo-controlled clinical trial, and all subjects were actively 
followed-up for incident colorectal adenomas by colonoscopy. Finally, randomly assigned 
aspirin treatment was not affected by other factors including BMI.  
In summary, our study suggests that obesity is a risk factor for incident colorectal 
adenomas in patients with a history of colorectal cancer, and effect of aspirin was not 
stronger in obese patients compared with non-obese patients. Given that obesity is a 
modifiable risk factor, patients with curatively resected colorectal cancer should be guided to 
maintain healthy weights.  
 
 176
6.6 Acknowledgement 
The CALGB 9270 was supported in part by grants from the National Institutes of 
Health (DK 34987 and RR00046) and by grants from the National Cancer Institute 
(CA31946, CA33601, CA67663, CA45418, CA45389, CA32291, CA04326, CA47577, 
CA35091, CA12449, CA45564, CA04457, CA25224, CA35279, CA08025, CA02599, 
CA45808, CA35421, CA21060, CA77658, CA11789, CA41287, CA74811, CA47642, 
CA31983, CA37135, CA16450, CA12046, CA77298, CA47559, CA47555, CA77406, 
CA52784, CA03927, CA77440, and CA07968). 
 
 177
6.7 References 
 
 1.  Leading Sites of New Cancer Cases and Deaths; 2007 estimates. American Cancer Society . 
2007. 1-9-2007. 
 2.  Gschwantler M, Kriwanek S, Langner E, Goritzer B, Schrutka-Kolbl C, Brownstone E et al. 
High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis 
of the impact of adenoma and patient characteristics. Eur.J Gastroenterol.Hepatol. 
2002;14:183-8. 
 3.  Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD et al. Colorectal 
cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642. 
 4.  Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS. Risk factors for 
advanced colorectal adenomas: a pooled analysis. Cancer Epidemiology, Biomarkers and 
Prevention 2002;11:622-9. 
 5.  Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut 
2002;51:191-4. 
 6.  Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality 
from cancer in a prospectively studied cohort of U.S. adults. N.Engl.J Med 2003;348:1625-38. 
 7.  Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body Mass Index and Colon 
Cancer Mortality in a Large Prospective Study. American Journal of Epidemiology 
2000;152:847-54. 
 8.  Brown JK, Byers T, Doyle C, Courneya KS, mark-Wahnefried W, Kushi LH et al. Nutrition 
and Physical Activity During and After Cancer Treatment: An American Cancer Society 
Guide for Informed Choices. CA: A Cancer Journal for Clinicians 2003;53:268-91. 
 9.  Kim S, Baron J, Mott LA, Burke CA, Church TR, McKeown-Eyssen G et al. Aspirin May Be 
More Effective in Preventing Colorectal Adenomas in Patients with Higher BMI. Cancer 
Causes and Control 2006;17:1299-304. 
 10.  Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al. A randomized trial 
of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New 
England Journal of Medicine 2003;348:883-90. 
 11.  WHO Consultation on Obesity. Obesity: Preventing and managing the Global Epidemic. 894. 
6-3-1997. Geneva, World Health Organization. WHO Technical Report Series.  
 12.  Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. 
American Journal of Epidemiology 2004;159:702-6. 
 13.  Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004;23:6365-78. 
 14.  Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JD. Risk Factors for 
Hyperplastic and Adenomatous Polyps: Evidence for Malignant Potential? Cancer 
Epidemiology Biomarkers Prevention 2002;11:1012-8. 
 178
 15.  West DW, Slattery ML, Robison LM, Schuman KL, Ford MH, Mahoney AW et al. Dietary 
intake and colon cancer: sex- and anatomic site-specific associations. Am.J Epidemiol 
1989;130:883-94. 
 16.  Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A et al. Body Size 
and Risk of Colon and Rectal Cancer in the European Prospective Investigation Into Cancer 
and Nutrition (EPIC). JNCI Cancer Spectrum 2006;98:920-31. 
 17.  Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN et al. Energy balance and colon 
cancer--beyond physical activity. Cancer Research 1997;57:75-80. 
 18.  Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer 
mortality in a large prospective study. Am.J Epidemiol 2000;152:847-54. 
 19.  Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the 
evidence. J Nutr. 2001;131:3109S-20S. 
 20.  Phillips RL, Snowdon DA. Dietary relationships with fatal colorectal cancer among Seventh-
Day Adventists. JNCI Cancer Spectrum 1985;74:307-17. 
 21.  Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of 
overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N.Engl.J 
Med 1992;327:1350-5. 
 22.  Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed 
mechanisms. Nat.Rev.Cancer 2004;4:579-91. 
 23.  Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-
45. 
 24.  Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an 
endocrine and secretory organ. Proc.Nutr.Soc. 2001;60:329-39. 
 25.  Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose 
tissue. Br.J Nutr 2004;92:347-55. 
 26.  Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I. Influence of aspirin on inflammatory 
markers in patients after acute myocardial infarction. Am.J Cardiol. 2003;92:843-5. 
 27.  Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. 
Increased proinflammatory cytokines in patients with chronic stable angina and their 
reduction by aspirin. Circulation 1999;100:793-8. 
 28.  Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat.Rev.Cancer 2004;4:11-
22. 
 179
6.8     Tables 
Table 6.1 Characteristics of 482 study subjects according to body mass index at baseline, 
CALGB* Study, 1993-2000 
 Body mass index (kg/m2) p-value 
Characteristics <25 25-29.9 ≥ 30  
No. of subjects 132 196 154  
     
Placebo (%) 64 (48.5) 100 (51.0%) 76 (49.4%) 0.896 
     
Age (years)     
30-49 24 (17.4) 26 (13.3) 25 (16.2)  
50-59 25 (18.9) 52 (26.5) 40 (26.0)  
60-69 42 (31.8) 76 (26.5) 58 (37.7)  
≥ 70 42 (31.8) 42 (21.4) 31 (20.1) 0.165 
     
Female sex (%) 85 (64.4) 75 (38.3) 70 (45.5) <0.001 
     
White race (%) 118 (89.4) 180 (91.8) 136 (88.3) 0.374 
     
Cancer stage     
Dukes’ A or B1 88 (66.7) 133 (67.9) 94 (61.0)  
Dukes’ B2 or C 44 (33.3) 63 (32.1) 60 (39.0) 0.385 
     
Type of surgery     
Right hemicolectomy 44 (33.3) 52 (26.5) 39 (25.3)  
Left hemicolectomy 9 (6.8) 21 (10.7) 17 (11.0)  
sigmoid colectomy 22 (16.7) 43 (21.9) 30 (19.5)  
Total abdominal colectomy 2 (1.5) 1 (0.51) 4 (2.6)  
Abdominal perineal resection  9 (6.8) 18 (9.2) 17 (11.0)  
Other 46 (34.9) 61 (31.1) 47 (30.5) 0.524 
     
Median time since diagnosis  
(IQR) 
2.3 
(0.3-6.0) 
1.2 
(0.2-5.7) 
1.4 
(0.2-5.7) 
0.1927‡ 
     
No. of colonoscopic examination after 
randomization 
    
1 74 (56.1) 107 (54.6) 90 (58.4)  
2 36(27.3) 65 (33.2) 35 (24.7)  
3 20 (15.2) 20 (10.2) 22 (14.3)  
≥ 4 2 (1.5) 4 (2.0) 4 (2.6) 0.979† 
     
Median time to first colonoscopy in 
year (IQR§) 
1.4  
(0.8-2.9) 
1.2 
(0.8-2.7) 
1.3 
(0.9-2.9) 
0.5573‡ 
     
Median time to last colonoscopy in 
year (IQR§) 
2.9  
(1.9-3.2) 
2.8 
(1.8-3.2) 
2.8 
(2.0-3.1) 
0.7954‡ 
*Cancer and Leukemia Group B 
†p-values were based on chi-square statistics 
‡p-values were based on Kruskal-Wallis tests 
§Interquartile range 
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Table 6.2 Distribution of body mass index, and adjusted* risk ratios (RR) and 95% confidence 
intervals (CI) for incident colorectal adenomas in relation to body mass index in all subjects† 
and by sex‡, CALGB§ 9270 Study, 1993-2000 
 Body mass index (kg/m2) † 
 <25  25-29.9   ≥ 30 
 RR* 95% CI  RR* 95% CI  RR* 95% CI 
Total 1. Referent  1.10  0.7-1.732  1.42 0.90-2.24 
         
Men‡ 1. Referent  0.99 0.54-1.78  1.44 0.79-2.60 
Women‡ 1. Referent  1.30 0.66-2.54  1.31 0.64-2.66 
*Adjusted for age (30-49, 50-59, 60-69, or ≥70 years), sex, treatment assignment (aspirin or placebo), 
cancer stage (Dukes’ A or B1, or Dukes’ B2 or C), time since diagnosis in years (continuous) number 
of colonoscopic examinations (continuous), time to the first colonoscopy in years (continuous), and 
time to the last colonoscopy in years (continuous)  
†35 subjects (20 men and 15 women) were missing either height or weight to compute body mass 
index 
‡Sex-specific models do not adjust for sex 
§ Cancer and Leukemia Group B  
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Table 6.3 Effect of aspirin 325 mg/day on incident colorectal adenomas, stratified by body mass 
index in all subjects and by sex, CALGB‡ 9270 Study, 1993-2000 
 Body mass index (kg/m2) † 
 <25  25-29.9   ≥ 30  
 RR* 95% CI  RR* 95% CI  RR* 95% CI p-value‡ 
Total 0.21 0.08-0.57  0.82 0.49-1.37  0.76 0.45-1.29 0.0522 
          
Men‡ 0.22 0.05-0.90  0.83 0.45-1.56  0.64 0.64-1.21 0.2385 
Women‡ 0.18 0.04-0.79  0.83 0.32-2.14  1.38 0.50-3.81 0.0853 
*Adjusted for age (30-49, 50-59, 60-69, or ≥70 years), sex, treatment assignment (aspirin or placebo), 
cancer stage (Dukes’ A or B1, or Dukes’ B2 or C), time since diagnosis in years (continuous) number 
of colonoscopic examinations (continuous), time to the first colonoscopy in years (continuous), and 
time to the last colonoscopy in years (continuous)  
†35 subjects (20 men and 15 women) were missing either height or weight to compute body mass 
index 
‡P-values are based on tests for interaction terms between aspirin and BMI (25-29.9 kg/m2 and ≥ 30 
kg/m2) 
§ Cancer and Leukemia Group B  
 
 
 
 
 
 
 
 
7.   DISCUSSION 
 
7.1 Findings and Aims 
This dissertation was composed of two parts: 1) to examine the association between 
circulating levels of proinflammatory cytokines and risk of colorectal neoplasia, and 2) to 
evaluate whether inverse associations between NSAID use and risk of colorectal neoplasia 
would be more pronounced in those with high body mass index (BMI) compared with those 
with normal BMI.   
The first aim was addressed using data and blood specimens from the Diet and Health 
Study (DHS), a colonoscopy-based cross-sectional study of colorectal adenomas. Circulating 
levels of CRP, IL-6, and TNF-α were quantified, and examined in relation to risk factors and 
the prevalence of colorectal adenomas. There were significant differences in median levels of 
IL-6 and TNF-α between patients with colorectal adenomas and patients without. In the 
multivariable models, circulating levels of IL-6 and TNF-α, and, to a lesser degree, CRP 
were positively associated with the prevalence of colorectal adenomas. Several known risk 
factors for colorectal neoplasia also were associated with high levels of inflammatory 
cytokines, specifically older age, current smoking, increasing adiposity, physical inactivity, 
and higher caloric and fat intake. Circulating inflammatory cytokines were also compared 
between adenoma subtypes depending on villous histology, size of adenomas, and multiple 
adenomas. Whereas median concentration of CRP was slightly higher in colorectal adenomas 
with villous component than ones without, there was no significant difference in median 
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concentrations of IL-6 and TNF-α according to villous histology. In addition, levels of 
inflammatory cytokines were not associated with large adenomas or multiple adenomas. 
The second aim was addressed using two datasets: (1) phase II of the North Carolina 
Colon Cancer Study (NCCCS-II), a population-based case-control study of 
sigmoid/rectosigmoid/rectal cancer, and (2) the Cancer and Leukemia Group B 9270 study 
(CALGB 9270), a randomized, double-blind, placebo-controlled trial of aspirin 325 mg to 
prevent colorectal adenomas in patients with a history of colorectal cancer.  
Association between regular NSAID use and distal large bowel cancer was also 
evaluated in the NCCCS data because the second specific aim of this dissertation presumes 
an inverse association between NSAID use and distal large bowel cancer (i.e., sigmoid, 
rectosigmoid and rectal cancer). Although there is a great deal of literature on inverse 
association between NSAIDs and colorectal cancer, relatively few studies have focused 
specifically on rectal cancer.  
Approximately 78 % of the study participants (72% cases and 82% controls) in the 
NCCCS-II were found to be regular NSAID users, defined as taking NSAIDs at least 3 times 
per week. Compared with non-regular use, regular NSAID use was inversely associated with 
distal large bowel cancer. The strength of the association among whites was similar for more 
recent use, longer duration of use, and any regular use. The inverse association with distal 
large bowel cancer was evident for all types of different NSAIDs, but was slightly stronger 
with prescription NSAIDs, particularly with COXibs, than with non-prescription NSAIDs. 
When stratified by race, regular NSAID use remained inversely associated with distal large 
bowel cancer in whites, but not in African Americans. In addition, whereas regular NSAID 
use was inversely associated with all subsites of distal large bowel cancer, there was a 
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slightly stronger inverse association with regular NSAID use for rectal cancer compared with 
sigmoid or rectosigmoid cancer. 
In CALGB 9270, effect of BMI on incident colorectal adenomas was also examined. 
Relative to subjects with normal BMI at baseline, obese subjects were at increased risk for 
colorectal adenomas. There was no risk increase among overweight subjects. The association 
between BMI and incident colorectal adenomas appeared similar in both men and women. 
However, none of the associations were statistically significant.  
Neither the analysis of the NCCCS nor CALGB 9270 supports the hypothesis for the 
second specific aim of this dissertation: a more pronounced inverse association between 
NSAIDs/aspirin and colorectal neoplasia among obese subjects compared with non-obese 
subjects. Several explanations are possible. First, the protective effect of NSAIDs might not 
be exerted via altering circulating cytokines, as hypothesized. There have been inconsistent 
findings; while aspirin administration has been shown to reduce levels of CRP by 29% and 
IL-6 by 37% in angina patients (1), Feldman et al. did not detect any significant change in 
serum CRP levels with low dose aspirin use (2). Second, although circulating levels of the 
inflammatory cytokines are elevated in the obese (3),  and adipose tissue produces and 
releases a wide range of protein factors including IL-6 and TNF-α (4;5), it might have been 
an oversimplification to use obesity or BMI as an indicator of individuals with high levels of 
systematic inflammation because as the cytokine analysis of this dissertation shows, not only 
obesity but also other factors such as age, smoking, gender, and comorbidity appeared related 
to circulating levels of inflammatory cytokines. Alternatively, patients with colorectal cancer 
might have disrupted cytokine environments, and there is no room for obesity-driven 
cytokine to exert the effects.  
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7.2       Strengths 
Major strengths of this dissertation lie in the investigation of interrelationship 
between various aspects of obesity, inflammation, and colorectal neoplasia in three studies. 
Particularly, the cytokine study of this dissertation is deemed novel in suggesting systemic 
inflammation as a risk factor for colorectal neoplasia. It is now recognized that adipocytes 
synthesize and release cytokines such as tumor necrosis factor-alpha (TNF-α) and 
interleukin-6 (IL-6) (3). The proinflammatory cytokines are positively correlated with 
increasing obesity and obesity-related metabolic conditions (6). Based on growing evidence 
suggesting procarcinogenic effects of the proinflammatory cytokines (7-9), it is plausible that 
systemic inflammation might mediate the association between obesity and colorectal 
neoplasia. However, previous studies have not evaluated associations between cytokine 
levels and colorectal adenomas, although several have studied in the relationship to 
colorectal cancer, none of the studies have evaluated plasma levels of IL-6 or TNF-α (10-13).  
Obesity refers to accumulation of excess adiposity (14). Therefore, obesity should be 
evaluated based on the amount of body fat rather than the amount of body weight. BMI has 
been widely used as a marker for obesity in epidemiologic studies because it is readily 
available from self-reported height and weight (15). Although studies have validated 
sufficient accuracy of self-reported height and weight in the epidemiologic research (15), 
usage of BMI as an indicator of adiposity should be articulated, whenever possible (14). 
There is new evidence suggesting that waist circumference may make it possible to 
subclassify individuals within BMI categories for more accurate prediction of risk of obesity-
related health conditions (16). In the cytokine analysis of this dissertation where waist 
circumference was available, combined measurement of BMI and waist circumference as 
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well as BMI alone were examined in relation to levels of circulating inflammatory cytokines, 
and the combined measurement produced a more pronounced association with high levels of 
CRP, IL-6 and TNF-α.  
 Whereas a wealth of data on NSAIDs and colorectal neoplasia exists (17), relatively 
few epidemiologic studies have been conducted  with an emphasis on 
sigmoid/rectosigmoid/rectal cancer. Etiology and risk factors for sigmoid/rectosigmoid/rectal 
cancer might differ from proximal colon cancer given anatomic and physiologic differences 
between the proximal colon and distal colon (18). Moreover, studies have shown different 
genetic aberrations in tumorigenesis in different colon sites (18). The analysis of the 
NCCCS-II exclusively focused on distal large bowel cancer, and yielded interesting results 
suggesting that the strength of the association with NSAIDs might vary by tumor location 
with more potent effects for rectal cancer than rectosigmoid or sigmoid cancers. 
Lastly, this dissertation had a unique opportunity to examine well-studied topics 
among understudied populations. The NCCCS included adequate numbers of African 
Americans. Whereas African Americans have the highest incidence and mortality rate for 
colorectal cancer among racial groups (19), etiologic studies in this group have been few.  
Similarly, despite a great deal of literature reporting an increased risk of colorectal adenomas, 
cancer, and cancer-related deaths with increasing BMI (15), effect of BMI on incident 
colorectal adenomas was rarely studied in cancer survivors.  
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7.3  Limitations 
Taking a single measurement of circulating cytokines was a major limitation to the 
cytokine study in this dissertation. As with other biomarkers, one time measurement of 
plasma levels of inflammation mediators may not represent an individual’s overall 
inflammatory status. Given that the inflammatory response is a dynamic process that 
involves a complex interaction between inflammation mediators in response to non-specific 
stimuli, the biologic nature of the inflammatory system as well as measurement errors are 
thought to affect levels of inflammatory cytokines (20). For example, patients in our study 
could have experienced a short-term increase in plasma levels of CRP, IL-6 and TNF-α given 
that they were awaiting colonoscopy, which may be a stressful event.  In addition, while 
there is a report that TNF-α is significantly lower in the morning than in the evening (21), 
CRP (22) and IL-6 (21) are tightly regulated over time, and are not affected by circadian 
variation (21).  
There is a temporal ambiguity inherent in a cross-sectional study. However, it is 
unlikely that adenomas themselves would cause a systemic increase in inflammatory 
cytokines in this study, given that the median size of the largest adenoma was only 5 
millimeters, and  macrophage infiltration, which is uncommon in adenomas in general, is 
particularly rare in small adenomas (23). The finding that IL-6 levels were below the 
detection limit in about 50% of cases and 65% of controls further assures that most subjects 
were free from inflammatory conditions since it has been recognized that IL-6 is generally 
undetectable in healthy individuals without infection, trauma or other inflammatory 
conditions (24).  
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Assessment of NSAID exposure based on self-report data is a limitation to the 
NCCCS study in this dissertation. According to a validation study, NSAID use is generally 
underestimated relative to pharmacy records (25). However, it is not feasible to rely strictly 
on pharmacy records because they do not capture over-the-counter NSAID use, which 
comprises the majority of NSAID use. In addition, filling a prescription does not mean that 
the medication is taken.  
Given the relatively high prevalence of regular NSAID use among the NCCCS 
participants, one might be concerned about a potential selection bias; for example, study 
participants, relative to non-participants, might be more educated and health-conscious, and 
thus, be more likely to use NSAIDs. NSAID users could have been underestimated in the 
NCCCS if individuals with chronic conditions requiring NSAID use were less likely to 
participate because of their health status. However, as there is no information on prevalence 
of NSAID use as well as other covariates such as education or comorbidity in non-
participants, it is hard to determine whether, and, if any, in which direction the observed 
associations have been biased.  
Limitations of the CALGB 9270 study in this dissertation include most drawbacks 
intrinsic in secondary analyses. First, the sample size of this study was not sufficient to test 
our study hypothesis with precision, and this imposes limits in exploratory research. Second, 
as BMI was not a key variable in the parent study, some subjects were missing weight or 
height, or had an implausible value. Also, there was no information on physical activity or 
diet that was potentially important to our analysis.  
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7.4  Public Health Significance 
Colorectal cancer is the third most common cancer in men and women in the United 
States with 153,760 new cases and 52,180 deaths estimated in 2007 (19). As with other 
cancers, both genetic and environmental factors contribute to the development of sporadic 
colorectal cancer. However, a potential role of environmental factors is highly relevant in 
colorectal carcinogenesis, based on the wide international variation in incidence of colorectal 
cancer and rapid changes, often within a generation, in incidence rates among immigrants 
from a low-incidence country to a high-incidence country (26).  
Obesity is one of the environmental factors that are most consistently associated with 
risk of colorectal cancer (27). Although obesity is more prevalent in the industrialized world 
including the U.S. and Europe than in developing countries (28), prevalence of obesity is 
rising rapidly in many developing countries, making obesity a global phenomenon estimated 
to involve 1.7 billion people (29).  
As a growing literature suggests procarcinogenic roles of systemic inflammation, 
which is increasingly prevalent in obese individuals relative to normal weight persons (30), 
the present dissertation has attempted to address the following two questions: first, does 
systemic inflammation mediate the positive association between obesity and colorectal 
neoplasia? Secondly, if so, do anti-inflammatory agent, aspirin, and other NSAIDs modify 
adipose-driven cytokines in preventing colorectal neoplasia so that obese individuals might 
benefit more from NSAID use. 
Our findings demonstrate that systemic inflammation, quantified by circulating levels 
of proinflammatory cytokines, was indeed associated with colorectal adenomas. Circulating 
levels of cytokines were also associated with obesity and other risk factors for colorectal 
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neoplasia, supporting a hypothesis that inflammation might mediate the association between 
colorectal cancer and obesity and other risk factors. Whereas this dissertation suggests that 
systemic inflammation might be involved in the early development of colorectal cancer, 
further studies with a reproducible measurement of systemic inflammation are warranted to 
establish systemic inflammation as a potential risk factor for colorectal neoplasia. It is 
recommended that future studies take multiple measurements of circulating cytokines over 
time, and prospectively follow up incident colorectal adenomas or cancer to minimize intra-
individual variation over time.  
We failed to show that aspirin/NSAIDs might be more protective in preventing 
colorectal neoplasia in obese individuals compared with non-obese individuals. Nonetheless, 
the idea that chemopreventive effects of NSAIDs might be differential among populations 
appears to hold true, as suggested from the differences in the associations between regular 
NSAID use and colorectal cancer by race, and by tumor location in the NCCCS. It is likely 
that colorectal cancer is not a single disease, but it is composed of several subtypes with 
different etiologies. Etiologic heterogeneity might underlie the possible differences in the 
association between NSAIDs and colorectal neoplasia. According to one recent study, 
regular use of aspirin was associated with a significant risk reduction in colorectal tumors 
with modest to strong COX-2 expression, while there was no association with tumors with 
weak or absent expression of COX-2 (31). In relation to effectiveness of aspirin/NSAIDs, 
comparison of risk factors between colorectal tumors with COX-2 expression and tumor 
without could be a good start to identify subgroups who are likely to benefit the most from 
NSAIDs in preventing colorectal cancer.  
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Appendix I: 
 
Principle diagram of a sandwich-type ELISA 
(Adapted from http://www.mabtech.com/elisa.asp, last accessed on March 11th, 2007) 
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Appendix II: 
 
Directed Acyclic Graph describing the associations between inflammatory cytokines 
and colorectal adenomas, Diet and Health Study 
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Appendix III:  
 
Study questionnaire used to obtain information on use of NSAIDs in the 
North Carolina Colon Cancer Study II (NCCCS II) 
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Appendix III (CONT.):  
 
Study questionnaire used to obtain information on use of NSAIDs in the 
North Carolina Colon Cancer Study II (NCCCS II) 
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Appendix IV: 
 
Flow diagram of treatment assignment, follow-up examination, and inclusion  
in the statistical analysis, Cancer Leukemia Group B 9270 Study 
 
 
 
 
 
